OHIO DEPARTMENT OF HEALTH

ANNUAL SUMMARY OF INFECTIOUS DISEASES OHIO 2007

REPORTED INCIDENCE OF SELECTED NOTIFIABLE DISEASES



PREPARED AND DISTRIBUTED BY:

BUREAU OF HEALTH SURVEILLANCE AND BUREAU OF INFECTIOUS DISEASE CONTROL

DIVISION OF PREVENTION

TABLE OF CONTENTS

Introduction	1
Ohio Notifiable Diseases	2
Ohio County Population Map	4
Tables of Notifiable Diseases	5
Reported Cases of Selected Notifiable Diseases by Year of Onset, Ohio, 2003-2007	6
Reported Cases of Selected Notifiable Diseases by Age in Years, Ohio, 2007	9
Reported Cases of Selected Notifiable Diseases by Gender, Ohio, 2007	13
Reported Cases of Selected Notifiable Diseases by Month of Onset, Ohio, 2007	15
Reported Cases of Selected Notifiable Diseases by County of Residence, Ohio, 2007	19
Salmonella Serotypes by Year of Onset, 2003-2007	45
Meningococcal Disease Serogroups by Year of Onset, 2003-2007	49
Profiles of Selected Notifiable Diseases	50
Cholera	50
Cryptosporidiosis	51
Enterohemorrhagic Escherichia coli	52
Haemophilus influenzae, Invasive Disease	53
Legionellosis	55
Listeriosis	56
Meningitis, Aseptic	57
Meningococcal Disease	59
Pertussis	61
Salmonellosis	62
Shigellosis	63
Streptococcal Disease, Group A, Invasive	64

TABLE OF CONTENTS

	Streptococcal Disease, Group B, in Newborn	65
	Varicella	66
Prof	iles of Selected Outbreaks	67
	Foodborne Outbreaks	67
	Unusual Incidence Outbreaks	68
	Waterborne Outbreaks	69
	Outbreaks Involving Staphylococcus aureus	70
	Multistate Investigations	72
Тес	hnical Notes	73
	Specific Diseases	73
	Outbreaks	74
	Diseases Not Included in Tables	75
	Salmonella Serotypes and Meningococcal Disease Serogroups	76
	References	76

INTRODUCTION

The Annual Summary of Infectious Diseases, Ohio, 2007 provides an overview of the incidence of selected notifiable infectious diseases. The report includes tables of disease by year, age group, gender, month of onset, county of residence, Salmonella serotypes and meningococcal disease serogroups. In addition, there are profiles of selected diseases and outbreaks that feature a brief description and recent epidemiologic trends.

The sources of these data are individual case and laboratory reports submitted to the Ohio Department of Health (ODH) by infection control practitioners, health care providers, laboratories and city, county and combined health districts throughout the state and entered into the Ohio Disease Reporting System (ODRS). Data reflect disease incidence for Ohio residents only, but include diseases (malaria, for example) acquired by Ohio residents while traveling out of state or overseas.

This summary includes confirmed, probable and suspected cases. For all diseases, the case criteria used are those provided in:

- "Case Definitions for Infectious Conditions Under Public Health Surveillance," MMWR (Morbidity and Mortality Weekly Report) 1997; 46 (No. RR-10) available online at http://www.cdc.gov/mmwr/preview/mmwrhtml/00047449.htm,
- The ODH Infectious Disease Control Manual (IDCM) available online at http://www.odh.ohio.gov/healthResources/infectiousDiseaseManual.aspx and
- The Centers for Disease Control and Prevention (CDC) National Notifiable Disease Surveillance System's nationally notifiable infectious disease case definitions available online at http://www.cdc.gov/ncphi/disss/nndss/phs/infdis2007r.htm.

HIV/AIDS, sexually transmitted diseases and tuberculosis surveillance data are not included in this report. Please refer to the ODH Web site for summary reports of these diseases as well as previous annual summaries at <u>http://www.odh.ohio.gov/healthStats/disease/id1.aspx</u>.

The diseases included in this report are part of a passive surveillance system, where infection control practitioners, health care providers and laboratories report cases without being actively contacted in a systematic manner. Therefore, these numbers do not represent a complete enumeration of all incident cases. A significant percentage of persons with these diseases are not specifically diagnosed or even seek treatment, so the true number of persons with these diseases is unknown. Even though only a portion of cases are reported, these data provide valuable insight into the demographic, geographic and secular trends for these diseases.

Thanks to all infection control practitioners, health care providers, laboratories and local health departments for their hard work and dedication to reporting infectious diseases in the most accurate, complete and timely manner. These efforts are essential in protecting and improving the health of all Ohioans.

Questions or comments regarding general infectious, hepatitis and vaccine-preventable disease surveillance data may be directed to the Bureau of Health Surveillance at (614) 995-5591. Questions regarding outbreaks or zoonotic disease surveillance data may be directed to the Bureau of Infectious Disease Control at (614) 466-0265.

OHIO NOTIFIABLE DISEASES

Ohio Administrative Code 3701-3-02 and 3701-3-13, effective Jan. 1, 2006

Class A(1): Diseases of major public health concern because of the severity of disease or the potential for epidemic spread. Report by telephone immediately upon recognition of a case, a suspected case or a positive laboratory result.

Anthrax

- Meningococcal disease
- Botulism, foodborne
- Cholera
- Diphtheria
- Measles

- Plague
- Rabies, human

•

- Rubella, not congenital
 - Severe acute respiratory syndrome
- Any unexpected pattern of cases, suspected cases, deaths or increased incidence of any other disease of major public health concern because of the severity of disease or potential for epidemic spread, which may indicate a newly recognized infectious agent, outbreak, epidemic, related public health hazard or act of bioterrorism

Class A(2): Diseases of public health concern needing a timely response because of the potential for epidemic spread. Report by the end of the next business day after the existence of a case, a suspected case or a positive laboratory result.

 Arboviral neuroinvasive and non-neuroinvasive

disease: Eastern equine encephalitis, LaCrosse encephalitis, Powassan encephalitis, St. Louis encephalitis, West Nile virus, Western equine encephalitis, other arthropod-borne disease

- Chancroid
- Cyclosporiasis
- Coccidioidomycosis
- Dengue
- Enterohemorrhagic Escherichia coli
- Foodborne outbreaks

- Granuloma inguinale
- Haemophilus influenzae,
 invasive disease
- Hantavirus
- Hemolytic uremic syndrome
- Hepatitis A
- Hepatitis B, perinatal
- Influenza-associated
 pediatric mortality
- Legionellosis
- Listeriosis
- Lymphogranuloma
 venereum
- Malaria
- Meningitis, aseptic
- Mumps

- Pertussis
- Poliomyelitis
- Psittacosis
- Q fever
- Rubella, congenital
- Salmonellosis
- Shigellosis
- Staphylococcus aureus, vancomycin resistant or intermediate resistant
- Syphilis
- Tetanus
- Tuberculosis
- Typhoid fever
- Waterborne disease
 outbreaks

Smallpox

•

- Tularemia
- Viral hemorrhagic fever
- Yellow fever

OHIO NOTIFIABLE DISEASES

Ohio Administrative Code 3701-3-02 and 3701-3-13, effective Jan. 1, 2006

Class A(3): Diseases of significant public health concern. Report by the end of the work week after the existence of a case, a suspected case or a positive laboratory result.

- Amebiasis •
- Botulism, infant •
- Botulism, wound •
- Brucellosis •
- Campylobacteriosis
- Chlamydia infections
- Creutzfeldt-Jakob • disease
- Cryptosporidiosis •
- Cytomegalovirus, • congenital
- Ehrlichiosis .
- Encephalitis, other viral
- Encephalitis, post ٠ infection
- Giardiasis
- Gonococcal infections

- Hepatitis B, non-perinatal
- Hepatitis C
- Hepatitis D •
- Hepatitis E •
- Herpes, congenital
- Kawasaki disease •
- Leprosv
- Leptospirosis •
- Lyme disease •
- Meningitis, bacterial •
- Mycobacterial disease, other than tuberculosis
- Reve syndrome •
- Rheumatic fever
- Rocky Mountain spotted fever

- Streptococcal disease, group A, invasive
- Streptococcal disease, group B, in newborn
- Streptococcal toxic shock syndrome
- Streptococcus • pneumoniae, invasive disease
- Toxic shock syndrome •
- Toxoplasmosis, • congenital
- Trichinosis
- Typhus fever •
- Varicella
- Vibriosis
- Yersiniosis

Class B: The number of cases is to be reported by the close of each working week.

Influenza •

Class C: Report an outbreak, unusual incidence or epidemic by the end of the next working day.

Blastomycosis •

•

- Pediculosis
- Staphylococcal skin


- Conjunctivitis, acute • Histoplasmosis
- Scabies • Sporotrichosis
- infections Toxoplasmosis

- Nosocomial infections •
- Outbreak, unusual incidence or epidemic of other infectious diseases of known etiology • not categorized as class A, class B or class C

Cases of AIDS, AIDS-related conditions, HIV infection, perinatal exposure to HIV and CD4 Tlymphocyte counts less than 200 or 14 percent must be reported on forms and in a manner prescribed by the director.

- •
- •

OHIO COUNTY POPULATION MAP



Source of populations by county is 2000 U.S. Census.

TABLES OF SELECTED NOTIFIABLE DISEASES

BY YEAR OF ONSET TABLE

This table displays case counts and rates for five years of data in addition to the mean and median counts and rates during 2003-2007. Means and medians were calculated only when five years of data were available. Population data come from the U.S. Census midpoint estimates for each year. Data for 2003 is by year of report. Data for all other years is by year of onset with the exception of acute hepatitis B, chronic hepatitis B, perinatal hepatitis B, acute hepatitis C, past or present hepatitis C, outbreaks and varicella. Hepatitis B and C and outbreaks are shown by date of report for all years, while varicella is shown by date of report for 2003-2005. Data in previous annual summaries before 2003 were by year of report.

BY AGE TABLE

This table provides case counts and rates by age group (in years) for 2007. Age refers to patient's age at the earliest known date associated with the case. Population data come from the 2000 U.S. Census counts by age. Outbreak data are not included in this table because numbers indicate the number of outbreaks and do not reflect the individual cases involved.

BY GENDER TABLE

This table contains case counts and rates by gender for 2007. Population data come from the 2000 U.S. Census counts by gender. Outbreak data are not included in this table because numbers indicate the number of outbreaks and do not reflect the individual cases involved.

BY MONTH OF ONSET TABLE

This table presents case counts and percents by month of onset for 2007. Month refers to the month of symptom onset except for hepatitis B and C conditions and all outbreaks, which are by month of report, and for influenza-associated pediatric mortality, which is by month of death. Population data are not available by month, so rates cannot be calculated.

BY COUNTY OF RESIDENCE TABLE

This table displays case counts and rates by county for 2007. County refers to the patient's county of residence. If a county of residence is unknown, then the county in which the hospital, physician or local health department is located is used. Population data come from the 2000 U.S. Census counts by county.

SALMONELLA SEROTYPES TABLE

This table contains Salmonella case counts and percents by serotype during 2003-2007. Serotypes, untyped serogroups and untyped/ungrouped isolates are provided. The bacteriology laboratory at ODH performs serotyping of Salmonella isolates.

MENINGOCOCCAL SEROGROUPS TABLE

This table shows meningococcal disease case counts and percents by serogroup during 2003-2007. The bacteriology laboratory at ODH performs serogrouping of Neisseria meningitidis isolates.

Page 9

Page 13

Page 6

Page 15

Page 19

Page 45

Page 49

REPORTED CASES OF SELECTED NOTIFIABLE DISEASES BY YEAR OF ONSET, OHIO, 2003-2007

	200	03*	20	04	20	05	20	06	20	07	MED	IAN	ME	AN
GENERAL INFECTIOUS DISEASES	Ν	Rate	N	Rate										
Amebiasis	14	0.1	11	0.1	17	0.1	14	0.1	33	0.3	14	0.1	18	0.2
Botulism, Foodborne*	0	0.0	1	0.0	0	0.0	0	0.0	3	0.0	0	0.0	1	0.0
Botulism, Infant	2	0.0	2	0.0	0	0.0	2	0.0	1	0.0	2	0.0	1	0.0
Campylobacteriosis	1,265	11.1	1,222	10.7	1,174	10.2	1,129	9.8	1,083	9.4	1,174	10.2	1,175	10.2
Cholera	0	0.0	0	0.0	0	0.0	0	0.0	1	0.0	0	0.0	0	0.0
Coccidioidomycosis*	-	-	-	-	-	-	8	0.1	11	0.1	-	-	-	-
Creutzfeldt-Jakob Disease (CJD)	9	0.1	11	0.1	10	0.1	15	0.1	10	0.1	10	0.1	11	0.1
Cryptosporidiosis	173	1.5	221	1.9	782	6.8	366	3.2	611	5.3	366	3.2	431	3.8
Cyclosporiasis	0	0.0	1	0.0	1	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Cytomegalovirus (CMV), Congenital	10	0.1	15	0.1	18	0.2	13	0.1	16	0.1	15	0.1	14	0.1
Encephalitis, Post Chickenpox	0	0.0	1	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Encephalitis, Post Other Infection*	11	0.1	7	0.1	9	0.1	10	0.1	5	0.0	9	0.1	8	0.1
Encephalitis, Primary Viral	48	0.4	32	0.3	17	0.1	30	0.3	24	0.2	30	0.3	30	0.3
Escherichia coli O157:H7	132	1.2	103	0.9	150	1.3	160	1.4	80	0.7	132	1.2	125	1.1
Escherichia coli, Shiga Toxin-Producing, Not O157:H7	16	0.1	4	0.0	13	0.1	20	0.2	19	0.2	16	0.1	14	0.1
Escherichia coli, Shiga Toxin-Producing, Unknown Serotype	20	0.2	17	0.1	6	0.1	31	0.3	39	0.3	20	0.2	23	0.2
Giardiasis	903	7.9	789	6.9	820	7.2	806	7.0	833	7.3	820	7.2	830	7.2
Haemophilus influenzae, Invasive Disease	78	0.7	108	0.9	107	0.9	93	0.8	114	1.0	107	0.9	100	0.9
Hemolytic Uremic Syndrome (HUS)	5	0.0	7	0.1	8	0.1	16	0.1	12	0.1	8	0.1	10	0.1
Herpes, Congenital*	10	0.1	13	0.1	6	0.1	*	*	*	*	*	*	10	*
Kawasaki Disease	68	0.6	51	0.4	55	0.5	35	0.3	38	0.3	51	0.4	49	0.4
Legionellosis	226	2.0	211	1.8	206	1.8	237	2.1	231	2.0	226	2.0	222	1.9
Leprosy (Hansen's Disease)	2	0.0	0	0.0	0	0.0	0	0.0	1	0.0	0	0.0	1	0.0
Listeriosis	27	0.2	38	0.3	36	0.3	43	0.4	33	0.3	36	0.3	35	0.3
Meningitis, Aseptic	1,284	11.2	1,407	12.3	1,469	12.8	905	7.9	816	7.1	1,284	11.2	1,176	10.3
Meningitis, Other Bacterial*	114	1.0	90	0.8	45	0.4	68	0.6	49	0.4	68	0.6	73	0.6
Meningococcal Disease	60	0.5	63	0.5	45	0.4	50	0.4	32	0.3	50	0.4	50	0.4
Rheumatic Fever	3	0.0	1	0.0	1	0.0	0	0.0	4	0.0	1	0.0	2	0.0
Salmonellosis	1,326	11.6	1,195	10.4	1,343	11.7	1,299	11.3	1,323	11.5	1,323	11.5	1,297	11.3
Shigellosis	301	2.6	166	1.4	140	1.2	200	1.7	1,277	11.1	200	1.7	417	3.6
Staphylococcus aureus, Intermediate Resistance to Vancomycin (VISA)	0	0.0	0	0.0	0	0.0	3	0.0	2	0.0	0	0.0	1	0.0
Streptococcal Disease, Group A, Invasive	287	2.5	204	1.8	199	1.7	245	2.1	226	2.0	226	2.0	232	2.0
Streptococcal Disease, Group B, in Newborn	72	0.6	54	0.5	61	0.5	63	0.5	49	0.4	61	0.5	60	0.5
Streptococcal Toxic Shock Syndrome (STSS)	24	0.2	20	0.2	17	0.1	18	0.2	12	0.1	18	0.2	18	0.2
Streptococcus pneumoniae, Invasive Disease, Ages < 5 Years*	159	1.4	120	1.0	134	1.2	144	1.3	117	1.0	134	1.2	135	1.2
Streptococcus pneumoniae, Invasive Disease, Drug Resistant, Ages 5+ Years*	273	2.4	276	2.4	351	3.1	396	3.5	302	2.6	302	2.6	320	2.8
Streptococcus pneumoniae, Invasive Disease, Drug Susceptible, Ages 5+ Years*	747	6.5	652	5.7	736	6.4	766	6.7	736	6.4	736	6.4	727	6.3
Toxic Shock Syndrome (TSS)	12	0.1	7	0.1	4	0.0	7	0.1	2	0.0	7	0.1	6	0.1
Typhoid Fever	2	0.0	6	0.1	2	0.0	11	0.1	11	0.1	6	0.1	6	0.1
Vancomycin-Resistant Enterococcal Disease (VRE)	1,095	9.6	-	-	-	-	-	-	-	-	-	-	-	-
Vibrio parahaemolyticus Infection	0	0.0	4	0.0	2	0.0	2	0.0	3	0.0	2	0.0	2	0.0
Vibrio vulnificus Infection	1	0.0	2	0.0	0	0.0	1	0.0	0	0.0	1	0.0	1	0.0
Vibriosis, Other (Not Cholera)	6	0.1	7	0.1	4	0.0	2	0.0	3	0.0	4	0.0	4	0.0
Yersiniosis	60	0.5	61	0.5	45	0.4	41	0.4	52	0.5	52	0.5	52	0.5
SUB-TOTAL	8,845	77.3	7,200	62.8	8,033	70.1	7,249	63.2	8,214	71.6	8,033	70.1	7,908	69.0

REPORTED CASES OF SELECTED NOTIFIABLE DISEASES BY YEAR OF ONSET, OHIO, 2003-2007

	200)3*	20	04	20	05	20	06	20	07	MED	IAN	ME	AN
HEPATITIS	Ν	Rate	N	Rate	N	Rate	N	Rate	N	Rate	N	Rate	N	Rate
Hepatitis A	171	1.5	50	0.4	51	0.4	49	0.4	69	0.6	51	0.4	78	0.7
Hepatitis B, Acute*	160	1.4	115	1.0	136	1.2	126	1.1	124	1.1	126	1.1	132	1.2
Hepatitis B, Chronic*	253	2.2	329	2.9	858	7.5	386	3.4	2,427	21.2	386	3.4	851	7.4
Hepatitis B, Perinatal Infection*	5	0.0	0	0.0	1	0.0	0	0.0	0	0.0	0	0.0	1	0.0
Hepatitis C, Acute*	9	0.1	6	0.1	9	0.1	7	0.1	19	0.2	9	0.1	10	0.1
Hepatitis C, Past or Present*	4,516	39.5	5,391	47.0	8,583	74.9	8,073	70.3	11,319	98.7	8,073	70.3	7,576	66.1
Hepatitis E	0	0.0	1	0.0	4	0.0	1	0.0	3	0.0	1	0.0	2	0.0
SUB-TOTAL	5,114	44.7	5,892	51.4	9,642	84.1	8,642	75.3	13,961	121.8	8,642	75.3	8,650	75.5
OUTBREAKS*	40	1	00	1	70	,	445	1	07	,	07	,	0.4	,
Foodborne*	48	n/a	90	n/a	79	n/a	115	n/a	87	n/a	87	n/a	84	n/a
Waterborne*	4	n/a	4	n/a	5	n/a	5	n/a	9	n/a	5	n/a	5	n/a
Unspecified*	37	n/a	35	n/a	4	n/a	9	n/a	28	n/a	28	n/a	23	n/a
Conjunctivitis*	0	n/a	0	n/a	1	n/a	0	n/a	2	n/a	0	n/a	1	n/a
Nosocomial*	0	n/a	0	n/a	0	n/a	4	n/a	8	n/a	0	n/a	2	n/a
Pediculosis*	0	n/a	0	n/a	0	n/a	0	n/a	1	n/a	0	n/a	0	n/a
Scabies*	0	n/a	0	n/a	7	n/a	8	n/a	18	n/a		n/a	7	n/a
Staphylococcal Skin Infections*	0	n/a	0	n/a	10	n/a	18	n/a	39	n/a	10	n/a	13	n/a
Unusual Incidence of Non-Class A, Class B or Class C Disease*	0	n/a	0	n/a	30	n/a	70	n/a	117	n/a	30	n/a	43	n/a
SUB-TOTAL	89	n/a	129	n/a	136	n/a	229	n/a	309	n/a	136	n/a	178	n/a
VACCINE-PREVENTABLE														
Influenza-Associated Pediatric Mortality*	-	-	-	-	2	0.0	1	0.0	2	0.0	-	-	-	-
Measles, Imported	2	0.0	0	0.0	1	0.0	0	0.0	0	0.0	0	0.0	1	0.0
Measles, Indigenous	0	0.0	0	0.0	2	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Mumps	7	0.1	10	0.1	8	0.1	45	0.4	26	0.2	10	0.1	19	0.2
Pertussis	328	2.9	885	7.7	1,094	9.5	594	5.2	837	7.3	837	7.3	748	6.5
Tetanus	2	0.0	0	0.0	1	0.0	3	0.0	0	0.0	1	0.0	1	0.0
Varicella*	1,247	10.9	1,610	14.1	2,021	17.6	8,859	77.2	4,364	38.1	2,021	17.6	3,620	31.6
SUB-TOTAL	1,586	13.9	2,505	21.9	3,129	27.3	9,502	82.8	5,229	45.6	3,129	27.3	4,390	38.3

REPORTED CASES OF SELECTED NOTIFIABLE DISEASES BY YEAR OF ONSET, OHIO, 2003-2007

	20	03*	20	04	20	05	20	06	20	07	MED	DIAN	ME	AN
ZOONOSES	Ν	Rate	N	Rate	N	Rate	N	Rate	N	Rate	N	Rate	N	Rate
Anaplasmosis*	6	0.1	0	0.0	1	0.0	5	0.0	2	0.0	2	0.0	3	0.0
Brucellosis	1	0.0	4	0.0	2	0.0	0	0.0	0	0.0	1	0.0	1	0.0
Dengue	4	0.0	4	0.0	11	0.1	9	0.1	11	0.1	9	0.1	8	0.1
Ehrlichia chaffeensis*	2	0.0	0	0.0	2	0.0	1	0.0	1	0.0	1	0.0	1	0.0
LaCrosse Encephalitis*	20	0.2	26	0.2	15	0.1	11	0.1	9	0.1	15	0.1	16	0.1
Leptospirosis	1	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Lyme Disease*	66	0.6	50	0.4	42	0.4	36	0.3	34	0.3	42	0.4	46	0.4
Malaria	23	0.2	30	0.3	29	0.3	28	0.2	28	0.2	28	0.2	28	0.2
Q Fever	8	0.1	2	0.0	2	0.0	3	0.0	2	0.0	2	0.0	3	0.0
Rabies, Animal*	53	n/a	77	n/a	70	n/a	59	n/a	86	n/a	70	n/a	69	n/a
Rocky Mountain Spotted Fever (RMSF)	10	0.1	11	0.1	20	0.2	26	0.2	9	0.1	11	0.1	15	0.1
St. Louis Encephalitis*	0	0.0	0	0.0	0	0.0	1	0.0	0	0.0	0	0.0	0	0.0
Toxoplasmosis, Congenital	0	0.0	1	0.0	0	0.0	1	0.0	1	0.0	1	0.0	1	0.0
Trichinosis	0	0.0	1	0.0	1	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Tularemia	0	0.0	1	0.0	1	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Typhus Fever, Murine	0	0.0	0	0.0	0	0.0	1	0.0	0	0.0	0	0.0	0	0.0
West Nile Virus*	108	0.9	12	0.1	61	0.5	48	0.4	23	0.2	48	0.4	50	0.4
SUB-TOTAL	302	2.2	219	1.2	257	1.6	229	1.5	206	1.0	229	1.5	243	1.5
GRAND TOTAL	15,936	138.1	15,945	137.4	21,197	183.1	25,851	222.7	27,919	240.0	21,197	183.1	21,370	184.3
POPULATION	11,43	5,798	11,45	9,011	11,46	64,042	11,47	8,006	11,46	6,917	11,46	4,042	11,46	0,755

	0	-4	5	-9	10-	-14	15	-19	20	-29	30	-39
GENERAL INFECTIOUS DISEASES	N	Rate	N	Rate	N	Rate	N N	Rate	N .	Rate	N	Rate
Amebiasis	0	0.0	5	0.6	2	0.2	7	0.9	3	0.2	6	0.4
Botulism. Foodborne*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	3	0.2
Botulism, Infant	1	0.1	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Campylobacteriosis	152	20.1	39	4.8	37	4.5	54	6.6	101	6.9	135	8.1
Cholera	0	0.0	0	0.0	1	0.1	0	0.0	0	0.0	0	0.0
Coccidioidomycosis*	0	0.0	0	0.0	0	0.0	1	0.1	3	0.2	1	0.1
Creutzfeldt-Jakob Disease (CJD)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Cryptosporidiosis	186	24.6	98	12.0	56	6.8	33	4.0	66	4.5	66	4.0
Cytomegalovirus (CMV), Congenital	16	2.1	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Encephalitis, Post Other Infection*	1	0.1	1	0.1	1	0.1	0	0.0	0	0.0	1	0.1
Encephalitis, Primary Viral	3	0.4	4	0.5	2	0.2	0	0.0	1	0.1	3	0.2
Escherichia coli O157:H7	18	2.4	13	1.6	8	1.0	10	1.2	8	0.6	4	0.2
Escherichia coli, Shiga Toxin-Producing, Not O157:H7	4	0.5	0	0.0	5	0.6	5	0.6	2	0.1	0	0.0
Escherichia coli, Shiga Toxin-Producing, Unknown Serotype	6	0.8	1	0.1	2	0.2	1	0.1	5	0.3	3	0.2
Giardiasis	186	24.6	106	13.0	38	4.6	33	4.0	74	5.1	106	6.4
Haemophilus influenzae, Invasive Disease	17	2.3	1	0.1	1	0.1	2	0.2	6	0.4	2	0.1
Hemolytic Uremic Syndrome (HUS)	6	0.8	3	0.4	2	0.2	0	0.0	0	0.0	0	0.0
Kawasaki Disease	28	3.7	9	1.1	1	0.1	0	0.0	0	0.0	0	0.0
Legionellosis	0	0.0	2	0.2	0	0.0	0	0.0	2	0.1	13	0.8
Leprosy (Hansen's Disease)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Listeriosis	6	0.8	0	0.0	0	0.0	0	0.0	2	0.1	1	0.1
Meningitis, Aseptic	182	24.1	51	6.3	43	5.2	68	8.3	126	8.6	133	8.0
Meningitis, Other Bacterial*	6	0.8	1	0.1	0	0.0	2	0.2	5	0.3	6	0.4
Meningococcal Disease	15	2.0	0	0.0	1	0.1	4	0.5	2	0.1	2	0.1
Rheumatic Fever	0	0.0	1	0.1	1	0.1	2	0.2	0	0.0	0	0.0
Salmonellosis	248	32.9	74	9.1	69	8.3	80	9.8	160	10.9	137	8.2
Shigellosis	613	81.2	318	39.0	88	10.6	34	4.2	98	6.7	50	3.0
Staphylococcus aureus, Intermediate Resistance to Vancomycin (VISA)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Streptococcal Disease, Group A, Invasive	16	2.1	9	1.1	6	0.7	2	0.2	14	1.0	18	1.1
Streptococcal Disease, Group B, in Newborn	49	6.5	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Streptococcal Toxic Shock Syndrome (STSS)	0	0.0	0	0.0	0	0.0	0	0.0	1	0.1	1	0.1
Streptococcus pneumoniae, Invasive Disease, Ages < 5 Years*	117	15.5	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Streptococcus pneumoniae, Invasive Disease, Drug Resistant, Ages 5+ Years*	0	0.0	8	1.0	1	0.1	4	0.5	16	1.1	21	1.3
Streptococcus pneumoniae, Invasive Disease, Drug Susceptible, Ages 5+ Years*	0	0.0	14	1.7	11	1.3	11	1.4	21	1.4	39	2.3
Toxic Shock Syndrome (TSS)	0	0.0	0	0.0	1	0.1	1	0.1	0	0.0	0	0.0
Typhoid Fever	2	0.3	2	0.2	0	0.0	1	0.1	3	0.2	1	0.1
Vibrio parahaemolyticus Infection	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.1
Vibriosis, Other (Not Cholera)	0	0.0	1	0.1	1	0.1	0	0.0	0	0.0	1	0.1
Yersiniosis	19	2.5	1	0.1	2	0.2	3	0.4	5	0.3	3	0.2
SUB-TOTAL	1,897	251.3	762	93.3	380	45.9	358	43.8	724	49.4	757	45.4
HEPATITIS												
Hepatitis A	1	0.1	3	0.4	5	0.6	10	1.2	15	1.0	6	0.4
Hepatitis B, Acute*	0	0.0	0	0.0	0	0.0	2	0.2	36	2.5	32	1.9
Hepatitis B, Chronic*	25	3.3	17	2.1	23	2.8	112	13.7	458	31.3	586	35.1
	-	0.0	0	0.0	0		0	0.0			0	0.5

SUB-TOTAL		
-----------	--	--

Hepatitis C, Acute*

Rates use 2000 U.S. Census counts and are per 100,000 population.

n/a = not applicable.

* Please see Technical Notes (pp. 73-77).

Hepatitis C, Past or Present*

0.0

2.9

0.0

0

2

0

22

0

22

0

48

0.0

0.2

0.0

2.7

0

8

0

36

0.0

1.0

0.0

4.3

0

109

0

233

0.0

13.3

0.0

28.5

5

1,288

1

1,803

0.3

87.9

0.1

123.1 2,259

8

1,626

1

0.5

97.5

0.1

135.4

	0	-4	5-	-9	10-	-14	15 [.]	-19	20	-29	30-	-39
VACCINE-PREVENTABLE	Ν	Rate	Ν	Rate	N	Rate	Ν	Rate	N	Rate	N	Rate
Influenza-Associated Pediatric Mortality*	1	0.1	0	0.0	0	0.0	1	0.1	0	0.0	0	0.0
Mumps	3	0.4	8	1.0	4	0.5	6	0.7	0	0.0	2	0.1
Pertussis	291	38.5	145	17.8	119	14.4	109	13.3	34	2.3	47	2.8
Varicella*	432	57.2	2,405	294.6	1,209	146.0	121	14.8	28	1.9	25	1.5
SUB-TOTAL	727	96.3	2,558	313.3	1,332	160.9	237	29.0	62	4.2	74	4.4
ZOONOSES												
Anaplasmosis*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Dengue	0	0.0	0	0.0	0	0.0	2	0.2	1	0.1	1	0.1
Ehrlichia chaffeensis*	0	0.0	0	0.0	0	0.0	0	0.0	1	0.1	0	0.0
LaCrosse Encephalitis*	3	0.4	1	0.1	3	0.4	1	0.1	0	0.0	1	0.1
Lyme Disease*	0	0.0	1	0.1	5	0.6	4	0.5	4	0.3	5	0.3
Malaria	1	0.1	2	0.2	4	0.5	5	0.6	7	0.5	5	0.3
Q Fever	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Rabies, Animal*	n/a	n/a	n/a	n/a	n/a	n/a						
Rocky Mountain Spotted Fever (RMSF)	0	0.0	1	0.1	1	0.1	0	0.0	1	0.1	2	0.1
Toxoplasmosis, Congenital	1	0.1	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
West Nile Virus*	0	0.0	0	0.0	1	0.1	0	0.0	4	0.3	2	0.1
SUB-TOTAL	5	0.7	5	0.6	14	1.7	12	1.5	18	1.2	16	1.0
GRAND TOTAL	2,677	354.6	3,347	410.0	1,762	212.9	840	102.8	2,607	178.0	3,106	186.2
POPULATION	754	,930	816	,346	827,	811	816	,868	1,464	4,510	1,66	8,083

	40	-49	50	-59	60)+	Unk	nown	TOT	ſAL 🗌
GENERAL INFECTIOUS DISEASES	Ν	Rate	N	Rate	N	Rate	N	Rate	Ν	Rate
Amebiasis	2	0.1	1	0.1	5	0.3	2	n/a	33	0.3
Botulism, Foodborne*	0	0.0	0	0.0	0	0.0	0	n/a	3	0.0
Botulism, Infant	0	0.0	0	0.0	0	0.0	0	n/a	1	0.0
Campylobacteriosis	180	10.3	157	12.2	224	11.4	4	n/a	1,083	9.5
Cholera	0	0.0	0	0.0	0	0.0	0	n/a	1	0.0
Coccidioidomycosis*	1	0.1	2	0.2	3	0.2	0	n/a	11	0.1
Creutzfeldt-Jakob Disease (CJD)	0	0.0	1	0.1	8	0.4	1	n/a	10	0.1
Cryptosporidiosis	37	2.1	16	1.3	46	2.3	7	n/a	611	5.4
Cytomegalovirus (CMV), Congenital	0	0.0	0	0.0	0	0.0	0	n/a	16	0.1
Encephalitis, Post Other Infection*	0	0.0	1	0.1	0	0.0	0	n/a	5	0.0
Encephalitis, Primary Viral	1	0.1	4	0.3	6	0.3	0	n/a	24	0.2
Escherichia coli O157:H7	4	0.2	4	0.3	10	0.5	1	n/a	80	0.7
Escherichia coli, Shiga Toxin-Producing, Not O157:H7	1	0.1	1	0.1	1	0.0	0	n/a	19	0.2
Escherichia coli, Shiga Toxin-Producing, Unknown Serotype	6	0.3	5	0.4	10	0.5	0	n/a	39	0.3
Giardiasis	108	6.2	86	6.7	90	4.6	6	n/a	833	7.3
Haemophilus influenzae. Invasive Disease	4	0.2	11	0.9	68	3.5	2	n/a	114	1.0
Hemolytic Uremic Syndrome (HUS)	0	0.2	0	0.0	1	0.1	0	n/a	12	0.1
Kawasaki Disease	0	0.0	0	0.0	0	0.0	0	n/a	38	0.1
Legionellosis	41	2.3	53	4.1	120	6.1	0	n/a	231	2.0
Leprosy (Hansen's Disease)	0	0.0	1	0.1	0	0.0	0	n/a	1	0.0
Listeriosis	2	0.0	2	0.1	20	1.0	0	n/a	33	0.3
Meningitis, Aseptic	86	4.9	64	5.0	56	2.9	7	n/a	816	7.2
Meningitis, Other Bacterial*	10	0.6	8	0.6	11	0.6	0	n/a	49	0.4
Meningococcal Disease	0	0.0	4	0.0	4	0.0	0	n/a	32	0.4
Rheumatic Fever	0	0.0	0	0.0	0	0.2	0	n/a	4	0.0
Salmonellosis	132	7.5	145	11.3	264	13.5	14	n/a	1,323	11.7
Shigellosis	25	1.4	26	2.0	204	13.5	5	n/a	1,323	11.3
		0.1		0.0			0		2	
Staphylococcus aureus, Intermediate Resistance to Vancomycin (VISA)	1	1.0	0	3.0	1 102	0.1 5.2	2	n/a	226	0.0
Streptococcal Disease, Group A, Invasive	-	-			-	-		n/a	49	
Streptococcal Disease, Group B, in Newborn	0	0.0	0	0.0	0	0.0	0	n/a	-	0.4
Streptococcal Toxic Shock Syndrome (STSS)	0	0.0	2		8	0.4	0	n/a	12	0.1
Streptococcus pneumoniae, Invasive Disease, Ages < 5 Years*	0	0.0	0	0.0	0	0.0	0	n/a	117	1.0
Streptococcus pneumoniae, Invasive Disease, Drug Resistant, Ages 5+ Years*	30	1.7	56	4.4	166	8.5	0	n/a	302	2.7
Streptococcus pneumoniae, Invasive Disease, Drug Susceptible, Ages 5+ Years*	112	6.4	148	11.5	375	19.1	5	n/a	736	6.5
Toxic Shock Syndrome (TSS)	0	0.0	0	0.0	0	0.0	0	n/a	2	0.0
Typhoid Fever	1	0.1	1	0.1	0	0.0	0	n/a	11	0.1
Vibrio parahaemolyticus Infection	0	0.0	1	0.1	1	0.1	0	n/a	3	0.0
Vibriosis, Other (Not Cholera)	0	0.0	0	0.0	0	0.0	0	n/a	3	0.0
Yersiniosis	2	0.1	9	0.7	8	0.4	0	n/a	52	0.5
SUB-TOTAL	804	45.8	848	66.0	1,628	82.9	56	n/a	8,214	72.4
HEPATITIS										
Hepatitis A	7	0.4	11	0.9	11	0.6	0	n/a	69	0.6
Hepatitis B, Acute*	28	1.6	16	1.2	10	0.6	0	n/a	124	1.1
	546	31.1	397	30.9	250	0.5	13			21.4
Hepatitis B, Chronic*								n/a	2,427	
Hepatitis C, Acute*	4	0.2	1	0.1	1	0.1	0	n/a	19	0.2
Hepatitis C, Past or Present*	3,915	222.9	3,468	269.9	811	41.3	70	n/a	11,319	99.7

Hepatitis E

SUB-TOTAL

1

0.1

256.3 3,893

0

0.0

303.0 1,083

0

0.0

55.2

0

83

n/a

n/a

3

13,961

0.0

123.0

	40	-49	50-	-59	60) +	Unk	nown	TO	ſAL
VACCINE-PREVENTABLE	N	Rate	N	Rate	N	Rate	N	Rate	Ν	Rate
Influenza-Associated Pediatric Mortality*	0	0.0	0	0.0	0	0.0	0	n/a	2	0.0
Mumps	3	0.2	0	0.0	0	0.0	0	n/a	26	0.2
Pertussis	34	1.9	26	2.0	23	1.2	9	n/a	837	7.4
Varicella*	5	0.3	2	0.2	2	0.1	135	n/a	4,364	38.4
SUB-TOTAL	42	2.4	28	2.2	25	1.3	144	n/a	5,229	46.1
ZOONOSES										
Anaplasmosis*	0	0.0	1	0.1	1	0.1	0	n/a	2	0.0
Dengue	2	0.1	3	0.2	2	0.1	0	n/a	11	0.1
Ehrlichia chaffeensis*	0	0.0	0	0.0	0	0.0	0	n/a	1	0.0
LaCrosse Encephalitis*	0	0.0	0	0.0	0	0.0	0	n/a	9	0.1
Lyme Disease*	6	0.3	6	0.5	3	0.2	0	n/a	34	0.3
Malaria	2	0.1	1	0.1	1	0.1	0	n/a	28	0.2
Q Fever	0	0.0	2	0.2	0	0.0	0	n/a	2	0.0
Rabies, Animal*	n/a	n/a	n/a	n/a	n/a	n/a	86	n/a	86	n/a
Rocky Mountain Spotted Fever (RMSF)	2	0.1	1	0.1	1	0.1	0	n/a	9	0.1
Toxoplasmosis, Congenital	0	0.0	0	0.0	0	0.0	0	n/a	1	0.0
West Nile Virus*	4	0.2	4	0.3	8	0.4	0	n/a	23	0.2
SUB-TOTAL	16	0.9	18	1.4	16	0.8	86	n/a	206	1.8
GRAND TOTAL	5,363	305.3	4,787	372.6	2,752	140.2	369	n/a	27,610	242.4
POPULATION	1 75	6,376	1 284	4,727	1 96	3,489		0	11 35	3,140

	Fer	nale	Ma	ale	Unk	nown	TO	TAL
GENERAL INFECTIOUS DISEASES	N	Rate	N	Rate	N	Rate	N	Rate
Amebiasis	12	0.2	16	0.3	5	n/a	33	0.3
Botulism, Foodborne*	0	0.0	3	0.1	0	n/a	3	0.0
Botulism, Infant	1	0.0	0	0.0	0	n/a	1	0.0
Campylobacteriosis	514	8.8	559	10.1	10	n/a	1,083	9.5
Cholera	1	0.0	0	0.0	0	n/a	1	0.0
Coccidioidomycosis*	5	0.1	6	0.1	0	n/a	11	0.1
Creutzfeldt-Jakob Disease (CJD)	5	0.1	5	0.1	0	n/a	10	0.1
Cryptosporidiosis	279	4.8	327	5.9	5	n/a	611	5.4
Cytomegalovirus (CMV), Congenital	7	0.1	9	0.2	0	n/a	16	0.1
Encephalitis, Post Other Infection*	2	0.0	3	0.1	0	n/a	5	0.0
Encephalitis, Primary Viral	9	0.2	15	0.3	0	n/a	24	0.2
Escherichia coli O157:H7	25	0.4	53	1.0	2	n/a	80	0.7
Escherichia coli, Shiga Toxin-Producing, Not O157:H7	10	0.2	9	0.2	0	n/a	19	0.2
Escherichia coli, Shiga Toxin-Producing, Unknown Serotype	27	0.5	12	0.2	0	n/a	39	0.3
Giardiasis	357	6.1	456	8.3	20	n/a	833	7.3
Haemophilus influenzae, Invasive Disease	70	1.2	43	0.8	1	n/a	114	1.0
Hemolytic Uremic Syndrome (HUS)	7	0.1	5	0.0	0	n/a	12	0.1
Kawasaki Disease	17	0.3	21	0.1	0	n/a	38	0.3
Legionellosis	75	1.3	156	2.8	0	n/a	231	2.0
Leprosy (Hansen's Disease)	1	0.0	0	0.0	0	n/a	1	0.0
Listeriosis	16	0.3	17	0.0	0	n/a	33	0.0
Meningitis, Aseptic	417	7.1	390	7.1	9	n/a	816	7.2
Meningitis, Other Bacterial*	23	0.4	25	0.5	1	n/a	49	0.4
Meningococcal Disease	9	0.4	23	0.3	0	n/a	32	0.4
Rheumatic Fever	2	0.2	23	0.4	0	n/a	4	0.0
Salmonellosis	731	12.5	577	10.5	15	n/a	1,323	11.7
Shigellosis	654	11.2	572	10.3	51	n/a	1,323	11.3
Staphylococcus aureus, Intermediate Resistance to Vancomycin (VISA)	1	0.0	1	0.0	0	n/a	2	0.0
Streptococcal Disease, Group A, Invasive	109	1.9	115	2.1	2	n/a	226	2.0
Streptococcal Disease, Group A, invasive	22	0.4	26	0.5	1	n/a	49	0.4
Streptococcal Toxic Shock Syndrome (STSS)	7	0.4	5	0.5	0	n/a	12	0.4
Streptococcus pneumoniae, Invasive Disease, Ages < 5 Years*	53	0.1	63	1.1	1	n/a	117	1.0
Streptococcus pneumoniae, Invasive Disease, Ages < 5 Years Streptococcus pneumoniae, Invasive Disease, Drug Resistant, Ages 5+ Years*	156	2.7	143	2.6	3		302	2.7
Streptococcus pneumoniae, Invasive Disease, Drug Resistant, Ages 5+ Years*	380		351	6.4	5	n/a n/a	736	6.5
	1	6.5	1		0		2	
Toxic Shock Syndrome (TSS) Typhoid Fever	4	0.0	6	0.0	-	n/a		0.0
	4	-	-	0.1	1	n/a	11 3	0.1
Vibrio parahaemolyticus Infection Vibriosis, Other (Not Cholera)	1	0.0	2	0.0	0	n/a	3	0.0
Yersiniosis	31		20	0.0	-	n/a	52	0.0
		0.5		0.4	1	n/a		
SUB-TOTAL	4,042	69.2	4,039	73.3	133	n/a	8,214	72.4
HEPATITIS								
Hepatitis A	33	0.6	35	0.6	1	n/a	69	0.6
Hepatitis B, Acute*	45	0.8	79	1.4	0	n/a	124	1.1
Hepatitis B, Chronic*	973	16.7	1,414	25.7	40	n/a	2,427	21.4
			1					
Hepatitis C, Acute*	6	0.1	13	0.2	0 92	n/a	19	0.2
Hepatitis C, Past or Present* Hepatitis E	3,844 0	65.8	7,383	133.9 0.1	92	n/a	11,319	99.7 0.0
SUB-TOTAL	4,901	0.0 83.9	3 8,927	161.9	133	n/a n/a	3 13,961	123.0
SOD-TOTAL	4,901	03.9	0,927	101.9	133	11/d	13,901	123.0
VACCINE-PREVENTABLE								
Influenza-Associated Pediatric Mortality*	1	0.0	1	0.0	0	n/a	2	0.0
Mumps	14	0.2	12	0.2	0	n/a	26	0.2
Pertussis	458	7.8	374	6.8	5	n/a	837	7.4
Varicella*	2,065	35.4	2,227	40.4	72	n/a	4,364	38.4
	2 5 2 8	13.5	2 614	17 1	77	n/a	5 2 2 0	46.1

SUB-TOTAL

2,538

43.5 2,614

47.4

77

n/a

5,229

46.1

	Fer	nale	M	ale	Unk	nown	TO	TAL
ZOONOSES	Ν	Rate	N	Rate	N	Rate	Ν	Rate
Anaplasmosis*	1	0.0	1	0.0	0	n/a	2	0.0
Dengue	3	0.1	8	0.1	0	n/a	11	0.1
Ehrlichia chaffeensis*	0	0.0	1	0.0	0	n/a	1	0.0
LaCrosse Encephalitis*	3	0.1	6	0.1	0	n/a	9	0.1
Lyme Disease*	7	0.1	27	0.5	0	n/a	34	0.3
Malaria	13	0.2	15	0.3	0	n/a	28	0.2
Q Fever	1	0.0	1	0.0	0	n/a	2	0.0
Rabies, Animal*	n/a	n/a	n/a	n/a	86	n/a	86	n/a
Rocky Mountain Spotted Fever (RMSF)	4	0.1	5	0.1	0	n/a	9	0.1
Toxoplasmosis, Congenital	0	0.0	1	0.0	0	n/a	1	0.0
West Nile Virus*	11	0.2	12	0.2	0	n/a	23	0.2
SUB-TOTAL	43	0.7	77	1.4	86	n/a	206	1.8

GRAND TOTAL	11,524	197.3	15,657	284.0	429	n/a	27,610	242.4
POPULATION	5,840	,878	5,512	.,262	()	11,35	3,140

	Jan	uary	Feb	ruary	Ma	rch	Ap	ril	N	lav	Ju	ine	Ju	lly
GENERAL INFECTIOUS DISEASES	Ν	%	N	%	N	%	N.	%	N	%	N	%	Ν	%
Amebiasis	0	0%	1	3%	4	12%	3	9%	6	18%	4	12%	2	6%
Botulism, Foodborne*	0	0%	0	0%	0	0%	0	0%	0	0%	1	33%	1	33%
Botulism, Infant	0	0%	0	0%	1	100%	0	0%	0	0%	0	0%	0	0%
Campylobacteriosis	58	5%	39	4%	70	6%	59	5%	87	8%	141	13%	139	13%
Cholera	0	0%	0	0%	0	0%	0	0%	0	0%	0	0%	0	0%
Coccidioidomycosis*	0	0%	1	9%	0	0%	0	0%	1	9%	1	9%	0	0%
Creutzfeldt-Jakob Disease (CJD)	0	0%	0	0%	4	40%	2	20%	0	0%	1	10%	0	0%
Cryptosporidiosis	18	3%	17	3%	16	3%	16	3%	12	2%	16	3%	49	8%
Cytomegalovirus (CMV), Congenital	3	19%	0	0%	3	19%	1	6%	0	0%	0	0%	2	13%
Encephalitis, Post Other Infection*	1	20%	0	0%	1	20%	1	20%	1	20%	1	20%	0	0%
Encephalitis, Primary Viral	2	8%	1	4%	1	4%	2	8%	1	4%	1	4%	5	21%
Escherichia coli O157:H7	3	4%	4	5%	0	0%	2	3%	5	6%	7	9%	19	24%
Escherichia coli, Shiga Toxin-Producing, Not O157:H7	0	0%	0	0%	0	0%	2	11%	1	5%	1	5%	6	32%
Escherichia coli, Shiga Toxin-Producing, Unknown Serotype	1	3%	2	5%	2	5%	5	13%	1	3%	5	13%	2	5%
Giardiasis	59	7%	60	7%	68	8%	47	6%	60	7%	60	7%	73	9%
Haemophilus influenzae, Invasive Disease	15	13%	11	10%	9	8%	8	7%	2	2%	10	9%	8	7%
Hemolytic Uremic Syndrome (HUS)	1	8%	0	0%	0	0%	0	0%	0	0%	1	8%	2	17%
Kawasaki Disease	5	13%	1	3%	5	13%	5	13%	5	13%	4	11%	3	8%
Legionellosis	10	4%	6	3%	11	5%	8	3%	14	6%	20	9%	22	10%
Leprosy (Hansen's Disease)	0	0%	0	0%	0	0%	0	0%	0	0%	0	0%	0	0%
Listeriosis	5	15%	1	3%	1	3%	1	3%	2	6%	0	0%	6	18%
Meningitis, Aseptic	32	4%	34	4%	23	3%	38	5%	46	6%	49	6%	108	13%
Meningitis, Other Bacterial*	4	8%	6	12%	4	8%	3	6%	0	0%	5	10%	7	14%
Meningococcal Disease	2	6%	4	13%	4	13%	3	9%	3	9%	3	9%	2	6%
Rheumatic Fever	0	0%	0	0%	1	25%	0	0%	0	0%	0	0%	1	25%
Salmonellosis	78	6%	49	4%	85	6%	91	7%	123	9%	167	13%	183	14%
Shigellosis	9	1%	23	2%	29	2%	35	3%	124	10%	248	19%	215	17%
Staphylococcus aureus, Intermediate Resistance to Vancomycin (VISA)	0	0%	0	0%	0	0%	0	0%	1	50%	0	0%	0	0%
Streptococcal Disease, Group A, Invasive	32	14%	22	10%	30	13%	25	11%	27	12%	16	7%	9	4%
Streptococcal Disease, Group B, in Newborn	3	6%	5	10%	4	8%	0	0%	3	6%	3	6%	2	4%
Streptococcal Toxic Shock Syndrome (STSS)	0	0%	0	0%	5	42%	3	25%	0	0%	0	0%	1	8%
Streptococcus pneumoniae, Invasive Disease, Ages < 5 Years*	15	13%	14	12%	11	9%	12	10%	4	3%	8	7%	6	5%
Streptococcus pneumoniae, Invasive Disease, Drug Resistant, Ages 5+ Years*	39	13%	26	9%	39	13%	34	11%	32	11%	14	5%	9	3%
Streptococcus pneumoniae, Invasive Disease, Drug Susceptible, Ages 5+ Years*	91	12%	62	8%	84	11%	80	11%	68	9%	45	6%	24	3%
Toxic Shock Syndrome (TSS)	0	0%	1	50%	0	0%	0	0%	1	50%	0	0%	0	0%
Typhoid Fever	0	0%	0	0%	1	9%	1	9%	0	0%	0	0%	0	0%
Vibrio parahaemolyticus Infection	1	33%	0	0%	1	33%	0	0%	0	0%	0	0%	0	0%
Vibriosis, Other (Not Cholera)	0	0%	0	0%	0	0%	0	0%	0	0%	0	0%	1	33%
Yersiniosis	9	17%	6	12%	5	10%	5	10%	2	4%	5	10%	4	8%
SUB-TOTAL	496	6%	396	5%	522	6%	492	6%	632	8%	837	10%	911	11%
				• / •		.,.				• / •			•••	
HEPATITIS														
Hepatitis A	6	9%	10	14%	4	6%	6	9%	6	9%	3	4%	10	14%
Hepatitis B, Acute*	15	12%	10	8%	10	8%	14	11%	13	10%	9	7%	3	2%
Hepatitis B, Chronic*	25	1%	25	1%	27	1%	155	6%	227	9%	282	12%	148	6%
Hepatitis C, Acute*	3	16%	1	5%	2	11%	0	0%	2	11%	1	5%	1	5%
Hepatitis C, Past or Present*	486	4%	844	7%	1,007	9%	1,187	10%	559	5%	1,243	11%	920	8%
Hepatitis E	0	0%	0	0%	1	33%	0	0%	0	0%	0	0%	1	33%
	U	0 /0		0 /0	1 1	00/0		0 /0	1 0	0 /0		0 /0	1	00/0

N = number of cases reported. % = percentage of cases occurring in t

SUB-TOTAL

% = percentage of cases occurring in the month for the disease.

* Please see Technical Notes (pp. 73-77).

6% 1,051

8% 1,362 10%

807

6%

1,538

11% 1,083

8%

535

4%

	Jan	uary	Febr	uary	Ma	rch	Ар	ril	Ma	ay	Ju	ne	Ju	ıly
OUTBREAKS*	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Foodborne*	6	7%	5	6%	8	9%	8	9%	16	18%	9	10%	8	9%
Waterborne*	0	0%	1	11%	4	44%	0	0%	0	0%	1	11%	0	0%
Unspecified*	0	0%	2	7%	1	4%	0	0%	0	0%	4	14%	3	11%
Conjunctivitis*	0	0%	0	0%	0	0%	0	0%	0	0%	0	0%	0	0%
Nosocomial*	1	13%	2	25%	0	0%	1	13%	1	13%	0	0%	0	0%
Pediculosis*	0	0%	0	0%	0	0%	0	0%	0	0%	0	0%	0	0%
Scabies*	0	0%	0	0%	2	11%	1	6%	0	0%	1	6%	3	17%
Staphylococcal Skin Infections*	0	0%	2	5%	5	13%	2	5%	1	3%	2	5%	0	0%
Unusual Incidence of Non-Class A, Class B or Class C Disease*	16	14%	22	19%	23	20%	8	7%	9	8%	6	5%	3	3%
SUB-TOTAL	23	7%	34	11%	43	14%	20	6%	27	9%	23	7%	17	6%
VACCINE-PREVENTABLE														
Influenza-Associated Pediatric Mortality*	0	0%	2	100%	0	0%	0	0%	0	0%	0	0%	0	0%
Mumps	3	12%	0	0%	3	12%	2	8%	2	8%	1	4%	3	12%
Pertussis	74	9%	50	6%	51	6%	68	8%	65	8%	59	7%	51	6%
Varicella*	703	16%	481	11%	556	13%	517	12%	613	14%	119	3%	51	1%
SUB-TOTAL	780	15%	533	1 0 %	610	1 2 %	587	11%	680	13%	179	3%	105	2%
ZOONOSES														
Anaplasmosis*	0	0%	0	0%	0	0%	0	0%	0	0%	1	50%	0	0%
Dengue	1	9%	0	0%	0	0%	1	9%	1	9%	0	0%	1	9%
Ehrlichia chaffeensis*	0	0%	0	0%	0	0%	0	<u> </u>	0	0%	0	0%	1	100%
LaCrosse Encephalitis*	0	0%	0	0%	0	0%	0	0%	0	0%	0	0%	2	22%
Lyme Disease*	0	0%	1	3%	0	0%	1	3%	2	6%	7	21%	9	26%
Malaria	1	4%	2	7%	2	7%	3	11%	1	4%	2	7%	2	7%
Q Fever	1	50%	0	0%	0	0%	0	0%	1	50%	0	0%	0	0%
Rabies, Animal*	1	1%	0	0%	0	0%	2	2%	10	12%	8	9%	14	16%
Rocky Mountain Spotted Fever (RMSF)	0	0%	0	0%	1	11%	0	0%	1	11%	1	11%	2	22%
Toxoplasmosis, Congenital	0	0%	0	0%	0	0%	0	0%	0	0%	0	0%	0	0%
West Nile Virus*	1	4%	0	0%	0	0%	0	0%	0	0%	0	0%	1	4%
SUB-TOTAL	5	<u>4%</u>	3	1%	3	1%	7	<u>3%</u>	16	<u> </u>	19	<u>9%</u>	32	4% 16%
SUD-TOTAL	5	2 /0	3	1 /0	3	1 /0		3/0	10	0 /0	19	J /0	32	10 /0
GRAND TOTAL	1,839	7%	1,856	7%	2,229	8%	2,468	9%	2,162	8%	2,596	9%	2,148	8%

	Au	gust	Sept	ember	Oct	ober	Nove	mber	Dece	ember	то	TAL
GENERAL INFECTIOUS DISEASES	N	%	N	%	N	%	N	%	N	%	N	%
Amebiasis	0	0%	6	18%	4	12%	3	9%	0	0%	33	100%
Botulism. Foodborne*	1	33%	0	0%	0	0%	0	0%	0	0%	3	100%
Botulism, Infant	0	0%	0	0%	0	0%	0	0%	0	0%	1	100%
Campylobacteriosis	133	12%	95	9%	91	8%	79	7%	92	8%	1,083	100%
Cholera	1	100%	0	0%	0	0%	0	0%	0	0%	1	100%
Coccidioidomycosis*	3	27%	1	9%	3	27%	1	9%	0	0%	11	100%
Creutzfeldt-Jakob Disease (CJD)	1	10%	1	10%	0	0%	1	10%	0	0%	10	100%
Cryptosporidiosis	207	34%	157	26%	62	10%	22	4%	19	3%	611	100%
Cytomegalovirus (CMV), Congenital	2	13%	0	0%	2	13%	2	13%	1	6%	16	100%
Encephalitis, Post Other Infection*	0	0%	0	0%	0	0%	0	0%	0	0%	5	100%
Encephalitis, Primary Viral	2	8%	4	17%	1	4%	4	17%	0	0%	24	100%
Escherichia coli O157:H7	17	21%	15	19%	6	8%	1	1%	1	1%	80	100%
Escherichia coli, Shiga Toxin-Producing, Not O157:H7	3	16%	2	11%	3	16%	1	5%	0	0%	19	100%
Escherichia coli, Shiga Toxin-Producing, Unknown Serotype	5	13%	6	15%	8	21%	1	3%	1	3%	39	100%
Giardiasis	99	12%	87	10%	96	12%	62	7%	62	7%	833	100%
Haemophilus influenzae, Invasive Disease	8	7%	6	5%	7	6%	10	9%	20	18%	114	100%
Hemolytic Uremic Syndrome (HUS)	4	33%	2	17%	2	17%	0	0%	0	0%	12	100%
Kawasaki Disease	3	8%	3	8%	0	0%	2	5%	2	5%	38	100%
Legionellosis	60	26%	20	9%	24	10%	14	6%	22	10%	231	100%
Leprosy (Hansen's Disease)	1	100%	0	0%	0	0%	0	0%	0	0%	1	100%
Listeriosis	2	6%	4	12%	6	18%	4	12%	1	3%	33	100%
Meningitis, Aseptic	154	19%	116	14%	98	12%	59	7%	59	7%	816	100%
Meningitis, Other Bacterial*	7	14%	3	6%	2	4%	3	6%	5	10%	49	100%
Meningococcal Disease	2	6%	3	9%	3	9%	3	9%	0	0%	32	100%
Rheumatic Fever	0	0%	0	0%	0	0%	1	25%	1	25%	4	100%
Salmonellosis	142	11%	121	9%	120	9%	91	7%	73	6%	1,323	100%
Shigellosis	152	12%	151	12%	99	8%	107	8%	85	7%	1,277	100%
Staphylococcus aureus, Intermediate Resistance to Vancomycin (VISA)	0	0%	0	0%	0	0%	0	0%	1	50%	2	100%
Streptococcal Disease, Group A, Invasive	10	4%	6	3%	8	4%	11	5%	30	13%	226	100%
Streptococcal Disease, Group B, in Newborn	4	8%	9	18%	3	6%	5	10%	8	16%	49	100%
Streptococcal Toxic Shock Syndrome (STSS)	1	8%	0	0%	0	0%	1	8%	1	8%	12	100%
Streptococcus pneumoniae, Invasive Disease, Ages < 5 Years*	5	4%	3	3%	9	8%	14	12%	16	14%	117	100%
Streptococcus pneumoniae, Invasive Disease, Drug Resistant, Ages 5+ Years*	7	2%	18	6%	12	4%	35	12%	37	12%	302	100%
Streptococcus pneumoniae, Invasive Disease, Drug Susceptible, Ages 5+ Years*	22	3%	33	4%	36	5%	92	13%	99	13%	736	100%
Toxic Shock Syndrome (TSS)	0	0%	0	0%	0	0%	0	0%	0	0%	2	100%
Typhoid Fever	4	36%	1	9%	4	36%	0	0%	0	0%	11	100%
Vibrio parahaemolyticus Infection	1	33%	0	0%	0	0%	0	0%	0	0%	3	100%
Vibriosis, Other (Not Cholera)	0	0%	1	33%	1	33%	0	0%	0	0%	3	100%
Yersiniosis	2	4%	2	4%	6	12%	5	10%	1	2%	52	100%
SUB-TOTAL	1,065	13%	876	11%	716	9%	634	8%	637	8%	8,214	100%
HEPATITIS	-	70/	0	00/	7	4.00/	7	4.00/	0	40/	00	4000/
Hepatitis A	5	7%	2	3%	7	10%	7	10%	3	4%	69	100%
Hepatitis B, Acute*	11	9%	10	8%	13	10%	6	5%	10	8%	124	100%
Hepatitis B, Chronic*	163	7%	253	10%	310	13%	517	21%	295	12%	2,427	100%
Hepatitis C, Acute*	3	16%	2	11%	1	5%	0	0%	3	16%	19	100%

N = number of cases reported. % = percentage of cases occurring in the month

% = percentage of cases occurring in the month for the disease.

Hepatitis C, Past or Present*

Hepatitis E

SUB-TOTAL

6%

33%

1,208

0

1,475

11%

0%

888

0

11% 1,219

8%

0%

9%

1,035

0

1,565

9%

0%

11%

1,313

0

1,624

12%

0%

12%

11,319

3

13,961

100%

100%

100%

629

1

812

	Aug	just	Septe	mber	Octo	ober	Nove	mber	Dece	mber	то	FAL
OUTBREAKS*	N	%	N	%	N	%	N	%	N	%	N	%
Foodborne*	8	9%	3	3%	5	6%	6	7%	5	6%	87	100%
Waterborne*	0	0%	1	11%	0	0%	0	0%	2	22%	9	100%
Unspecified*	6	21%	2	7%	4	14%	2	7%	4	14%	28	100%
Conjunctivitis*	0	0%	0	0%	0	0%	1	50%	1	50%	2	100%
Nosocomial*	0	0%	1	13%	1	13%	0	0%	1	13%	8	100%
Pediculosis*	0	0%	0	0%	0	0%	0	0%	1	100%	1	100%
Scabies*	2	11%	0	0%	4	22%	2	11%	3	17%	18	100%
Staphylococcal Skin Infections*	2	5%	5	13%	9	23%	4	10%	7	18%	39	100%
Unusual Incidence of Non-Class A, Class B or Class C Disease*	0	0%	2	2%	3	3%	6	5%	19	16%	117	100%
SUB-TOTAL	18	6%	14	5%	26	8%	21	7%	43	14%	309	100%
VACCINE-PREVENTABLE												
Influenza-Associated Pediatric Mortality*	0	0%	0	0%	0	0%	0	0%	0	0%	2	100%
Mumps	2	8%	3	12%	2	8%	4	15%	1	4%	26	100%
Pertussis	64	8%	52	6%	104	12%	116	14%	83	10%	837	100%
Varicella*	83	2%	249	6%	309	7%	370	8%	313	7%	4,364	100%
SUB-TOTAL	149	3%	304	6%	415	8%	490	9%	397	8%	5,229	100%
ZOONOSES												
Anaplasmosis*	1	50%	0	0%	0	0%	0	0%	0	0%	2	100%
Dengue	3	27%	2	18%	1	9%	1	9%	0	0%	11	100%
Ehrlichia chaffeensis*	0	0%	0	0%	0	0%	0	0%	0	0%	1	100%
LaCrosse Encephalitis*	5	56%	2	22%	0	0%	0	0%	0	0%	9	100%
Lyme Disease*	6	18%	3	9%	4	12%	0	0%	1	3%	34	100%
Malaria	3	11%	1	4%	3	11%	5	18%	3	11%	28	100%
Q Fever	0	0%	0	0%	0	0%	0	0%	0	0%	2	100%
Rabies, Animal*	19	22%	13	15%	11	13%	8	9%	0	0%	86	100%
Rocky Mountain Spotted Fever (RMSF)	3	33%	1	11%	0	0%	0	0%	0	0%	9	100%
Toxoplasmosis, Congenital	0	0%	0	0%	0	0%	0	0%	1	100%	1	100%
West Nile Virus*	4	17%	14	61%	3	13%	0	0%	0	0%	23	100%
SUB-TOTAL	44	21%	36	17%	22	11%	14	7%	5	2%	206	100%
GRAND TOTAL	2,088	7%	2,705	10%	2,398	9%	2,724	10%	2,706	10%	27,919	100%

	Ac	lams	Α	llen	Asł	nland	Asht	abula	Atl	hens	Aug	laize	Beli	mont
GENERAL INFECTIOUS DISEASES	N	Rate	Ν	Rate	Ν	Rate	Ν	Rate	Ν	Rate	N	Rate	Ν	Rate
Amebiasis	0	0.0	1	0.9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Botulism, Foodborne*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Botulism, Infant	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Campylobacteriosis	3	11.0	3	2.8	6	11.4	0	0.0	1	1.6	11	23.6	1	1.4
Cholera	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Coccidioidomycosis*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	2.2	0	0.0
Creutzfeldt-Jakob Disease (CJD)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Cryptosporidiosis	0	0.0	1	0.9	2	3.8	0	0.0	0	0.0	10	21.5	2	2.9
Cytomegalovirus (CMV), Congenital	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Encephalitis, Post Other Infection*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Encephalitis, Primary Viral	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	2.2	0	0.0
Escherichia coli O157:H7	2	7.3	3	2.8	1	1.9	0	0.0	0	0.0	0	0.0	1	1.4
Escherichia coli, Shiga Toxin-Producing, Not O157:H7	0	0.0	0	0.0	1	1.9	0	0.0	0	0.0	0	0.0	0	0.0
Escherichia coli, Shiga Toxin-Producing, Unknown Serotype	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Giardiasis	1	3.7	12	11.1	6	11.4	3	2.9	3	4.8	4	8.6	6	8.5
Haemophilus influenzae, Invasive Disease	0	0.0	2	1.8	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Hemolytic Uremic Syndrome (HUS)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Kawasaki Disease	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Legionellosis	0	0.0	4	3.7	0	0.0	2	2.0	1	1.6	0	0.0	2	2.9
Leprosy (Hansen's Disease)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Listeriosis	0	0.0	1	0.9	0	0.0	0	0.0	0	0.0	0	0.0	1	1.4
Meningitis, Aseptic	3	11.0	22	20.3	4	7.6	1	1.0	2	3.2	3	6.4	11	15.7
Meningitis, Other Bacterial*	0	0.0	5	4.6	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Meningococcal Disease	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Rheumatic Fever	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Salmonellosis	6	22.0	12	11.1	0	0.0	9	8.8	8	12.9	5	10.7	8	11.4
Shigellosis	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Staphylococcus aureus, Intermediate Resistance to Vancomycin (VISA)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Streptococcal Disease, Group A, Invasive	0	0.0	0	0.0	1	1.9	0	0.0	2	3.2	0	0.0	1	1.4
Streptococcal Disease, Group B, in Newborn	0	0.0	1	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Streptococcal Toxic Shock Syndrome (STSS)	0	0.0	0	0.9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Streptococcus pneumoniae, Invasive Disease, Ages < 5 Years*	0	0.0	7	6.5	0	0.0	0	0.0	1	1.6	2	4.3	0	0.0
Streptococcus pneumoniae, Invasive Disease, Ages < 5 Tears	0	0.0	4	3.7	0	0.0	3	2.9	0	0.0	3	6.4	2	2.9
Streptococcus pneumoniae, Invasive Disease, Drug Resistant, Ages 5+ Years*	1	3.7	8	7.4	1	1.9	3	2.9	2	3.2	6	12.9	5	7.1
Toxic Shock Syndrome (TSS)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Typhoid Fever	0	0.0	0	0.0	0	0.0	0	0.0	1	1.6	0	0.0	0	0.0
Vibrio parahaemolyticus Infection	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Vibriosis, Other (Not Cholera)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
	0		1		0		-		1		0		1	
Yersiniosis SUB-TOTAL	16	0.0 58.5	87	0.9 80.2	22	0.0 41.9	0 21	0.0 20.4	22	1.6 35.4	46	0.0 98.7	41	1.4 58.4
SUB-IUTAL	10	38.3	87	80.2	22	41.9	21	20.4	22	35.4	40	98.7	41	58.4
HEPATITIS														
Hepatitis A	0	0.0	1	0.9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Hepatitis B, Acute*	0	0.0	1	0.9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Hepatitis B, Chronic*	5	18.3	8	7.4	4	7.6	6	5.8	11	17.7	1	2.1	4	5.7
Hepatitis C, Acute*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Hepatitis C, Past or Present*	15	54.9	66	60.8	15	28.6	36	35.0	40	64.3	8	17.2	32	45.6
		0.0	0	0.0	0	0.0	0		0	0.0	0		0	0.0
Hepatitis E	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	

	Ac	lams	Α	llen	Ast	nland	Asht	abula	At	nens	Aug	laize	Bel	mont
OUTBREAKS*	Ν	Rate	Ν	Rate	Ν	Rate	Ν	Rate	N	Rate	Ν	Rate	Ν	Rate
Foodborne*	0	n/a	1	n/a	1	n/a	1	n/a	0	n/a	0	n/a	0	n/a
Waterborne*	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	1	n/a	0	n/a
Unspecified*	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a
Conjunctivitis*	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a
Nosocomial*	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a
Pediculosis*	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a
Scabies*	0	n/a	1	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a
Staphylococcal Skin Infections*	0	n/a	2	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a
Unusual Incidence of Non-Class A, Class B or Class C Disease*	0	n/a	3	n/a	2	n/a	1	n/a	0	n/a	0	n/a	1	n/a
SUB-TOTAL	0	n/a	7	n/a	3	n/a	2	n/a	0	n/a	1	n/a	1	n/a
VACCINE-PREVENTABLE														
Influenza-Associated Pediatric Mortality*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Mumps	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Pertussis	2	7.3	1	0.9	7	13.3	0	0.0	5	8.0	2	4.3	0	0.0
Varicella*	0	0.0	14	12.9	64	121.9	0	0.0	30	48.2	66	141.6	20	28.5
SUB-TOTAL	2	7.3	15	13.8	71	135.2	0	0.0	35	56.2	68	145.9	20	28.5
ZOONOSES														
Anaplasmosis*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Dengue	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Ehrlichia chaffeensis*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
LaCrosse Encephalitis*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	2.1	0	0.0
Lyme Disease*	0	0.0	1	0.9	0	0.0	0	0.0	0	0.0	0	0.0	1	1.4
Malaria	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Q Fever	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Rabies, Animal*	0	n/a	1	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a
Rocky Mountain Spotted Fever (RMSF)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Toxoplasmosis, Congenital	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
West Nile Virus*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
SUB-TOTAL	0	0.0	2	0.9	0	0.0	0	0.0	0	0.0	1	2.1	1	1.4
GRAND TOTAL	38	139.0	187	165.0	115	213.2	65	61.3	108	173.6	125	266.0	99	139.5
POPULATION	27	,330	108	3,473	52	,523	102	,728	62	,223	46	,611	70	,226

	Bi	rown	Βι	ıtler	Ca	rroll	Chan	npaign	CI	ark	Cler	mont	Clii	nton
GENERAL INFECTIOUS DISEASES	N	Rate	Ν	Rate	Ν	Rate	N	Rate	Ν	Rate	N	Rate	Ν	Rate
Amebiasis	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Botulism, Foodborne*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Botulism, Infant	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Campylobacteriosis	5	11.8	23	6.9	9	31.2	1	2.6	17	11.8	6	3.4	6	14.8
Cholera	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Coccidioidomvcosis*	0	0.0	1	0.3	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Creutzfeldt-Jakob Disease (CJD)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Cryptosporidiosis	4	9.5	37	11.1	1	3.5	0	0.0	0	0.0	93	52.3	2	4.9
Cytomegalovirus (CMV), Congenital	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Encephalitis, Post Other Infection*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Encephalitis, Primary Viral	0	0.0	0	0.0	0	0.0	0	0.0	1	0.7	0	0.0	0	0.0
Escherichia coli O157:H7	0	0.0	2	0.6	0	0.0	1	2.6	2	1.4	4	2.3	0	0.0
Escherichia coli, Shiga Toxin-Producing, Not O157:H7	0	0.0	0	0.0	0	0.0	0	0.0	2	1.4	0	0.0	0	0.0
Escherichia coli, Shiga Toxin-Producing, Unknown Serotype	0	0.0	0	0.0	0	0.0	0	0.0	1	0.7	0	0.0	0	0.0
Giardiasis	5	11.8	27	8.1	2	6.9	3	7.7	6	4.2	20	11.2	1	2.5
Haemophilus influenzae, Invasive Disease	1	2.4	21	0.6	0	0.0	0	0.0	2	1.4	1	0.6	1	2.5
Hemolytic Uremic Syndrome (HUS)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.6	0	0.0
Kawasaki Disease	0	0.0	3	0.0	0	0.0	1	2.6	0	0.0	3	1.7	0	0.0
Legionellosis	0	0.0	1	0.3	1	3.5	2	5.1	4	2.8	0	0.0	1	2.5
Leprosy (Hansen's Disease)	0	0.0	0	0.0	0	0.0	0	0.0	- 4	0.0	0	0.0	0	0.0
Listeriosis	0	0.0	0	0.0	1	3.5	0	0.0	0	0.0	0	0.0	0	0.0
Meningitis, Aseptic	0	0.0	27	8.1	1	3.5	4	10.3	8	5.5	21	11.8	5	12.3
Meningitis, Other Bacterial*	0	0.0	0	0.1	0	0.0	4	0.0	0 1	0.7	0	0.0	0	0.0
	0	0.0	2	0.6	0		-	0.0	1	0.7	1	0.0	0	
Meningococcal Disease Rheumatic Fever	0	0.0	0	0.6	0	0.0	0	0.0	0	0.7	0	0.6	0	0.0
Salmonellosis	5	11.8	51		2	6.9	4	10.3	-	8.3	13	7.3	7	
	3	7.1	-	15.3		0.0	4		12	0.7	59	33.2		17.3
Shigellosis			41	12.3	0			0.0	1				0	0.0
Staphylococcus aureus, Intermediate Resistance to Vancomycin (VISA)	0	0.0	0	0.0	0	0.0	0	0.0	-	0.0	0	0.0	0	0.0
Streptococcal Disease, Group A, Invasive	0	0.0	7	2.1		3.5	0	0.0	3	2.1	3	1.7	1	2.5
Streptococcal Disease, Group B, in Newborn	1	2.4	1	0.3	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Streptococcal Toxic Shock Syndrome (STSS)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Streptococcus pneumoniae, Invasive Disease, Ages < 5 Years*	3	7.1	4	1.2	0	0.0	0	0.0	1	0.7	2	1.1	1	2.5
Streptococcus pneumoniae, Invasive Disease, Drug Resistant, Ages 5+ Years*	1	2.4	2	0.6	2	6.9	0	0.0	5	3.5	6	3.4	1	2.5
Streptococcus pneumoniae, Invasive Disease, Drug Susceptible, Ages 5+ Years*	0	0.0	9	2.7	5	17.3	3	7.7	17	11.8	14	7.9	4	9.9
Toxic Shock Syndrome (TSS)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Typhoid Fever	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Vibrio parahaemolyticus Infection	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Vibriosis, Other (Not Cholera)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Yersiniosis	0	0.0	5	1.5	0	0.0	0	0.0	3	2.1	0	0.0	0	0.0
SUB-TOTAL	28	66.2	245	73.6	25	86.7	19	48.9	87	60.1	247	138.8	30	74.0
HEPATITIS	~		~	0.0		0 -	-		-	0.0	~		6	
Hepatitis A	0	0.0	0	0.0	1	3.5	0	0.0	0	0.0	0	0.0	0	0.0
Hepatitis B, Acute*	0	0.0	0	0.0	0	0.0	1	2.6	2	1.4	2	1.1	0	0.0
Hepatitis B, Chronic*	4	9.5	56	16.8	1	3.5	2	5.1	19	13.1	20	11.2	1	2.5
Hepatitis C, Acute*	0	0.0	1	0.3	0	0.0	0	0.0	0	0.0	2	1.1	0	0.0
Hepatitis C, Past or Present*	39	92.2	236	70.9	16	55.5	21	54.0	158	109.2	162	91.0	16	39.5
Hepatitis E	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
SUB-TOTAL	43	101.7	293	88.0	18	62.4	24	61.7	179	123.7	186	104.5	17	41.9

	Br	own	Βι	utler	Ca	rroll	Chan	npaign	С	lark	Cler	mont	Cli	nton
OUTBREAKS*	N	Rate	Ν	Rate	Ν	Rate	Ν	Rate	Ν	Rate	Ν	Rate	Ν	Rate
Foodborne*	0	n/a	5	n/a	0	n/a	1	n/a	7	n/a	1	n/a	0	n/a
Waterborne*	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a
Unspecified*	0	n/a	1	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a
Conjunctivitis*	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a
Nosocomial*	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a
Pediculosis*	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a
Scabies*	0	n/a	0	n/a	0	n/a	0	n/a	1	n/a	0	n/a	0	n/a
Staphylococcal Skin Infections*	0	n/a	1	n/a	0	n/a	0	n/a	1	n/a	0	n/a	1	n/a
Unusual Incidence of Non-Class A, Class B or Class C Disease*	0	n/a	1	n/a	0	n/a	0	n/a	4	n/a	2	n/a	1	n/a
SUB-TOTAL	0	n/a	8	n/a	0	n/a	1	n/a	13	n/a	3	n/a	2	n/a
VACCINE-PREVENTABLE	1													
Influenza-Associated Pediatric Mortality*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Mumps	0	0.0	0	0.0	0	0.0	1	2.6	0	0.0	4	2.2	0	0.0
Pertussis	0	0.0	2	0.6	1	3.5	1	2.6	3	2.1	17	9.6	6	14.8
Varicella*	48	113.5	158	47.5	2	6.9	6	15.4	30	20.7	77	43.3	5	12.3
SUB-TOTAL	48	113.5	160	48.1	3	10.4	8	20.6	33	22.8	98	55.1	11	27.1
ZOONOSES														
Anaplasmosis*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Dengue	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.6	0	0.0
Ehrlichia chaffeensis*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
LaCrosse Encephalitis*	0	0.0	1	0.3	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Lyme Disease*	0	0.0	1	0.3	0	0.0	0	0.0	1	0.7	0	0.0	0	0.0
Malaria	0	0.0	1	0.3	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Q Fever	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Rabies, Animal*	0	n/a	1	n/a	0	n/a	0	n/a	5	n/a	1	n/a	0	n/a
Rocky Mountain Spotted Fever (RMSF)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.6	0	0.0
Toxoplasmosis, Congenital	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
West Nile Virus*	0	0.0	1	0.3	0	0.0	0	0.0	0	0.0	1	0.6	1	2.5
SUB-TOTAL	0	0.0	5	1.2	0	0.0	0	0.0	6	0.7	4	1.7	1	2.5
GRAND TOTAL	119	281.4	711	210.9	46	159.5	52	131.1	318	210.0	538	300.0	61	145.5
POPULATION	42	,285	332	2,807	28	,836	38	,890	144	1,742	177	,977	40	,543

	Colu	mbiana	Cosł	nocton	Cra	wford	Cuya	hoga	Da	arke	Def	iance	Dela	aware
GENERAL INFECTIOUS DISEASES	N	Rate	Ν	Rate	Ν	Rate	N	Rate	Ν	Rate	N	Rate	Ν	Rate
Amebiasis	0	0.0	0	0.0	0	0.0	2	0.1	0	0.0	0	0.0	0	0.0
Botulism, Foodborne*	0	0.0	0	0.0	0	0.0	1	0.1	0	0.0	0	0.0	0	0.0
Botulism, Infant	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Campylobacteriosis	10	8.9	3	8.2	2	4.3	163	11.7	5	9.4	5	12.7	8	7.3
Cholera	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Coccidioidomycosis*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Creutzfeldt-Jakob Disease (CJD)	0	0.0	0	0.0	0	0.0	2	0.1	0	0.0	0	0.0	0	0.0
Cryptosporidiosis	3	2.7	4	10.9	4	8.5	23	1.7	4	7.5	0	0.0	7	6.4
Cytomegalovirus (CMV), Congenital	0	0.0	0	0.0	0	0.0	3	0.2	0	0.0	0	0.0	0	0.0
Encephalitis, Post Other Infection*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Encephalitis, Primary Viral	0	0.0	0	0.0	0	0.0	3	0.2	0	0.0	0	0.0	0	0.0
Escherichia coli O157:H7	0	0.0	1	2.7	0	0.0	6	0.4	0	0.0	0	0.0	1	0.9
Escherichia coli, Shiga Toxin-Producing, Not O157:H7	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	2.5	0	0.0
Escherichia coli, Shiga Toxin-Producing, Unknown Serotype	1	0.9	1	2.7	0	0.0	0	0.0	0	0.0	1	2.5	1	0.9
Giardiasis	7	6.3	1	2.7	4	8.5	74	5.3	3	5.6	1	2.5	7	6.4
Haemophilus influenzae, Invasive Disease	1	0.0	0	0.0	0	0.0	18	1.3	1	1.9	0	0.0	0	0.0
Hemolytic Uremic Syndrome (HUS)	1	0.9	0	0.0	0	0.0	1	0.1	0	0.0	0	0.0	0	0.0
Kawasaki Disease	0	0.0	0	0.0	0	0.0	6	0.4	0	0.0	0	0.0	0	0.0
Legionellosis	1	0.9	1	2.7	0	0.0	52	3.7	0	0.0	0	0.0	2	1.8
Leprosy (Hansen's Disease)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Listeriosis	0	0.0	0	0.0	0	0.0	5	0.4	0	0.0	0	0.0	0	0.0
Meningitis, Aseptic	1	0.0	1	2.7	2	4.3	76	5.5	0	0.0	0	0.0	11	10.0
Meningitis, Other Bacterial*	0	0.9	0	0.0	0	0.0	11	0.8	0	0.0	0	0.0	0	0.0
Meningococcal Disease	0	0.0	0	0.0	0	0.0	5	0.8	0	0.0	0	0.0	0	0.0
Rheumatic Fever	0	0.0	0	0.0	0	0.0	1	0.4	0	0.0	0	0.0	0	0.0
Salmonellosis	7	6.3	3	8.2	4	8.5	150	10.8	12	22.5	9	22.8	26	23.6
	0	0.0	0	0.2	0	0.0	100	7.2	0	0.0	0	0.0	0	0.0
Shigellosis	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Staphylococcus aureus, Intermediate Resistance to Vancomycin (VISA) Streptococcal Disease, Group A, Invasive	5		1		1	2.1	28		0	0.0	1	2.5	1	
		4.5		2.7				2.0	-		0			0.9
Streptococcal Disease, Group B, in Newborn	0	0.0	0	0.0	0	0.0	11	0.8	0	0.0	-	0.0	0	0.0
Streptococcal Toxic Shock Syndrome (STSS)	0	0.0	0	0.0	0	0.0	1	0.1	0	0.0	0	0.0	0	0.0
Streptococcus pneumoniae, Invasive Disease, Ages < 5 Years*	0	0.0	0	0.0	0	0.0	13	0.9	1	1.9	0	0.0	4	3.6
Streptococcus pneumoniae, Invasive Disease, Drug Resistant, Ages 5+ Years*	4	3.6	1	2.7	0	0.0	31	2.2	0	0.0	0	0.0	2	1.8
Streptococcus pneumoniae, Invasive Disease, Drug Susceptible, Ages 5+ Years*	9	8.0	5	13.6	3	6.4	54	3.9	3	5.6	3	7.6	13	11.8
Toxic Shock Syndrome (TSS)	0	0.0	0	0.0	0	0.0	1	0.1	0	0.0	0	0.0	0	0.0
Typhoid Fever	0	0.0	0	0.0	0	0.0	1	0.1	0	0.0	0	0.0	1	0.9
Vibrio parahaemolyticus Infection	0	0.0	0	0.0	0	0.0	1	0.1	0	0.0	0	0.0	0	0.0
Vibriosis, Other (Not Cholera)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.9
Yersiniosis	1	0.9	0	0.0	0	0.0	10	0.7	0	0.0	0	0.0	1	0.9
SUB-TOTAL	51	45.5	22	60.0	20	42.6	853	61.2	29	54.4	21	53.2	86	78.2
HEPATITIS														
Hepatitis A	0	0.0	0	0.0	0	0.0	16	1.2	0	0.0	0	0.0	1	0.9
Hepatitis B, Acute*	0	0.0	0	0.0	0	0.0	24	1.7	0	0.0	0	0.0	1	0.9
Hepatitis B, Chronic*	7	6.2	2	5.5	2	4.3	315	22.6	2	3.8	3	7.6	18	16.4
Hepatitis C, Acute*	1	0.2	2	0.0	0	<u>4.3</u> 0.0	10	0.7	0	0.0	0	0.0	0	0.0
Hepatitis C, Acute Hepatitis C. Past or Present*	53	47.3	16	43.7	25	53.2	1.388	99.6	13	24.4	8	20.3	34	30.9
Hepatitis E	0	<u>47.3</u> 0.0	0	<u>43.7</u> 0.0	 0	0.0	1,388	0.1	0	0.0	0	0.0	<u> </u>	0.0
	61	54.4	18	49.1	27	57.5	1,754	125.8	15	28.1	11		54	
SUB-TOTAL	01	54.4	18	49.1	21	57.5	1,754	125.8	15	28.1	11	27.8	54	49.1

	Colu	mbiana	Cos	nocton	Cra	wford	Cuya	hoga	Da	arke	Def	ance	Dela	aware
OUTBREAKS*	Ν	Rate	Ν	Rate	Ν	Rate	N	Rate	Ν	Rate	Ν	Rate	Ν	Rate
Foodborne*	0	n/a	1	n/a	0	n/a	11	n/a	2	n/a	0	n/a	1	n/a
Waterborne*	0	n/a	0	n/a	0	n/a	3	n/a	0	n/a	0	n/a	0	n/a
Unspecified*	0	n/a	0	n/a	0	n/a	7	n/a	0	n/a	0	n/a	0	n/a
Conjunctivitis*	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	1	n/a
Nosocomial*	0	n/a	0	n/a	0	n/a	1	n/a	0	n/a	0	n/a	0	n/a
Pediculosis*	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a
Scabies*	0	n/a	0	n/a	0	n/a	2	n/a	0	n/a	0	n/a	0	n/a
Staphylococcal Skin Infections*	0	n/a	0	n/a	0	n/a	8	n/a	2	n/a	0	n/a	0	n/a
Unusual Incidence of Non-Class A, Class B or Class C Disease*	0	n/a	0	n/a	0	n/a	28	n/a	0	n/a	0	n/a	3	n/a
SUB-TOTAL	0	n/a	1	n/a	0	n/a	60	n/a	4	n/a	0	n/a	5	n/a
VACCINE-PREVENTABLE	-													
Influenza-Associated Pediatric Mortality*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Mumps	0	0.0	0	0.0	0	0.0	4	0.3	0	0.0	1	2.5	0	0.0
Pertussis	1	0.9	0	0.0	1	2.1	37	2.7	2	3.8	0	0.0	182	165.5
Varicella*	38	33.9	15	40.9	8	17.0	185	13.3	15	28.1	42	106.3	84	76.4
SUB-TOTAL	39	34.8	15	40.9	9	19.2	226	16.2	17	31.9	43	108.9	266	241.8
ZOONOSES														
Anaplasmosis*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Dengue	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	2.5	1	0.9
Ehrlichia chaffeensis*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
LaCrosse Encephalitis*	0	0.0	0	0.0	1	2.1	0	0.0	0	0.0	0	0.0	0	0.0
Lyme Disease*	1	0.9	0	0.0	0	0.0	5	0.4	0	0.0	0	0.0	1	0.9
Malaria	0	0.0	0	0.0	0	0.0	4	0.3	0	0.0	0	0.0	0	0.0
Q Fever	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	2.5	0	0.0
Rabies, Animal*	0	n/a	0	n/a	0	n/a	6	n/a	1	n/a	0	n/a	3	n/a
Rocky Mountain Spotted Fever (RMSF)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Toxoplasmosis, Congenital	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
West Nile Virus*	0	0.0	0	0.0	0	0.0	6	0.4	0	0.0	0	0.0	0	0.0
SUB-TOTAL	1	0.9	0	0.0	1	2.1	21	1.1	1	0.0	2	5.1	5	1.8
GRAND TOTAL	152	135.6	56	150.0	57	121.4	2,914	204.3	66	114.4	77	194.9	416	370.9
POPULATION	11:	2,075	36	,655	46	,966	1,393	3,978	53	,309	39	,500	109	9,989

	E	rie	Fai	rfield	Fa	yette	Frai	nklin	Fu	lton	G	allia	Gea	auga
GENERAL INFECTIOUS DISEASES	N	Rate	Ν	Rate	N	Rate	N	Rate	Ν	Rate	N	Rate	Ν	Rate
Amebiasis	0	0.0	3	2.4	0	0.0	16	1.5	0	0.0	0	0.0	0	0.0
Botulism, Foodborne*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Botulism, Infant	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Campylobacteriosis	3	3.8	8	6.5	1	3.5	70	6.6	3	7.1	0	0.0	19	20.9
Cholera	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Coccidioidomycosis*	0	0.0	1	0.8	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Creutzfeldt-Jakob Disease (CJD)	0	0.0	0	0.0	0	0.0	2	0.2	0	0.0	0	0.0	0	0.0
Cryptosporidiosis	0	0.0	1	0.8	0	0.0	25	2.3	0	0.0	0	0.0	2	2.2
Cytomegalovirus (CMV), Congenital	0	0.0	1	0.8	0	0.0	5	0.5	0	0.0	0	0.0	0	0.0
Encephalitis, Post Other Infection*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Encephalitis, Primary Viral	0	0.0	0	0.0	0	0.0	1	0.1	1	2.4	0	0.0	0	0.0
Escherichia coli O157:H7	0	0.0	0	0.0	0	0.0	4	0.4	0	0.0	1	3.2	2	2.2
Escherichia coli, Shiga Toxin-Producing, Not O157:H7	0	0.0	0	0.0	0	0.0	1	0.1	1	2.4	0	0.0	0	0.0
Escherichia coli, Shiga Toxin-Producing, Unknown Serotype	0	0.0	1	0.8	1	3.5	2	0.2	0	0.0	1	3.2	0	0.0
Giardiasis	1	1.3	9	7.3	0	0.0	110	10.3	2	4.8	0	0.0	10	11.0
Haemophilus influenzae, Invasive Disease	0	0.0	0	0.0	0	0.0	3	0.3	0	0.0	0	0.0	1	1.1
Hemolytic Uremic Syndrome (HUS)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Kawasaki Disease	0	0.0	1	0.8	0	0.0	2	0.2	0	0.0	0	0.0	0	0.0
Legionellosis	0	0.0	2	1.6	0	0.0	39	3.7	0	0.0	0	0.0	2	2.2
Leprosy (Hansen's Disease)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Listeriosis	0	0.0	0	0.0	0	0.0	4	0.4	0	0.0	0	0.0	0	0.0
Meningitis, Aseptic	0	0.0	20	16.3	1	3.5	74	6.9	0	0.0	1	3.2	5	5.5
Meningitis, Other Bacterial*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	1.1
Meningococcal Disease	1	1.3	0	0.0	0	0.0	5	0.5	0	0.0	0	0.0	0	0.0
Rheumatic Fever	0	0.0	0	0.0	0	0.0	0	0.0	1	2.4	0	0.0	0	0.0
Salmonellosis	8	10.1	22	17.9	4	14.1	123	11.5	7	16.6	6	19.3	14	15.4
Shigellosis	0	0.0	0	0.0	0	0.0	14	1.3	0	0.0	0	0.0	0	0.0
Staphylococcus aureus, Intermediate Resistance to Vancomycin (VISA)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Streptococcal Disease, Group A, Invasive	0	0.0	0	0.0	0	0.0	33	3.1	0	0.0	0	0.0	2	2.2
Streptococcal Disease, Group B, in Newborn	0	0.0	0	0.0	1	3.5	6	0.6	0	0.0	0	0.0	0	0.0
Streptococcal Disease, Gloup D, in Newborn Streptococcal Toxic Shock Syndrome (STSS)	0	0.0	0	0.0	0	0.0	4	0.0	0	0.0	0	0.0	0	0.0
Streptococcus pneumoniae, Invasive Disease, Ages < 5 Years*	0	0.0	1	0.0	0	0.0	8	0.4	0	0.0	0	0.0	0	0.0
Streptococcus pneumoniae, invasive Disease, Ages < 5 Tears	2	2.5	0	0.0	0	0.0	25	2.3	0	0.0	0	0.0	0	0.0
Streptococcus pneumoniae, Invasive Disease, Drug Resistant, Ages 5+ Years Streptococcus pneumoniae, Invasive Disease, Drug Susceptible, Ages 5+ Years*	2	2.5	4	3.3	2	7.0	87	2.3 8.1	0	0.0	0	0.0	7	7.7
Toxic Shock Syndrome (TSS)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Typhoid Fever	0	0.0	0	0.0	0	0.0	1	0.0	0	0.0	0	0.0	0	0.0
Vibrio parahaemolyticus Infection	0	0.0	0	0.0	0	0.0	0	0.1	0	0.0	0	0.0	0	0.0
Vibriosis, Other (Not Cholera)	0	0.0	0	0.0	0	0.0	1	0.0	0	0.0	0	0.0	0	
			1		-			-			-		1	0.0
Yersiniosis	0	0.0		0.8	0	0.0	7	0.7	0	0.0	0	0.0		1.1
SUB-TOTAL	17	21.4	75	61.1	10	35.2	672	62.9	15	35.6	9	29.0	66	72.6
HEPATITIS														
Hepatitis A	1	1.3	0	0.0	0	0.0	10	0.9	0	0.0	0	0.0	1	1.1
Hepatitis B, Acute*	0	0.0	0	0.0	0	0.0	15	1.4	0	0.0	0	0.0	1	1.1
Hepatitis B, Chronic*	1	1.3	20	16.3	1	3.5	730	68.3	2	4.8	2	6.4	9	9.9
Hepatitis C, Acute*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Hepatitis C, Past or Present*	20	25.1	98	79.8	5	17.6	1.144	107.0	10	23.8	31	99.8	28	30.8
Hepatitis E	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
SUB-TOTAL	22	27.7	118	96.1	6	21.1	1,899	177.6	12	28.5	33	106.2	39	42.9
		21.1	110			-1.1	1,000	111.0		20.0		100.2		

	I	Erie		rfield	Fayette		Franklin		Fulton		Gallia		Geauga	
OUTBREAKS*	Ν	Rate	Ν	Rate	N	Rate	N	Rate	Ν	Rate	Ν	Rate	Ν	Rate
Foodborne*	0	n/a	0	n/a	0	n/a	8	n/a	0	n/a	0	n/a	0	n/a
Waterborne*	0	n/a	0	n/a	0	n/a	1	n/a	0	n/a	0	n/a	0	n/a
Unspecified*	0	n/a	0	n/a	0	n/a	2	n/a	0	n/a	0	n/a	0	n/a
Conjunctivitis*	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a
Nosocomial*	0	n/a	0	n/a	1	n/a	2	n/a	0	n/a	0	n/a	0	n/a
Pediculosis*	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	1	n/a	0	n/a
Scabies*	0	n/a	0	n/a	0	n/a	3	n/a	0	n/a	0	n/a	0	n/a
Staphylococcal Skin Infections*	0	n/a	1	n/a	0	n/a	3	n/a	1	n/a	1	n/a	1	n/a
Unusual Incidence of Non-Class A, Class B or Class C Disease*	1	n/a	1	n/a	0	n/a	9	n/a	0	n/a	0	n/a	0	n/a
SUB-TOTAL	1	n/a	2	n/a	1	n/a	28	n/a	1	n/a	2	n/a	1	n/a
VACCINE-PREVENTABLE	-													
Influenza-Associated Pediatric Mortality*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Mumps	0	0.0	0	0.0	0	0.0	1	0.1	0	0.0	0	0.0	0	0.0
Pertussis	0	0.0	20	16.3	0	0.0	284	26.6	0	0.0	0	0.0	4	4.4
Varicella*	4	5.0	92	74.9	27	95.0	295	27.6	41	97.4	43	138.4	88	96.8
SUB-TOTAL	4	5.0	112	91.2	27	95.0	580	54.3	41	97.4	43	138.4	92	101.2
ZOONOSES														
Anaplasmosis*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Dengue	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Ehrlichia chaffeensis*	0	0.0	0	0.0	0	0.0	1	0.1	0	0.0	0	0.0	0	0.0
LaCrosse Encephalitis*	0	0.0	1	0.8	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Lyme Disease*	0	0.0	1	0.8	0	0.0	2	0.2	0	0.0	0	0.0	1	1.1
Malaria	0	0.0	0	0.0	0	0.0	8	0.7	0	0.0	0	0.0	4	4.4
Q Fever	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Rabies, Animal*	1	n/a	0	n/a	0	n/a	8	n/a	0	n/a	1	n/a	0	n/a
Rocky Mountain Spotted Fever (RMSF)	0	0.0	0	0.0	0	0.0	1	0.1	0	0.0	0	0.0	0	0.0
Toxoplasmosis, Congenital	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
West Nile Virus*	0	0.0	0	0.0	1	3.5	0	0.0	0	0.0	0	0.0	1	1.1
SUB-TOTAL	1	0.0	2	1.6	1	3.5	20	1.1	0	0.0	1	0.0	6	6.6
GRAND TOTAL	45	54.1	309	250.1	45	154.7	3,199	295.9	69	161.6	88	273.6	204	223.3
POPULATION	79	9,551	122	2,759	28	,433	1,068	3,978	42	.,084	31	,069	90	,895

	Gr	eene	Gue	ernsey	Ham	ilton	Han	cock	На	rdin	Har	rison	Не	enry
GENERAL INFECTIOUS DISEASES	N	Rate	N	Rate	N	Rate	Ν	Rate	Ν	Rate	N	Rate	Ν	Rate
Amebiasis	0	0.0	0	0.0	7	0.8	0	0.0	0	0.0	0	0.0	0	0.0
Botulism, Foodborne*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Botulism, Infant	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Campylobacteriosis	13	8.8	1	2.5	86	10.2	7	9.8	2	6.3	3	18.9	3	10.3
Cholera	0	0.0	0	0.0	1	0.1	0	0.0	0	0.0	0	0.0	0	0.0
Coccidioidomvcosis*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Creutzfeldt-Jakob Disease (CJD)	0	0.0	0	0.0	1	0.1	0	0.0	0	0.0	0	0.0	0	0.0
Cryptosporidiosis	2	1.4	7	17.2	115	13.6	11	15.4	0	0.0	1	6.3	0	0.0
Cytomegalovirus (CMV), Congenital	0	0.0	0	0.0	1	0.1	1	1.4	0	0.0	0	0.0	0	0.0
Encephalitis, Post Other Infection*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Encephalitis, Primary Viral	1	0.7	2	4.9	0	0.0	0	0.0	1	3.1	0	0.0	0	0.0
Escherichia coli O157:H7	0	0.0	0	0.0	8	1.0	0	0.0	1	3.1	0	0.0	0	0.0
Escherichia coli, Shiga Toxin-Producing, Not O157:H7	0	0.0	0	0.0	3	0.4	0	0.0	0	0.0	0	0.0	0	0.0
Escherichia coli, Shiga Toxin-Producing, Unknown Serotype	4	2.7	0	0.0	0	0.0	2	2.8	0	0.0	0	0.0	0	0.0
Giardiasis	7	4.7	10	24.5	70	8.3	5	7.0	1	3.1	0	0.0	1	3.4
Haemophilus influenzae, Invasive Disease	1	0.7	0	0.0	12	1.4	0	0.0	0	0.0	2	12.6	0	0.0
Hemolytic Uremic Syndrome (HUS)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Kawasaki Disease	0	0.0	0	0.0	6	0.7	0	0.0	0	0.0	0	0.0	0	0.0
Legionellosis	1	0.7	0	0.0	2	0.2	1	1.4	0	0.0	1	6.3	1	3.4
Leprosy (Hansen's Disease)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Listeriosis	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Meningitis, Aseptic	7	4.7	5	12.3	63	7.5	3	4.2	1	3.1	0	0.0	1	3.4
Meningitis, Other Bacterial*	0	0.0	0	0.0	2	0.2	0	0.0	0	0.0	0	0.0	1	3.4
Meningococcal Disease	0	0.0	0	0.0	3	0.2	0	0.0	0	0.0	0	0.0	0	0.0
Rheumatic Fever	0	0.0	0	0.0	0	0.4	0	0.0	0	0.0	0	0.0	0	0.0
Salmonellosis	14	9.5	4	9.8	119	14.1	16	22.4	3	9.4	1	6.3	5	17.1
Shigellosis	8	5.4	0	0.0	899	106.4	0	0.0	0	0.0	0	0.0	0	0.0
Staphylococcus aureus, Intermediate Resistance to Vancomycin (VISA)	0	0.0	0	0.0	000	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Streptococcal Disease, Group A, Invasive	0	0.0	0	0.0	14	1.7	0	0.0	1	3.1	0	0.0	1	3.4
Streptococcal Disease, Group B, in Newborn	3	2.0	0	0.0	2	0.2	0	0.0	0	0.0	0	0.0	0	0.0
Streptococcal Disease, Group D, in Newborn Streptococcal Toxic Shock Syndrome (STSS)	0	0.0	0	0.0	0	0.2	0	0.0	0	0.0	0	0.0	0	0.0
Streptococcus pneumoniae, Invasive Disease, Ages < 5 Years*	2	1.4	1	2.5	8	1.0	0	0.0	0	0.0	0	0.0	0	0.0
Streptococcus pneumoniae, invasive Disease, Ages < 5 rears	2	1.4	0	0.0	26	3.1	1	1.4	1	3.1	1	6.3	1	3.4
Streptococcus pneumoniae, invasive Disease, Drug Resistant, Ages 5+ Years Streptococcus pneumoniae, Invasive Disease, Drug Susceptible, Ages 5+ Years*	9	6.1	3	7.4	58	6.9	3	4.2	0	0.0	1	6.3	1	3.4
Toxic Shock Syndrome (TSS)	0	0.0	0	0.0	0	0.9	0	0.0	0	0.0	0	0.0	0	0.0
Typhoid Fever	2	1.4	0	0.0	1	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Vibrio parahaemolyticus Infection	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Vibrio paralaemolyadus intection Vibriosis, Other (Not Cholera)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
							-		-					
Yersiniosis SUB-TOTAL	0 76	0.0 51.4	0	0.0	2 1.509	0.2	0 50	0.0 70.1	0	0.0 34.4	0	0.0 63.1	0	0.0 51.4
SUB-TOTAL	70	51.4	33	80.9	1,509	1/8.5	50	70.1	11	34.4	10	03.1	15	51.4
HEPATITIS														
Hepatitis A	0	0.0	0	0.0	7	0.8	0	0.0	0	0.0	0	0.0	1	3.4
Hepatitis B, Acute*	1	0.7	0	0.0	4	0.5	0	0.0	0	0.0	0	0.0	0	0.0
Hepatitis B, Chronic*	23	15.6	2	4.9	222	26.3	10	14.0	2	6.3	0	0.0	2	6.8
Hepatitis C, Acute*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Hepatitis C, Past or Present*	78	52.7	47	115.2	1,019	120.5	29	40.7	7	21.9	13	82.0	0	0.0
Hepatitis E	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
SUB-TOTAL	102	69.0	49	120.1	1.252	148.1	39	54.7	9	28.2	13	82.0	3	10.3
JUD-TOTAL	102	09.0	43	120.1	1,252	140.1	33	34.7	3	20.2	13	02.0	3	10.3

	Gr	Greene		rnsey	Hamilton		Hancock		Hardin		Harrison		Henry	
OUTBREAKS*	N	Rate	Ν	Rate	Ν	Rate	Ν	Rate	Ν	Rate	Ν	Rate	Ν	Rate
Foodborne*	0	n/a	1	n/a	1	n/a	0	n/a	0	n/a	0	n/a	0	n/a
Waterborne*	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a
Unspecified*	1	n/a	0	n/a	5	n/a	1	n/a	0	n/a	0	n/a	0	n/a
Conjunctivitis*	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a
Nosocomial*	0	n/a	0	n/a	1	n/a	0	n/a	0	n/a	0	n/a	0	n/a
Pediculosis*	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a
Scabies*	0	n/a	0	n/a	1	n/a	0	n/a	0	n/a	0	n/a	0	n/a
Staphylococcal Skin Infections*	1	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a
Unusual Incidence of Non-Class A, Class B or Class C Disease*	0	n/a	0	n/a	7	n/a	0	n/a	0	n/a	1	n/a	1	n/a
SUB-TOTAL	2	n/a	1	n/a	15	n/a	1	n/a	0	n/a	1	n/a	1	n/a
VACCINE-PREVENTABLE														
Influenza-Associated Pediatric Mortality*	0	0.0	0	0.0	1	0.1	0	0.0	0	0.0	0	0.0	0	0.0
Mumps	0	0.0	0	0.0	1	0.1	0	0.0	0	0.0	0	0.0	0	0.0
Pertussis	2	1.4	0	0.0	18	2.1	0	0.0	0	0.0	0	0.0	0	0.0
Varicella*	169	114.3	4	9.8	174	20.6	32	44.9	25	78.3	5	31.5	10	34.2
SUB-TOTAL	171	115.6	4	9.8	194	23.0	32	44.9	25	78.3	5	31.5	10	34.2
ZOONOSES														
Anaplasmosis*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Dengue	0	0.0	0	0.0	3	0.4	0	0.0	0	0.0	0	0.0	0	0.0
Ehrlichia chaffeensis*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
LaCrosse Encephalitis*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Lyme Disease*	1	0.7	0	0.0	3	0.4	0	0.0	0	0.0	1	6.3	0	0.0
Malaria	1	0.7	0	0.0	4	0.5	0	0.0	0	0.0	0	0.0	0	0.0
Q Fever	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Rabies, Animal*	2	n/a	2	n/a	6	n/a	2	n/a	0	n/a	0	n/a	1	n/a
Rocky Mountain Spotted Fever (RMSF)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Toxoplasmosis, Congenital	1	0.7	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
West Nile Virus*	0	0.0	0	0.0	4	0.5	2	2.8	0	0.0	0	0.0	0	0.0
SUB-TOTAL	5	2.0	2	0.0	20	1.7	4	2.8	0	0.0	1	6.3	1	0.0
GRAND TOTAL	356	238.0	89	210.8	2,990	351.2	126	172.5	45	140.9	30	182.9	30	95.9
POPULATION	147	7,886	40	,792	845	,303	71	,295	31	,945	15	,856	29	,210

	Hig	hland	Но	cking	Но	Imes	Hu	ron	Jac	kson	Jeff	erson	Kı	nox
GENERAL INFECTIOUS DISEASES	N	Rate	Ν	Rate	Ν	Rate	N	Rate	Ν	Rate	Ν	Rate	Ν	Rate
Amebiasis	0	0.0	0	0.0	1	2.6	0	0.0	0	0.0	0	0.0	0	0.0
Botulism, Foodborne*	0	0.0	0	0.0	0	0.0	1	1.7	0	0.0	0	0.0	0	0.0
Botulism, Infant	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Campylobacteriosis	7	17.1	2	7.1	5	12.8	4	6.7	1	3.1	8	10.8	3	5.5
Cholera	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Coccidioidomycosis*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Creutzfeldt-Jakob Disease (CJD)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Cryptosporidiosis	0	0.0	1	3.5	0	0.0	2	3.4	0	0.0	0	0.0	4	7.3
Cytomegalovirus (CMV), Congenital	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Encephalitis, Post Other Infection*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	1.4	0	0.0
Encephalitis, Primary Viral	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	1.4	0	0.0
Escherichia coli O157:H7	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Escherichia coli, Shiga Toxin-Producing, Not O157:H7	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	1.8
Escherichia coli, Shiga Toxin-Producing, Unknown Serotype	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Giardiasis	3	7.3	0	0.0	5	12.8	8	13.5	0	0.0	4	5.4	6	11.0
Haemophilus influenzae, Invasive Disease	0	0.0	0	0.0	1	2.6	0	0.0	0	0.0	2	2.7	0	0.0
Hemolytic Uremic Syndrome (HUS)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Kawasaki Disease	1	2.5	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Legionellosis	2	4.9	0	0.0	2	5.1	1	1.7	2	6.1	3	4.1	0	0.0
Leprosy (Hansen's Disease)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Listeriosis	0	0.0	1	3.5	0	0.0	0	0.0	0	0.0	0	0.0	1	1.8
Meningitis, Aseptic	2	4.9	4	14.2	1	2.6	0	0.0	1	3.1	4	5.4	6	11.0
Meningitis, Other Bacterial*	1	2.5	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Meningococcal Disease	1	2.5	1	3.5	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Rheumatic Fever	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Salmonellosis	4	9.8	0	0.0	7	18.0	7	11.8	2	6.1	4	5.4	9	16.5
Shigellosis	4	2.5	0	0.0	1	2.6	0	0.0	0	0.0	7	9.5	0	0.0
Staphylococcus aureus, Intermediate Resistance to Vancomycin (VISA)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Stephylococcal Disease, Group A, Invasive	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	1.4	0	0.0
Streptococcal Disease, Group B, in Newborn	0	0.0	0	0.0	0	0.0	0	0.0	1	3.1	0	0.0	1	1.8
Streptococcal Disease, Gloup B, in Newborn Streptococcal Toxic Shock Syndrome (STSS)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
	3	7.3		0.0	0		-	0.0	0		0	0.0		
Streptococcus pneumoniae, Invasive Disease, Ages < 5 Years* Streptococcus pneumoniae, Invasive Disease, Drug Resistant, Ages 5+ Years*	2	4.9	0	0.0	0	0.0	0	0.0	2	0.0 6.1	1		1 3	1.8 5.5
Streptococcus pneumoniae, Invasive Disease, Drug Resistant, Ages 5+ Years Streptococcus pneumoniae, Invasive Disease, Drug Susceptible, Ages 5+ Years*		-	1	3.5			0			-	8	1.4		
	2	4.9			0	0.0	0	0.0	1	3.1		10.8	0	0.0
Toxic Shock Syndrome (TSS)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Typhoid Fever	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Vibrio parahaemolyticus Infection	-	0.0	0	0.0	0	0.0	0	0.0	-	0.0	0	0.0	0	0.0
Vibriosis, Other (Not Cholera)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Yersiniosis	0	0.0	0	0.0	0	0.0	0	0.0	1	3.1	0	0.0	0	0.0
SUB-TOTAL	29	70.9	10	35.4	23	59.1	23	38.7	11	33.7	44	59.5	35	64.2
HEPATITIS Hepatitis A	0	0.0	0	0.0	1	2.6	0	0.0	0	0.0	0	0.0	0	0.0
Hepatitis B. Acute*	0	0.0	0	0.0	0	2.6	0	0.0	0	0.0	0	0.0	0	0.0
	0	2.4	3		1	2.6	6		3	9.2	8		5	9.2
Hepatitis B, Chronic*			-	10.6				10.1				10.8		
Hepatitis C, Acute*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Hepatitis C, Past or Present*	19	46.5	17	60.2	8	20.5	28	47.1	37	113.4	58	78.5	25	45.9
Hepatitis E	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
SUB-TOTAL	20	48.9	20	70.8	10	25.7	34	57.2	40	122.5	66	89.3	30	55.0

			Holmes Huron				kson	Jeff	erson	Knox				
OUTBREAKS*	N	Rate	Ν	Rate	Ν	Rate	Ν	Rate	Ν	Rate	Ν	Rate	Ν	Rate
Foodborne*	0	n/a	1	n/a	1	n/a	0	n/a	0	n/a	0	n/a	1	n/a
Waterborne*	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a
Unspecified*	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a
Conjunctivitis*	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a
Nosocomial*	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a
Pediculosis*	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a
Scabies*	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a
Staphylococcal Skin Infections*	0	n/a	0	n/a	1	n/a	0	n/a	0	n/a	0	n/a	0	n/a
Unusual Incidence of Non-Class A, Class B or Class C Disease*	0	n/a	1	n/a	0	n/a	0	n/a	0	n/a	1	n/a	0	n/a
SUB-TOTAL	0	n/a	2	n/a	2	n/a	0	n/a	0	n/a	1	n/a	1	n/a
VACCINE-PREVENTABLE														
Influenza-Associated Pediatric Mortality*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Mumps	1	2.4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Pertussis	0	0.0	1	3.5	0	0.0	1	1.7	1	3.1	0	0.0	4	7.3
Varicella*	37	90.5	11	39.0	20	51.4	42	70.6	27	82.7	55	74.4	21	38.5
SUB-TOTAL	38	93.0	12	42.5	20	51.4	43	72.3	28	85.8	55	74.4	25	45.9
ZOONOSES														
Anaplasmosis*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Dengue	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Ehrlichia chaffeensis*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
LaCrosse Encephalitis*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Lyme Disease*	0	0.0	1	3.5	0	0.0	0	0.0	1	3.1	0	0.0	0	0.0
Malaria	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Q Fever	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Rabies, Animal*	0	n/a	0	n/a	1	n/a	0	n/a	0	n/a	0	n/a	0	n/a
Rocky Mountain Spotted Fever (RMSF)	0	0.0	1	3.5	0	0.0	0	0.0	3	9.2	0	0.0	0	0.0
Toxoplasmosis, Congenital	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
West Nile Virus*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
SUB-TOTAL	0	0.0	2	7.1	1	0.0	0	0.0	4	12.3	0	0.0	0	0.0
GRAND TOTAL	87	212.8	46	155.8	56	136.1	100	168.1	83	254.3	166	223.3	91	165.1
POPULATION	40	,875	28	,241	38	,943	59,	487	32	,641	73	,894	54	,500

	Li	ake	Law	rence	Lic	king	Lo	gan	Lo	rain	Lu	cas	Mac	dison
GENERAL INFECTIOUS DISEASES	Ν	Rate	Ν	Rate	Ν	Rate	Ν	Rate	Ν	Rate	N	Rate	Ν	Rate
Amebiasis	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Botulism, Foodborne*	0	0.0	0	0.0	0	0.0	0	0.0	1	0.4	0	0.0	0	0.0
Botulism, Infant	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Campylobacteriosis	28	12.3	2	3.2	17	11.7	4	8.7	22	7.7	53	11.7	5	12.4
Cholera	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Coccidioidomycosis*	1	0.4	0	0.0	1	0.7	0	0.0	0	0.0	0	0.0	0	0.0
Creutzfeldt-Jakob Disease (CJD)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	2	0.4	0	0.0
Cryptosporidiosis	3	1.3	1	1.6	3	2.1	1	2.2	18	6.3	21	4.6	0	0.0
Cytomegalovirus (CMV), Congenital	0	0.0	0	0.0	0	0.0	0	0.0	1	0.4	0	0.0	0	0.0
Encephalitis, Post Other Infection*	1	0.4	0	0.0	0	0.0	0	0.0	0	0.0	1	0.2	0	0.0
Encephalitis, Primary Viral	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	3	0.7	0	0.0
Escherichia coli O157:H7	0	0.0	0	0.0	0	0.0	0	0.0	1	0.4	0	0.0	1	2.5
Escherichia coli, Shiga Toxin-Producing, Not O157:H7	1	0.4	0	0.0	0	0.0	0	0.0	0	0.0	4	0.9	0	0.0
Escherichia coli, Shiga Toxin-Producing, Unknown Serotype	2	0.9	0	0.0	3	2.1	0	0.0	0	0.0	3	0.7	0	0.0
Giardiasis	26	11.4	4	6.4	5	3.4	1	2.2	19	6.7	23	5.1	0	0.0
Haemophilus influenzae, Invasive Disease	4	1.8	2	3.2	2	1.4	0	0.0	2	0.7	7	1.5	0	0.0
Hemolytic Uremic Syndrome (HUS)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	2.5
Kawasaki Disease	2	0.9	0	0.0	0	0.0	0	0.0	1	0.4	0	0.0	0	0.0
Legionellosis	2	0.9	1	1.6	6	4.1	1	2.2	6	2.1	6	1.3	0	0.0
Leprosy (Hansen's Disease)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Listeriosis	1	0.4	0	0.0	1	0.7	0	0.0	1	0.4	2	0.4	0	0.0
Meningitis, Aseptic	6	2.6	9	14.4	2	1.4	1	2.2	10	3.5	30	6.6	4	10.0
Meningitis, Other Bacterial*	1	0.4	1	1.6	0	0.0	0	0.0	1	0.4	5	1.1	0	0.0
Meningococcal Disease	1	0.4	0	0.0	0	0.0	0	0.0	1	0.4	1	0.2	0	0.0
Rheumatic Fever	1	0.4	0	0.0	0	0.0	0	0.0	0	0.4	0	0.2	0	0.0
Salmonellosis	30	13.2	4	6.4	18	12.4	1	2.2	28	9.8	52	11.4	4	10.0
Shigellosis	1	0.4	0	0.4	4	2.8	0	0.0	1	0.4	1	0.2	0	0.0
Staphylococcus aureus, Intermediate Resistance to Vancomycin (VISA)	0	0.4	0	0.0		0.0	0	0.0	0	0.4	1	0.2	0	0.0
Streptococcal Disease, Group A, Invasive	6	2.6	0	0.0	1	0.0	2	4.4	3	1.1	13	2.9	1	2.5
Streptococcal Disease, Group A, invasive	1	0.4	0	0.0	0	0.7	0	0.0	1	0.4	13	0.2	0	0.0
Streptococcal Disease, Group B, in Newborn Streptococcal Toxic Shock Syndrome (STSS)	0	0.4	0	0.0	0	0.0	0	0.0	1	0.4	1	0.2	0	0.0
	2	0.0	0	0.0	-	0.0	-	0.0	2	0.4	4	-	0	
Streptococcus pneumoniae, Invasive Disease, Ages < 5 Years* Streptococcus pneumoniae, Invasive Disease, Drug Resistant, Ages 5+ Years*			4		0		0		10		13	0.9	0	0.0
	3	1.3		6.4	7	4.8 10.3	6	13.0		3.5	31	2.9		0.0
Streptococcus pneumoniae, Invasive Disease, Drug Susceptible, Ages 5+ Years*	18	7.9	5	8.0	15		8	17.4	11	3.9		6.8	3	7.5
Toxic Shock Syndrome (TSS)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Typhoid Fever	0	0.0	-	0.0	0	0.0	0	0.0	-	0.0	1	0.0	-	0.0
Vibrio parahaemolyticus Infection	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.2	0	0.0
Vibriosis, Other (Not Cholera)	0	0.0	0	0.0	0	0.0	0	0.0	-	0.0	-	0.0	0	0.0
Yersiniosis	0	0.0	0	0.0	0	0.0	2	4.4	0	0.0	1	0.2	0	0.0
SUB-TOTAL	141	62.0	33	53.0	85	58.4	27	58.7	141	49.5	280	61.5	19	47.2
HEPATITIS Hepatitis A	2	0.9	0	0.0	1	0.7	0	0.0	1	0.4	8	1.8	0	0.0
Hepatitis B. Acute*	1	0.9	1	1.6	1	0.7	0	0.0	2	0.4	0	0.0	0	0.0
Hepatitis B, Chronic*	23	10.4	5	8.0	10	6.9	2	4.3	39	13.7	61	13.4	10	24.9
Hepatitis C, Acute*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Hepatitis C, Past or Present*	98	43.1	76	122.0	89	61.2	13	28.3	668	234.7	386	84.8	104	258.6
Hepatitis E	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
SUB-TOTAL	124	54.5	82	131.6	101	69.4	15	32.6	710	249.4	455	100.0	114	283.5

	L	Lake		rence	Licking		Logan		Lorain		Lucas		Madison	
OUTBREAKS*	Ν	Rate	Ν	Rate	Ν	Rate	Ν	Rate	Ν	Rate	Ν	Rate	Ν	Rate
Foodborne*	3	n/a	0	n/a	0	n/a	0	n/a	2	n/a	2	n/a	0	n/a
Waterborne*	1	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a
Unspecified*	1	n/a	0	n/a	0	n/a	0	n/a	2	n/a	1	n/a	0	n/a
Conjunctivitis*	0	n/a	1	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a
Nosocomial*	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a
Pediculosis*	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a
Scabies*	0	n/a	0	n/a	0	n/a	1	n/a	1	n/a	0	n/a	1	n/a
Staphylococcal Skin Infections*	0	n/a	0	n/a	0	n/a	2	n/a	0	n/a	2	n/a	3	n/a
Unusual Incidence of Non-Class A, Class B or Class C Disease*	7	n/a	0	n/a	0	n/a	1	n/a	7	n/a	3	n/a	0	n/a
SUB-TOTAL	12	n/a	1	n/a	0	n/a	4	n/a	12	n/a	8	n/a	4	n/a
VACCINE-PREVENTABLE	1													
Influenza-Associated Pediatric Mortality*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Mumps	0	0.0	0	0.0	0	0.0	0	0.0	2	0.7	0	0.0	0	0.0
Pertussis	6	2.6	1	1.6	21	14.4	2	4.3	2	0.7	7	1.5	1	2.5
Varicella*	52	22.9	91	146.0	79	54.3	30	65.2	92	32.3	97	21.3	17	42.3
SUB-TOTAL	58	25.5	92	147.6	100	68.7	32	69.6	96	33.7	104	22.9	18	44.8
ZOONOSES														
Anaplasmosis*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Dengue	0	0.0	0	0.0	0	0.0	0	0.0	1	0.4	0	0.0	0	0.0
Ehrlichia chaffeensis*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
LaCrosse Encephalitis*	0	0.0	0	0.0	1	0.7	0	0.0	0	0.0	0	0.0	0	0.0
Lyme Disease*	1	0.4	0	0.0	0	0.0	0	0.0	2	0.7	0	0.0	0	0.0
Malaria	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Q Fever	1	0.4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Rabies, Animal*	19	n/a	0	n/a	0	n/a	0	n/a	1	n/a	1	n/a	1	n/a
Rocky Mountain Spotted Fever (RMSF)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.2	0	0.0
Toxoplasmosis, Congenital	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
West Nile Virus*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	2	0.4	0	0.0
SUB-TOTAL	21	0.9	0	0.0	1	0.7	0	0.0	4	1.1	4	0.7	1	0.0
GRAND TOTAL	356	142.9	208	332.2	287	197.3	78	160.9	963	333.7	851	185.0	156	375.5
POPULATION	227	7,511	62	,319	145	5,491	46	,005	284	1,664	455	i, 0 54	40	,213

	Mah	oning	Ма	rion	Me	dina	Me	eigs	Ме	ercer	Mi	ami	Мо	onroe
GENERAL INFECTIOUS DISEASES	Ν	Rate	Ν	Rate	Ν	Rate	Ν	Rate	Ν	Rate	Ν	Rate	Ν	Rate
Amebiasis	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Botulism, Foodborne*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Botulism, Infant	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Campylobacteriosis	12	4.7	2	3.0	23	15.2	2	8.7	20	48.9	10	10.1	0	0.0
Cholera	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Coccidioidomycosis*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Creutzfeldt-Jakob Disease (CJD)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Cryptosporidiosis	4	1.6	5	7.6	13	8.6	0	0.0	37	90.4	1	1.0	0	0.0
Cytomegalovirus (CMV), Congenital	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Encephalitis, Post Other Infection*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	6.6
Encephalitis, Primary Viral	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	1.0	0	0.0
Escherichia coli O157:H7	4	1.6	1	1.5	4	2.7	0	0.0	3	7.3	1	1.0	0	0.0
Escherichia coli, Shiga Toxin-Producing, Not O157:H7	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Escherichia coli, Shiga Toxin-Producing, Unknown Serotype	1	0.4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Giardiasis	4	1.6	0	0.0	16	10.6	2	8.7	7	17.1	6	6.1	0	0.0
Haemophilus influenzae, Invasive Disease	1	0.4	0	0.0	3	2.0	0	0.0	0	0.0	2	2.0	0	0.0
Hemolytic Uremic Syndrome (HUS)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Kawasaki Disease	1	0.4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Legionellosis	2	0.8	0	0.0	5	3.3	0	0.0	0	0.0	1	1.0	0	0.0
Leprosy (Hansen's Disease)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Listeriosis	0	0.0	0	0.0	1	0.7	0	0.0	1	2.4	0	0.0	0	0.0
Meningitis, Aseptic	6	2.3	11	16.6	8	5.3	0	0.0	0	0.0	6	6.1	2	13.2
Meningitis, Aseptic	2	0.8	0	0.0	2	1.3	0	0.0	0	0.0	1	1.0	0	0.0
Meningococcal Disease	1	0.0	0	0.0	1	0.7	0	0.0	0	0.0	0	0.0	0	0.0
Rheumatic Fever	0	0.4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Salmonellosis	15	5.8	11	16.6	23	15.2	3	13.0	7	17.1	16	16.2	3	19.8
Shigellosis	10	0.4	1	1.5	0	0.0	0	0.0	4	9.8	10	1.0	0	0.0
	0	0.4	0	0.0	0	0.0	0	0.0	0	9.8	0	0.0	0	0.0
Staphylococcus aureus, Intermediate Resistance to Vancomycin (VISA)	-		1		4		-		<u> </u>				0	
Streptococcal Disease, Group A, Invasive	2	0.8		1.5		2.7	0	0.0		2.4	2	2.0		0.0
Streptococcal Disease, Group B, in Newborn	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	1.0	0	0.0
Streptococcal Toxic Shock Syndrome (STSS)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Streptococcus pneumoniae, Invasive Disease, Ages < 5 Years*	2	0.8	0	0.0	1	0.7	0	0.0	1	2.4	0	0.0	0	0.0
Streptococcus pneumoniae, Invasive Disease, Drug Resistant, Ages 5+ Years*	9	3.5	0	0.0	5	3.3	0	0.0	0	0.0	4	4.1	0	0.0
Streptococcus pneumoniae, Invasive Disease, Drug Susceptible, Ages 5+ Years*	23	8.9	0	0.0	10	6.6	0	0.0	5	12.2	7	7.1	0	0.0
Toxic Shock Syndrome (TSS)	0	0.0	0	0.0	1	0.7	0	0.0	0	0.0	0	0.0	0	0.0
Typhoid Fever	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Vibrio parahaemolyticus Infection	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Vibriosis, Other (Not Cholera)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Yersiniosis	1	0.4	1	1.5	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
SUB-TOTAL	91	35.3	33	49.8	120	79.4	7	30.3	86	210.1	60	60.7	6	39.5
HEPATITIS														
Hepatitis A	1	0.4	0	0.0	1	0.7	0	0.0	0	0.0	0	0.0	0	0.0
Hepatitis B, Acute*	6	2.3	0	0.0	1	0.7	0	0.0	0	0.0	0	0.0	0	0.0
Hepatitis B, Chronic*	22	8.5	11	16.6	14	9.3	0	0.0	3	7.3	3	3.0	0	0.0
Hepatitis C. Acute*	0	0.0	0	0.0	0	9.3 0.0	0	0.0	0	0.0	0	0.0	0	0.0
Hepatitis C, Acute Hepatitis C, Past or Present*	283	109.9	89	134.4	57	37.7	17	73.7	8	19.5	66	66.8	9	59.3
Hepatitis E	203	0.0	0	0.0	0	0.0	0	0.0	2	4.9	00	0.0	0	0.0
SUB-TOTAL	312	121.1	100	151.0	73	48.3	17	73.7	 13	4.9 31.8	69	69.8	9	59.3
SUD-IUTAL	312	121.1	100	151.0	13	46.3	17	13.1	13	31.8	69	09.8	9	59.3

	Mah	oning	Ма	rion	Ме	dina	Me	eigs	Me	ercer	Mi	ami	Мо	nroe
OUTBREAKS*	N	Rate	Ν	Rate	Ν	Rate	Ν	Rate	Ν	Rate	Ν	Rate	Ν	Rate
Foodborne*	7	n/a	1	n/a	1	n/a	0	n/a	0	n/a	0	n/a	1	n/a
Waterborne*	0	n/a	0	n/a	1	n/a	0	n/a	1	n/a	0	n/a	0	n/a
Unspecified*	0	n/a	0	n/a	1	n/a	0	n/a	0	n/a	0	n/a	0	n/a
Conjunctivitis*	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a
Nosocomial*	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a
Pediculosis*	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a
Scabies*	0	n/a	1	n/a	1	n/a	0	n/a	0	n/a	0	n/a	0	n/a
Staphylococcal Skin Infections*	1	n/a	1	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a
Unusual Incidence of Non-Class A, Class B or Class C Disease*	0	n/a	0	n/a	5	n/a	0	n/a	0	n/a	0	n/a	0	n/a
SUB-TOTAL	8	n/a	3	n/a	9	n/a	0	n/a	1	n/a	0	n/a	1	n/a
VACCINE-PREVENTABLE														
Influenza-Associated Pediatric Mortality*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Mumps	0	0.0	0	0.0	0	0.0	1	4.3	0	0.0	0	0.0	0	0.0
Pertussis	1	0.4	1	1.5	10	6.6	0	0.0	1	2.4	4	4.0	1	6.6
Varicella*	37	14.4	26	39.3	141	93.3	10	43.3	77	188.2	88	89.0	9	59.3
SUB-TOTAL	38	14.8	27	40.8	151	99.9	11	47.7	78	190.6	92	93.1	10	65.9
ZOONOSES														
Anaplasmosis*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Dengue	1	0.4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Ehrlichia chaffeensis*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
LaCrosse Encephalitis*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Lyme Disease*	1	0.4	1	1.5	0	0.0	0	0.0	0	0.0	0	0.0	1	6.6
Malaria	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Q Fever	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Rabies, Animal*	1	n/a	2	n/a	1	n/a	0	n/a	0	n/a	0	n/a	0	n/a
Rocky Mountain Spotted Fever (RMSF)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Toxoplasmosis, Congenital	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
West Nile Virus*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
SUB-TOTAL	3	0.8	3	1.5	1	0.0	0	0.0	0	0.0	0	0.0	1	6.6
GRAND TOTAL	452	172.0	166	243.1	354	227.7	35	151.7	178	432.5	221	223.5	27	171.3
POPULATION	257	7,555	66	,217	151	1,095	23	,072	40	,924	98	,868	15	,180

		gomery		organ		rrow		ingum		oble		tawa		lding
GENERAL INFECTIOUS DISEASES	N	Rate	N	Rate	N	Rate	N	Rate	N	Rate	N	Rate	N	Rate
Amebiasis	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Botulism, Foodborne*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Botulism, Infant	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Campylobacteriosis	31	5.6	4	26.9	1	3.2	3	3.6	1	7.1	3	7.3	3	14.8
Cholera	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Coccidioidomycosis*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Creutzfeldt-Jakob Disease (CJD)	1	0.2	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Cryptosporidiosis	15	2.7	0	0.0	1	3.2	0	0.0	0	0.0	1	2.4	2	9.9
Cytomegalovirus (CMV), Congenital	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Encephalitis, Post Other Infection*	1	0.2	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Encephalitis, Primary Viral	0	0.0	0	0.0	0	0.0	1	1.2	0	0.0	0	0.0	0	0.0
Escherichia coli O157:H7	3	0.5	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	4.9
Escherichia coli, Shiga Toxin-Producing, Not O157:H7	1	0.2	1	6.7	0	0.0	0	0.0	0	0.0	1	2.4	0	0.0
Escherichia coli, Shiga Toxin-Producing, Unknown Serotype	6	1.1	0	0.0	0	0.0	1	1.2	0	0.0	0	0.0	0	0.0
Giardiasis	25	4.5	0	0.0	0	0.0	11	13.0	0	0.0	2	4.9	0	0.0
Haemophilus influenzae, Invasive Disease	12	2.2	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Hemolytic Uremic Syndrome (HUS)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	2.4	0	0.0
Kawasaki Disease	4	0.7	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Legionellosis	11	2.0	0	0.0	0	0.0	4	4.7	0	0.0	0	0.0	0	0.0
Leprosy (Hansen's Disease)	1	0.2	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Listeriosis	1	0.2	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Meningitis, Aseptic	50	8.9	0	0.0	2	6.3	11	13.0	0	0.0	0	0.0	1	4.9
Meningitis, Other Bacterial*	5	0.9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Meningococcal Disease	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Rheumatic Fever	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Salmonellosis	49	8.8	1	6.7	7	22.1	10	11.8	0	0.0	7	17.1	2	9.9
Shigellosis	51	9.1	0	0.0	1	3.2	0	0.0	0	0.0	0	0.0	0	0.0
Staphylococcus aureus, Intermediate Resistance to Vancomycin (VISA)	1	0.2	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Streptococcal Disease, Group A, Invasive	12	2.2	1	6.7	0	0.0	2	2.4	0	0.0	1	2.4	0	0.0
Streptococcal Disease, Group B, in Newborn	4	0.7	0	0.0	0	0.0	3	3.6	0	0.0	0	0.0	0	0.0
Streptococcal Disease, Group B, in Newborn Streptococcal Toxic Shock Syndrome (STSS)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
	8	1.4	0	0.0	-	0.0	2	2.4	0	0.0	0		-	
Streptococcus pneumoniae, Invasive Disease, Ages < 5 Years* Streptococcus pneumoniae, Invasive Disease, Drug Resistant, Ages 5+ Years*	22		0	0.0	0					0.0	2	0.0	1	4.9
		3.9			0	0.0	5	5.9	0			4.9	0	
Streptococcus pneumoniae, Invasive Disease, Drug Susceptible, Ages 5+ Years*	57	10.2	1	6.7	2	6.3	17	20.1	1	7.1	1	2.4	3	14.8
Toxic Shock Syndrome (TSS)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Typhoid Fever	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Vibrio parahaemolyticus Infection	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Vibriosis, Other (Not Cholera)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Yersiniosis	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
SUB-TOTAL	371	66.4	8	53.7	14	44.3	70	82.8	2	14.2	19	46.4	13	64.1
HEPATITIS														
Hepatitis A	3	0.5	1	6.7	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Hepatitis B. Acute*	14	2.5	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Hepatitis B, Chronic*	138	24.7	0	0.0	2	6.3	10	11.8	3	21.3	1	2.4	0	0.0
Hepatitis C, Acute*	130	0.2	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Hepatitis C, Past or Present*	632	113.0	2	13.4	17	53.7	53	62.7	33	234.7	7	17.1	3	14.8
Hepatitis E	032	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
SUB-TOTAL	788	141.0	3	20.1	19	60.1	63	74.5	36	256.1	8	19.5	3	
SUD-TUTAL	/00	141.0	3	20.1	19	60.1	03	74.5	30	200.1	Ö	19.5	3	14.8

N = number of cases reported. Rates use 2000 U.S. Census counts and are per 100,000 population. n/a = not applicable. * Please see Technical Notes (pp. 73-77).

	Monto	gomery	Мо	rgan	Мо	rrow	Musk	ingum	N	oble	Ot	tawa	Pau	Ilding
OUTBREAKS*	Ν	Rate	Ν	Rate	Ν	Rate	Ν	Rate	Ν	Rate	Ν	Rate	Ν	Rate
Foodborne*	1	n/a	0	n/a	2	n/a	1	n/a	0	n/a	0	n/a	1	n/a
Waterborne*	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a
Unspecified*	2	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a
Conjunctivitis*	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a
Nosocomial*	1	n/a	0	n/a	0	n/a	1	n/a	0	n/a	0	n/a	0	n/a
Pediculosis*	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a
Scabies*	1	n/a	0	n/a	0	n/a	1	n/a	0	n/a	0	n/a	0	n/a
Staphylococcal Skin Infections*	0	n/a	0	n/a	1	n/a	0	n/a	0	n/a	0	n/a	0	n/a
Unusual Incidence of Non-Class A, Class B or Class C Disease*	4	n/a	0	n/a	0	n/a	2	n/a	0	n/a	0	n/a	0	n/a
SUB-TOTAL	9	n/a	0	n/a	3	n/a	5	n/a	0	n/a	0	n/a	1	n/a
VACCINE-PREVENTABLE							-							
Influenza-Associated Pediatric Mortality*	1	0.2	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Mumps	5	0.9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Pertussis	28	5.0	1	6.7	6	19.0	1	1.2	0	0.0	0	0.0	0	0.0
Varicella*	112	20.0	2	13.4	10	31.6	25	29.6	21	149.4	13	31.7	12	59.1
SUB-TOTAL	146	26.1	3	20.1	16	50.6	26	30.7	21	149.4	13	31.7	12	59.1
ZOONOSES														
Anaplasmosis*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Dengue	1	0.2	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Ehrlichia chaffeensis*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
LaCrosse Encephalitis*	1	0.2	0	0.0	0	0.0	1	1.2	0	0.0	0	0.0	0	0.0
Lyme Disease*	1	0.2	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Malaria	3	0.5	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Q Fever	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Rabies, Animal*	4	n/a	0	n/a	0	n/a	1	n/a	0	n/a	0	n/a	0	n/a
Rocky Mountain Spotted Fever (RMSF)	2	0.4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Toxoplasmosis, Congenital	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
West Nile Virus*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
SUB-TOTAL	12	1.4	0	0.0	0	0.0	2	1.2	0	0.0	0	0.0	0	0.0
GRAND TOTAL	1,326	234.9	14	94.0	52	154.9	166	189.2	59	419.7	40	97.6	29	138.0
POPULATION	559	,062	14	,897	31	,628	84	,585	14	,058	40	,985	20	,293

	P	erry	Picl	kaway	F	Pike	Por	tage	Pr	eble	Put	tnam	Rich	hland
GENERAL INFECTIOUS DISEASES	N	Rate	N	Rate	Ν	Rate	N	Rate	N	Rate	N	Rate	N	Rate
Amebiasis	0	0.0	0	0.0	0	0.0	0	0.0	1	2.4	0	0.0	0	0.0
Botulism, Foodborne*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Botulism, Infant	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Campylobacteriosis	3	8.8	0	0.0	5	18.1	8	5.3	4	9.5	6	17.3	14	10.9
Cholera	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Coccidioidomycosis*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Creutzfeldt-Jakob Disease (CJD)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.8
Cryptosporidiosis	1	2.9	1	1.9	0	0.0	1	0.7	3	7.1	3	8.6	5	3.9
Cytomegalovirus (CMV), Congenital	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	3	2.3
Encephalitis, Post Other Infection*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Encephalitis, Primary Viral	0	0.0	1	1.9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Escherichia coli O157:H7	0	0.0	1	1.9	0	0.0	2	1.3	0	0.0	0	0.0	1	0.8
Escherichia coli, Shiga Toxin-Producing, Not O157:H7	0	0.0	0	0.0	0	0.0	0	0.0	1	2.4	0	0.0	0	0.0
Escherichia coli, Shiga Toxin-Producing, Unknown Serotype	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Giardiasis	2	5.9	3	5.7	1	3.6	9	5.9	3	7.1	1	2.9	8	6.2
Haemophilus influenzae, Invasive Disease	0	0.0	0	0.0	1	3.6	0	0.0	0	0.0	0	0.0	1	0.2
Hemolytic Uremic Syndrome (HUS)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	2.9	0	0.0
Kawasaki Disease	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Legionellosis	1	2.9	1	1.9	1	3.6	2	1.3	1	2.4	0	0.0	2	1.6
Leprosy (Hansen's Disease)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Listeriosis	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Meningitis, Aseptic	5	14.7	5	9.5	4	14.4	18	11.8	1	2.4	4	11.5	10	7.8
Meningitis, Other Bacterial*	0	0.0	1	1.9	1	3.6	0	0.0	0	0.0	0	0.0	1	0.8
Meningococcal Disease	0	0.0	1	1.9	0	0.0	0	0.0	0	0.0	0	0.0	2	1.6
Rheumatic Fever	0	0.0	0	0.0	1	3.6	0	0.0	0	0.0	0	0.0	0	0.0
Salmonellosis	5	14.7	5	9.5	1	3.6	26	17.1	5	11.8	2	5.8	8	6.2
Shigellosis	0	0.0	0	0.0	0	0.0	20	1.3	1	2.4	0	0.0	0	0.2
	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Staphylococcus aureus, Intermediate Resistance to Vancomycin (VISA) Streptococcal Disease, Group A, Invasive	0		2		-	0.0	5		1	2.4	0		5	
	-	0.0		3.8	0			3.3	0		-	0.0	-	3.9
Streptococcal Disease, Group B, in Newborn	0	0.0	0	0.0	0	0.0	0	0.0	-	0.0	0	0.0	4	3.1
Streptococcal Toxic Shock Syndrome (STSS)	0	0.0	0	0.0	0	0.0	1	0.7	0	0.0	0	0.0	0	0.0
Streptococcus pneumoniae, Invasive Disease, Ages < 5 Years*	0	0.0	0	0.0	0	0.0	2	1.3	1	2.4	1	2.9	2	1.6
Streptococcus pneumoniae, Invasive Disease, Drug Resistant, Ages 5+ Years*	0	0.0	3	5.7	0	0.0	2	1.3	0	0.0	0	0.0	3	2.3
Streptococcus pneumoniae, Invasive Disease, Drug Susceptible, Ages 5+ Years*	0	0.0	5	9.5	1	3.6	6	4.0	3	7.1	1	2.9	5	3.9
Toxic Shock Syndrome (TSS)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Typhoid Fever	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Vibrio parahaemolyticus Infection	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Vibriosis, Other (Not Cholera)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Yersiniosis	0	0.0	1	1.9	0	0.0	0	0.0	2	4.7	0	0.0	0	0.0
SUB-TOTAL	17	49.9	30	56.9	16	57.8	84	55.2	27	63.8	19	54.7	75	58.2
HEPATITIS														
Hepatitis A	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Hepatitis B, Acute*	0	0.0	0	0.0	0	0.0	1	0.7	0	0.0	1	2.9	0	0.0
Hepatitis B, Chronic*	5	14.7	48	91.0	3	10.8	17	11.2	0	0.0	1	2.9	13	10.1
Hepatitis C, Acute*	0	0.0	-40	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Hepatitis C, Past or Present*	13	38.1	818	1.551.4	30	108.3	94	61.8	16	37.8	5	14.4	131	101.7
Hepatitis E	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
SUB-TOTAL	18	52.8	866	1,642.4	33	119.2	112	73.7	16	37.8	7	20.2	144	111.8
SUD-TUTAL	10	52.8	000	1,042.4	- 33	119.2	112	13.1	10	37.8	1	20.2	144	0.111

N = number of cases reported. Rates use 2000 U.S. Census counts and are per 100,000 population. n/a = not applicable. * Please see Technical Notes (pp. 73-77).

	P	erry	Picl	kaway	P	Pike	Por	tage	Pr	eble	Put	nam	Ricl	hland
OUTBREAKS*	Ν	Rate	Ν	Rate	Ν	Rate	N	Rate	Ν	Rate	Ν	Rate	Ν	Rate
Foodborne*	0	n/a	1	n/a	0	n/a	0	n/a	0	n/a	0	n/a	1	n/a
Waterborne*	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a
Unspecified*	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a
Conjunctivitis*	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a
Nosocomial*	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a
Pediculosis*	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a
Scabies*	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a
Staphylococcal Skin Infections*	0	n/a	0	n/a	0	n/a	1	n/a	0	n/a	0	n/a	1	n/a
Unusual Incidence of Non-Class A, Class B or Class C Disease*	0	n/a	1	n/a	1	n/a	0	n/a	0	n/a	0	n/a	3	n/a
SUB-TOTAL	0	n/a	2	n/a	1	n/a	1	n/a	0	n/a	0	n/a	5	n/a
VACCINE-PREVENTABLE														
Influenza-Associated Pediatric Mortality*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Mumps	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Pertussis	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	68	52.8
Varicella*	16	47.0	16	30.3	17	61.4	138	90.8	80	189.0	8	23.0	23	17.8
SUB-TOTAL	16	47.0	16	30.3	17	61.4	138	90.8	80	189.0	8	23.0	91	70.6
ZOONOSES														
Anaplasmosis*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Dengue	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.8
Ehrlichia chaffeensis*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
LaCrosse Encephalitis*	0	0.0	0	0.0	1	3.6	0	0.0	0	0.0	0	0.0	1	0.8
Lyme Disease*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Malaria	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	2	1.6
Q Fever	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Rabies, Animal*	0	n/a	0	n/a	0	n/a	2	n/a	0	n/a	0	n/a	1	n/a
Rocky Mountain Spotted Fever (RMSF)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Toxoplasmosis, Congenital	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
West Nile Virus*	0	0.0	0	0.0	0	0.0	0	0.0	1	2.4	0	0.0	0	0.0
SUB-TOTAL	0	0.0	0	0.0	1	3.6	2	0.0	1	2.4	0	0.0	5	3.1
GRAND TOTAL	51	149.7	914	1,729.7	68	241.9	337	219.6	124	292.9	34	97.9	320	243.7
POPULATION	34	l,078	52	.,727	27	,695	152	2,061	42	,337	34	,726	128	3,852

	R	oss	San	dusky	Sc	ioto	Sei	neca	Sh	elby	St	ark	Sun	nmit
GENERAL INFECTIOUS DISEASES	N	Rate	N	Rate	N	Rate	Ν	Rate	N	Rate	N	Rate	N	Rate
Amebiasis	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	2	0.4
Botulism, Foodborne*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Botulism, Infant	0	0.0	0	0.0	1	1.3	0	0.0	0	0.0	0	0.0	0	0.0
Campylobacteriosis	14	19.1	6	9.7	10	12.6	10	17.0	3	6.3	51	13.5	61	11.2
Cholera	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Coccidioidomycosis*	0	0.0	1	1.6	0	0.0	0	0.0	1	2.1	0	0.0	2	0.4
Creutzfeldt-Jakob Disease (CJD)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Cryptosporidiosis	4	5.5	6	9.7	2	2.5	1	1.7	2	4.2	25	6.6	10	1.8
Cytomegalovirus (CMV), Congenital	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Encephalitis, Post Other Infection*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Encephalitis, Primary Viral	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	2	0.5	2	0.4
Escherichia coli O157:H7	0	0.0	3	4.9	1	1.3	1	1.7	0	0.0	2	0.5	2	0.4
Escherichia coli, Shiga Toxin-Producing, Not O157:H7	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Escherichia coli, Shiga Toxin-Producing, Unknown Serotype	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.0	1	0.0
Giardiasis	3	4.1	5	8.1	9	11.4	1	1.7	2	4.2	40	10.6	75	13.8
Haemophilus influenzae, Invasive Disease	0	0.0	0	0.0	0	0.0	2	3.4	0	0.0	2	0.5	9	1.7
Hemolytic Uremic Syndrome (HUS)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.3	0	0.0
Kawasaki Disease	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	3	0.6
Legionellosis	3	4.1	0	0.0	1	1.3	0	0.0	0	0.0	9	2.4	17	3.1
Leprosy (Hansen's Disease)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Listeriosis	0	0.0	0	0.0	1	1.3	0	0.0	0	0.0	2	0.5	2	0.0
Meningitis, Aseptic	10	13.6	2	3.2	36	45.5	0	0.0	2	4.2	59	15.6	37	6.8
Meningitis, Other Bacterial*	0	0.0	0	0.0	1	1.3	0	0.0	1	2.1	1	0.3	1	0.8
	-		0						0	0.0	-			
Meningococcal Disease	0	0.0	•	0.0	0	0.0	0	0.0	-		1	0.3	3	0.6
Rheumatic Fever	0	0.0	0	0.0	0	0.0 10.1	0	0.0 15.3	0	0.0	0 35	0.0 9.3	0 53	0.0
Salmonellosis	6	8.2	13	21.0	8		9		11	23.0				9.8
Shigellosis		0.0	0	0.0	0	0.0	0	0.0	2	4.2	6	1.6	51	9.4
Staphylococcus aureus, Intermediate Resistance to Vancomycin (VISA)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Streptococcal Disease, Group A, Invasive	0	0.0	2	3.2	1	1.3	2	3.4	1	2.1	7	1.9	24	4.4
Streptococcal Disease, Group B, in Newborn	0	0.0	1	1.6	0	0.0	0	0.0	0	0.0	4	1.1	0	0.0
Streptococcal Toxic Shock Syndrome (STSS)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	2	0.5	2	0.4
Streptococcus pneumoniae, Invasive Disease, Ages < 5 Years*	2	2.7	0	0.0	2	2.5	0	0.0	0	0.0	5	1.3	6	1.1
Streptococcus pneumoniae, Invasive Disease, Drug Resistant, Ages 5+ Years*	2	2.7	1	1.6	5	6.3	1	1.7	1	2.1	21	5.6	19	3.5
Streptococcus pneumoniae, Invasive Disease, Drug Susceptible, Ages 5+ Years*	6	8.2	3	4.9	7	8.8	3	5.1	1	2.1	26	6.9	39	7.2
Toxic Shock Syndrome (TSS)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Typhoid Fever	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	3	0.6
Vibrio parahaemolyticus Infection	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.2
Vibriosis, Other (Not Cholera)	0	0.0	1	1.6	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Yersiniosis	1	1.4	0	0.0	0	0.0	0	0.0	0	0.0	4	1.1	2	0.4
SUB-TOTAL	51	69.5	44	71.2	85	107.3	30	51.1	27	56.4	306	80.9	427	78.7
HEPATITIS														
Hepatitis A	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	5	1.3	2	0.4
Hepatitis B, Acute*	0	0.0	0	0.0	3	3.8	0	0.0	0	0.0	3	0.8	17	3.1
Hepatitis B, Chronic*	15	20.5	2	3.2	21	26.5	4	6.8	0	0.0	49	13.0	84	15.5
Hepatitis C, Acute*	0	0.0	0	0.0	1	1.3	4	0.0	0	0.0	49	0.3	0	0.0
Hepatitis C, Acute Hepatitis C. Past or Present*	118	160.9	23	37.2	217	274.0	21	35.8	28	58.4	285	75.4	386	71.1
Hepatitis E	0	0.0	23	0.0	0	0.0	0	0.0	28	0.0	285	0.0	0	0.0
	133		25	40.5	242	305.6	25	42.6	28	58.4	343	90.7	489	
SUB-TOTAL	133	181.3	25	40.5	242	305.6	25	42.0	28	58.4	343	90.7	489	90.1

N = number of cases reported. Rates use 2000 U.S. Census counts and are per 100,000 population. n/a = not applicable. * Please see Technical Notes (pp. 73-77).

	R	oss	San	dusky	Sc	ioto	Ser	neca	Sh	elby	St	ark	Sur	nmit
OUTBREAKS*	Ν	Rate	Ν	Rate	Ν	Rate	Ν	Rate	Ν	Rate	N	Rate	N	Rate
Foodborne*	0	n/a	1	n/a	0	n/a	0	n/a	1	n/a	4	n/a	4	n/a
Waterborne*	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a
Unspecified*	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	2	n/a
Conjunctivitis*	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a
Nosocomial*	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	1	n/a
Pediculosis*	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a
Scabies*	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	1	n/a
Staphylococcal Skin Infections*	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a
Unusual Incidence of Non-Class A, Class B or Class C Disease*	1	n/a	7	n/a	0	n/a	1	n/a	1	n/a	2	n/a	2	n/a
SUB-TOTAL	1	n/a	8	n/a	0	n/a	1	n/a	2	n/a	6	n/a	10	n/a
VACCINE-PREVENTABLE	-													
Influenza-Associated Pediatric Mortality*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Mumps	0	0.0	0	0.0	0	0.0	0	0.0	2	4.2	0	0.0	1	0.2
Pertussis	3	4.1	0	0.0	4	5.1	0	0.0	2	4.2	2	0.5	12	2.2
Varicella*	5	6.8	27	43.7	56	70.7	20	34.1	13	27.1	148	39.1	277	51.0
SUB-TOTAL	8	10.9	27	43.7	60	75.8	20	34.1	17	35.5	150	39.7	290	53.4
ZOONOSES														
Anaplasmosis*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.3	1	0.2
Dengue	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.2
Ehrlichia chaffeensis*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
LaCrosse Encephalitis*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Lyme Disease*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	3	0.6
Malaria	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.2
Q Fever	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Rabies, Animal*	1	n/a	0	n/a	0	n/a	0	n/a	0	n/a	1	n/a	2	n/a
Rocky Mountain Spotted Fever (RMSF)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Toxoplasmosis, Congenital	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
West Nile Virus*	0	0.0	0	0.0	0	0.0	1	1.7	0	0.0	1	0.3	0	0.0
SUB-TOTAL	1	0.0	0	0.0	0	0.0	1	1.7	0	0.0	3	0.5	8	1.1
GRAND TOTAL	194	261.8	104	155.4	387	488.7	77	129.5	74	150.3	808	211.8	1,224	223.2
POPULATION	73	,345	61	,792	79	,195	58,	683	47	,910	378	3,098	542	,899

	Tru	mbull	Tusc	arawas	U	nion	Van	Wert	Vi	nton	Wa	rren	Wash	nington
GENERAL INFECTIOUS DISEASES	N	Rate	N	Rate	N	Rate	N	Rate	N	Rate	N	Rate	N	Rate
Amebiasis	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Botulism, Foodborne*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Botulism, Infant	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Campylobacteriosis	21	9.3	17	18.7	2	4.9	2	6.7	2	15.6	25	15.8	5	7.9
Cholera	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Coccidioidomycosis*	1	0.4	0	0.0	1	2.4	0	0.0	0	0.0	0	0.0	0	0.0
Creutzfeldt-Jakob Disease (CJD)	0	0.0	1	1.1	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Cryptosporidiosis	8	3.6	2	2.2	3	7.3	0	0.0	0	0.0	35	22.1	0	0.0
Cytomegalovirus (CMV), Congenital	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Encephalitis, Post Other Infection*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Encephalitis, Primary Viral	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Escherichia coli O157:H7	1	0.4	0	0.0	0	0.0	1	3.4	0	0.0	1	0.6	0	0.0
Escherichia coli, Shiga Toxin-Producing, Not O157:H7	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Escherichia coli, Shiga Toxin-Producing, Unknown Serotype	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	3	1.9	1	1.6
Giardiasis	10	4.4	16	17.6	4	9.8	3	10.1	0	0.0	18	11.4	0	0.0
Haemophilus influenzae , Invasive Disease	4	1.8	2	2.2	4	0.0	1	3.4	1	7.8	2	1.3	0	0.0
Hemolytic Uremic Syndrome (HUS)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Kawasaki Disease	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	4	2.5	0	0.0
Legionellosis	6	2.7	0	0.0	0	0.0	0	0.0	0	0.0	3	1.9	1	1.6
Leprosy (Hansen's Disease)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Listeriosis	1	0.0	3	3.3	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
	7	3.1		<u> </u>	4	9.8	0	0.0	1	7.8	15	9.5	5	7.9
Meningitis, Aseptic		-	-	0.0	4			0.0	0	-	0		2	
Meningitis, Other Bacterial*	0	0.0	0		-	0.0	0		-	0.0	-	0.0		3.2
Meningococcal Disease	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Rheumatic Fever	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Salmonellosis	21	9.3	15	16.5	13	31.8	1	3.4	0	0.0	22	13.9	7	11.1
Shigellosis	0	0.0	0	0.0	2	4.9	0	0.0	0	0.0	13	8.2	0	0.0
Staphylococcus aureus, Intermediate Resistance to Vancomycin (VISA)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Streptococcal Disease, Group A, Invasive	6	2.7	1	1.1	0	0.0	0	0.0	2	15.6	7	4.4	0	0.0
Streptococcal Disease, Group B, in Newborn	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Streptococcal Toxic Shock Syndrome (STSS)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Streptococcus pneumoniae, Invasive Disease, Ages < 5 Years*	2	0.9	1	1.1	0	0.0	0	0.0	0	0.0	5	3.2	0	0.0
Streptococcus pneumoniae, Invasive Disease, Drug Resistant, Ages 5+ Years*	6	2.7	2	2.2	0	0.0	2	6.7	1	7.8	3	1.9	0	0.0
Streptococcus pneumoniae, Invasive Disease, Drug Susceptible, Ages 5+ Years*	26	11.6	7	7.7	2	4.9	0	0.0	2	15.6	4	2.5	3	4.7
Toxic Shock Syndrome (TSS)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Typhoid Fever	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.6	0	0.0
Vibrio parahaemolyticus Infection	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Vibriosis, Other (Not Cholera)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Yersiniosis	0	0.0	1	1.1	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
SUB-TOTAL	120	53.3	78	85.8	31	75.8	10	33.7	9	70.3	161	101.7	24	37.9
HEPATITIS														
Hepatitis A	0	0.0	1	1.1	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Hepatitis B, Acute*	16	7.1	1	1.1	0	0.0	0	0.0	0	0.0	1	0.6	1	1.6
Hepatitis B, Chronic*	42	18.7	3	3.3	16	39.1	4	13.5	0	0.0	42	26.5	7	11.1
Hepatitis C, Acute*	1	0.4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Hepatitis C, Past or Present*	181	80.4	32	35.2	200	488.9	18	60.7	10	78.1	111	70.1	65	102.8
Hepatitis E	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
SUB-TOTAL	240	106.6	37	40.7	216	528.0	22	74.2	10	78.1	154	97.2	73	115.4

N = number of cases reported. Rates use 2000 U.S. Census counts and are per 100,000 population. n/a = not applicable. * Please see Technical Notes (pp. 73-77).

	Tru	mbull	Tusc	arawas	Ur	nion	Van	Wert	Vi	nton	Wa	rren	Wash	ington
OUTBREAKS*	Ν	Rate	Ν	Rate	Ν	Rate	Ν	Rate	Ν	Rate	Ν	Rate	Ν	Rate
Foodborne*	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a
Waterborne*	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	1	n/a	0	n/a
Unspecified*	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a
Conjunctivitis*	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a
Nosocomial*	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a
Pediculosis*	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a
Scabies*	0	n/a	0	n/a	0	n/a	0	n/a	1	n/a	0	n/a	0	n/a
Staphylococcal Skin Infections*	0	n/a	0	n/a	0	n/a	0	n/a	1	n/a	0	n/a	0	n/a
Unusual Incidence of Non-Class A, Class B or Class C Disease*	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a
SUB-TOTAL	0	n/a	0	n/a	0	n/a	0	n/a	2	n/a	1	n/a	0	n/a
VACCINE-PREVENTABLE	_													
Influenza-Associated Pediatric Mortality*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Mumps	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.6	0	0.0
Pertussis	0	0.0	24	26.4	9	22.0	0	0.0	1	7.8	6	3.8	5	7.9
Varicella*	82	36.4	61	67.1	40	97.8	17	57.3	6	46.9	37	23.4	5	7.9
SUB-TOTAL	82	36.4	85	93.5	49	119.8	17	57.3	7	54.7	44	27.8	10	15.8
ZOONOSES														
Anaplasmosis*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Dengue	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Ehrlichia chaffeensis*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
LaCrosse Encephalitis*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Lyme Disease*	1	0.4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Malaria	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Q Fever	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Rabies, Animal*	0	n/a	0	n/a	1	n/a	2	n/a	0	n/a	1	n/a	0	n/a
Rocky Mountain Spotted Fever (RMSF)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Toxoplasmosis, Congenital	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
West Nile Virus*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
SUB-TOTAL	1	0.4	0	0.0	1	0.0	2	0.0	0	0.0	1	0.0	0	0.0
GRAND TOTAL	443	196.8	200	220.0	297	723.6	51	165.2	28	203.0	361	226.7	107	169.2
POPULATION	225	5,116	90	,914	40	,909	29	659	12	,806	158	,383	63	,251

	W	ayne	Wil	liams	W	ood	Wva	andot	Unk	nown	тот	AL
GENERAL INFECTIOUS DISEASES	N	Rate	N	Rate	N	Rate	N	Rate	N	Rate	N	Rate
Amebiasis	0	0.0	0	0.0	0	0.0	0	0.0	0	n/a	33	0.3
Botulism, Foodborne*	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	3	0.0
Botulism, Infant	0	0.0	0	0.0	0	0.0	0	0.0	0	n/a	1	0.0
Campylobacteriosis	20	17.9	1	2.6	9	7.4	1	4.4	0	n/a	1,083	9.5
Cholera	0	0.0	0	0.0	0	0.0	0	0.0	0	n/a	1	0.0
Coccidioidomycosis*	0	0.0	0	0.0	0	0.0	0	0.0	0	n/a	11	0.1
Creutzfeldt-Jakob Disease (CJD)	0	0.0	0	0.0	0	0.0	0	0.0	0	n/a	10	0.1
Cryptosporidiosis	0	0.0	0	0.0	5	4.1	0	0.0	0	n/a	611	5.4
Cytomegalovirus (CMV), Congenital	0	0.0	0	0.0	1	0.8	0	0.0	0	n/a	16	0.1
Encephalitis, Post Other Infection*	0	0.0	0	0.0	0	0.0	0	0.0	0	n/a	5	0.0
Encephalitis, Primary Viral	0	0.0	1	2.6	0	0.0	1	4.4	0	n/a	24	0.2
Escherichia coli O157:H7	1	0.9	0	0.0	4	3.3	0	0.0	0	n/a	80	0.7
Escherichia coli, Shiga Toxin-Producing, Not O157:H7	0	0.0	0	0.0	0	0.0	0	0.0	0	n/a	19	0.2
Escherichia coli, Shiga Toxin-Producing, Unknown Serotype	0	0.0	0	0.0	1	0.8	0	0.0	0	n/a	39	0.3
Giardiasis	7	6.3	0	0.0	13	10.7	1	4.4	0	n/a	833	7.3
Haemophilus influenzae, Invasive Disease	1	0.9	0	0.0	2	1.7	0	0.0	0	n/a	114	1.0
Hemolytic Uremic Syndrome (HUS)	1	0.9	0	0.0	4	3.3	0	0.0	0	n/a	12	0.1
Kawasaki Disease	0	0.0	0	0.0	0	0.0	0	0.0	0	n/a	38	0.3
Legionellosis	4	3.6	0	0.0	1	0.8	0	0.0	0	n/a	231	2.0
Leprosy (Hansen's Disease)	0	0.0	0	0.0	0	0.0	0	0.0	0	n/a	1	0.0
Listeriosis	0	0.0	0	0.0	2	1.7	0	0.0	0	n/a	33	0.3
Meningitis, Aseptic	11	9.9	1	2.6	8	6.6	0	0.0	0	n/a	816	7.2
Meningitis, Other Bacterial*	0	0.0	0	0.0	0	0.0	0	0.0	0	n/a	49	0.4
Meningococcal Disease	0	0.0	0	0.0	0	0.0	0	0.0	0	n/a	32	0.3
Rheumatic Fever	0	0.0	0	0.0	0	0.0	0	0.0	0	n/a	4	0.0
Salmonellosis	16	14.3	2	5.1	15	12.4	1	4.4	0	n/a	1,323	11.7
Shigellosis	0	0.0	0	0.0	0	0.0	0	0.0	0	n/a	1,277	11.3
Staphylococcus aureus, Intermediate Resistance to Vancomycin (VISA)	0	0.0	0	0.0	0	0.0	0	0.0	0	n/a	2	0.0
Streptococcal Disease, Group A, Invasive	0	0.0	0	0.0	0	0.0	0	0.0	0	n/a	226	2.0
Streptococcal Disease, Group B, in Newborn	1	0.9	0	0.0	0	0.0	0	0.0	0	n/a	49	0.4
Streptococcal Toxic Shock Syndrome (STSS)	0	0.0	0	0.0	0	0.0	0	0.0	0	n/a	12	0.1
Streptococcus pneumoniae, Invasive Disease, Ages < 5 Years*	1	0.9	0	0.0	1	0.8	0	0.0	0	n/a	117	1.0
Streptococcus pneumoniae, Invasive Disease, Drug Resistant, Ages 5+ Years*	1	0.9	0	0.0	5	4.1	0	0.0	0	n/a	302	2.7
Streptococcus pneumoniae, Invasive Disease, Drug Susceptible, Ages 5+ Years*	4	3.6	0	0.0	6	5.0	1	4.4	0	n/a	736	6.5
Toxic Shock Syndrome (TSS)	0	0.0	0	0.0	0	0.0	0	0.0	0	n/a	2	0.0
Typhoid Fever	0	0.0	0	0.0	0	0.0	0	0.0	0	n/a	11	0.1
Vibrio parahaemolyticus Infection	0	0.0	0	0.0	0	0.0	0	0.0	0	n/a	3	0.0
Vibriosis, Other (Not Cholera)	0	0.0	0	0.0	0	0.0	0	0.0	0	n/a	3	0.0
Yersiniosis	1	0.9	0	0.0	0	0.0	0	0.0	0	n/a	52	0.5
SUB-TOTAL	69	61.8	5	12.8	77	63.6	5	21.8	0	n/a	8,214	72.4
HEPATITIS												
Hepatitis A	3	2.7	0	0.0	0	0.0	0	0.0	0	n/a	69	0.6
Hepatitis B, Acute*	1	0.9	0	0.0	0	0.0	0	0.0	1	n/a	124	1.1
Hepatitis B, Chronic*	8	7.2	1	2.6	10	8.3	1	4.4	130	n/a	2,427	21.4
Hopetitic C. Acuto*	0	0.0		0.0	1	0.0		0.0	.00	n/a	10	0.2

N = number of cases reported.

Hepatitis C, Past or Present*

Rates use 2000 U.S. Census counts and are per 100,000 population. n/a = not applicable.

* Please see Technical Notes (pp. 73-77).

Hepatitis C, Acute*

Hepatitis E

SUB-TOTAL

0.0

26.0

0.0

36.8

0

10

0

11

0.0

25.5

0.0

28.1

1

25

0

36

0.8

20.7

0.0

29.7

0

2

0

3

0.0

8.7

0.0

13.1

0

623

0

754

n/a

n/a

n/a

n/a

19

11,319

3

13,961

0.2

99.7

0.0

123.0

0

29

0

41

		iyne	VV III	iams	W	ood	Wya	andot	Unk	nown	то	TAL
OUTBREAKS*	Ν	Rate	Ν	Rate	N	Rate	Ν	Rate	N	Rate	Ν	Rate
Foodborne*	0	n/a	0	n/a	3	n/a	1	n/a	0	n/a	83	n/a
Waterborne*	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	9	n/a
Unspecified*	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	26	n/a
Conjunctivitis*	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	2	n/a
Nosocomial*	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	8	n/a
Pediculosis*	0	n/a	0	n/a	0	n/a	0	n/a	0	n/a	1	n/a
Scabies*	1	n/a	0	n/a	0	n/a	0	n/a	0	n/a	18	n/a
Staphylococcal Skin Infections*	0	n/a	0	n/a	2	n/a	0	n/a	0	n/a	39	n/a
Unusual Incidence of Non-Class A, Class B or Class C Disease*	0	n/a	0	n/a	1	n/a	0	n/a	0	n/a	117	n/a
SUB-TOTAL	1	n/a	0	n/a	6	n/a	1	n/a	0	n/a	303	n/a
VACCINE-PREVENTABLE			•				2		•	,		
Influenza-Associated Pediatric Mortality*	0	0.0	0	0.0	0	0.0	0	0.0	0	n/a	2	0.0
Mumps	0	0.0	0	0.0	1	0.8	0	0.0	0	n/a	26	0.2
Pertussis	2	1.8	0	0.0	0	0.0	0	0.0	0	n/a	837	7.4
Varicella*	50	44.8	1	2.6	29	24.0	22	96.0	0	n/a	4,364	38.4
SUB-TOTAL	52	46.6	1	2.6	30	24.8	22	96.0	0	n/a	5,229	46.1
ZOONOSES												
Anaplasmosis*	0	0.0	0	0.0	0	0.0	0	0.0	0	n/a	2	0.0
Dengue	0	0.0	0	0.0	0	0.0	0	0.0	0	n/a	11	0.1
Ehrlichia chaffeensis*	0	0.0	0	0.0	0	0.0	0	0.0	0	n/a	1	0.0
LaCrosse Encephalitis*	0	0.0	0	0.0	0	0.0	0	0.0	0	n/a	9	0.1
Lyme Disease*	0	0.0	0	0.0	1	0.8	0	0.0	0	n/a	34	0.3
Malaria	0	0.0	0	0.0	0	0.0	0	0.0	0	n/a	28	0.2
Q Fever	0	0.0	0	0.0	0	0.0	0	0.0	0	n/a	2	0.0
Rabies, Animal*	1	n/a	0	n/a	1	n/a	0	n/a	0	n/a	86	n/a
Rocky Mountain Spotted Fever (RMSF)	0	0.0	0	0.0	0	0.0	0	0.0	0	n/a	9	0.1
Toxoplasmosis, Congenital	0	0.0	0	0.0	0	0.0	0	0.0	0	n/a	1	0.0
West Nile Virus*	0	0.0	0	0.0	1	0.8	0	0.0	0	n/a	23	0.2
SUB-TOTAL	1	0.0	0	0.0	3	1.7	0	0.0	0	n/a	206	1.1
GRAND TOTAL	164	145.2	17	43.4	152	119.8	31	131.0	754	n/a	27,913	242.4
POPULATION	111	.564	30	.188	121	.065	22	.908		0	11 35	3.140

SEROTYPE	2003*	2004	2005	2006	2007
Aberdeen	0	0	0	2	0
Adelaide	2	0	0	2	1
Agbeni	4	1	5	8	3
Ago Agona	0	0	0	1	0
Ajiobo	0	1	0	0	0
Alachua	0	2	0	0	0
Albany	0	0	0	2	1
Anatum	7	6	7	8	5
Арара	0	0	0	0	1
Apeyeme	0	1	1	0	0
Aqua	0	0	1	0	0
Augustenborg	0	0	1	0	0
Babelsberg Baildon	0	1	0	0	0
Bareilly	2	10	3	3	3
Barranquilla	0	0	0	0	1
Berta	4	5	1	15	10
Blockley	1	2	3	2	0
Bonariensis	0	0	0	1	0
Bovis-morbificans	4	2	11	4	2
Braenderup	31	38	57	20	12
Brandenburg	5	1	1	0	3
Brazil	0	0	1	0	0
Bredeney	1	1	0	2	0
Bsilla	0	1	0	0	0
California Carmel	0	0	0	1	0
Carrau	1	0	0	0	0
Cerro	1	0	0	1	0
Chester	0	0	0	1	3
Choleraesuis	0	1	1	0	0
Choleraesuis, var Kunzendorf	1	1	0	0	0
Coeln	0	1	0	0	0
Colindale	0	0	1	0	0
Cubana	4	1	0	1	1
Derby	5	4	3	5	5
Dublin Durban	4	0	0	0	5
Ealing	0	0	1	0	1
Eastbourne	2	0	0	0	1
Edinburg	0	0	1	1	0
Elomrane	0	1	0	0	0
Enteritidis	259	228	284	280	268
Farsta	0	1	0	0	0
Gaminara	2	1	1	1	0
Georgia	1	0	0	0	0
Give	8	7	4	2	1
Give, var 15 +	1	0	0	0	1
Gombe	0	1	0	0	0
Grumpensis Guinea	0	0	0	1	1
Hadar	6	4	5	9	6
Haifa	0	1	0	0	1
Hartford	32	11	21	27	25
Havana	2	1	2	0	0
Heidelberg	54	56	66	46	47
Hindmarsh	0	0	1	2	0
Holcomb	0	0	1	1	1
Hvittingfoss	0	2	1	1	1
Indiana	4	1	0	1	0
Infantis	10	5	18	8	12
Irumu	0	0	0	0	1
Isangi Javiana	1 16	0 38	0 26	1 44	0
Johannesburg	1	1	20	1	2
Kaapstad	1	0	0	0	0
naupsiau		0	0	0	0

N = number of cases reported.
% = percentage of cases with the serotype occurring for the year.
* Please see Technical Notes (pp. 73-77).

SEROTYPE	2003*	2004	2005	2006	2007
Kaduna	0	0	0	1	0
Kapemba	0	1	0	0	0
Kedougou	0	0	1	0	0
Kentucky Kiambu	1	0	1	3	0
Kingabwa	0	0	1	0	2
Kingston	0	0	1	0	0
Kintambo	2	2	0	0	0
Kokomlemle	1	0	0	0	0
Kotu	0	0	1	0	0
Labadi	0	0	0	0	2
Lexington	0	2	0	0	0
Lindenburg	0	0	1	0	0
Litchfield Liverpool	7	5	1	6 0	10
Livingstone	0	0	0	1	0
Loma Linda	1	0	1	0	1
London	. 1	1	1	1	1
Madelia	0	0	0	1	0
Manhattan	1	1	0	4	3
Matadi	0	1	0	0	1
Mbandaka	1	3	11	8	6
Meleagridis	1	0	0	5	4
Mendoza	0	6	1	0	0
Miami	3	2	6	1	0
Michigan Minnesota	0	0	0	1	0
Mississippi	6	0	3	9	3
Monschaui	2	0	2	0	0
Montevideo	28	19	24	25	19
Morotai	0	1	0	0	0
Muenchen	18	15	11	17	17
Muenster	3	0	2	3	1
Muenster, var 15 +	0	0	1	0	0
Newport	100	80	80	71	58
Nima Norwich	0	0	2	0	0
Ohio	3	2	1	1	5
Oranienburg	35	16	23	30	51
Oslo	1	1	1	0	0
Othmarschen	0	0	1	0	0
Overschie	0	0	0	1	0
Panama	0	3	2	1	12
Paratyphi A	1	6	2	6	7
Paratyphi B	3	11	1	1	1
Paratyphi B, var L - Tartrate + Paratyphi B, var Tartrate +	0 44	20 7	38 0	15 28	11 40
Parera	1	0	0	0	- 4 0
Poano	1	2	0	0	0
Pomona	2	5	4	1	1
Poona	4	2	6	5	10
Potsdam	0	0	0	0	1
Putten	1	0	0	0	0
Reading	2	3	2	0	2
Roodepoort Rubislaw	0	0	1 0	0	0
Saint Paul	25	15	23	16	9
Saint Paul Sal. (I) 3,10,19:g,s,t:-	25	0	0	0	0
Sal. (I) 4,5,12:i:-	1	1	0	30	88
Sal. (I) 6,7:-:5	0	0	0	0	4
Sal. (I) 6,7:b:-	0	0	0	0	1
Sal. (I) 6,8:d:-	0	0	0	0	1
Sal. (I) 6,14,25:b:-	0	1	0	0	0
Sal. (I) 9,12:I,z28:-	0	0	1	0	0
Sal. (I) 9,12:Non-motile	0	1	1	0	0
Sal. (I) 43:k:-	0	0	0	1	0
Sal. (I) 44:z4	0	0	1	0	0

N = number of cases reported.
% = percentage of cases with the serotype occurring for the year.
* Please see Technical Notes (pp. 73-77).

SEROTYPE	2003*	2004	2005	2006	2007
Sal. (I) Rough:d:1,2	0	0	1	0	0
Sal. (I) Rough:r:e,n,x	0	0	0	1	0
Sal. (II) 9,12:d:x	1	0	0	0	0
Sal. (II) 9,46:m,t:x	0	1	0	0	0
Sal. (II) 21:z10:- Sal. (II) 47:a:1,5 (Bilthoven)	0	0	0	0	0
Sal. (II) 47.a. 1,5 (Bithoven) Sal. (II) 50:b:z6	1	0	0	0	0
Sal. (II) 58:1,z13,z28:z6	0	1	0	0	0
Sal. (III) Arizona	3	3	0	4	0
Sal. (IIIa) 13,23:H Undetermined	1	0	0	0	0
Sal. (IIIa) 13,23:z4,:-	0	0	0	0	1
Sal. (IIIa) 21:g,z51:-	0	0	1	0	0
Sal. (IIIa) 35:z4,z23:-	0	0	1	0	0
Sal. (IIIa) 41:z4,z23:-	0	1	2	0	1
Sal. (IIIa) 42:z4,z23:- Sal. (IIIa) 42:z4,z24:-	0	0	0	1	0
Sal. (IIIa) 42:24,224. Sal. (IIIa) 51:z4,223:-	0	1	0	0	0
Sal. (IIIa) 53:z4	0	0	0	2	0
Sal. (IIIa) 53:z4,z23:-	0	0	1	0	0
Sal. (IIIb) 48:i:z	0	0	0	2	0
Sal. (IIIb) 50:1,v:z35	0	1	0	0	0
Sal. (IIIb) 53:z10:z	0	0	0	1	0
Sal. (IIIb) 60:r:e,n,x,z15	1	0	0	0	0
Sal. (IIIb) 60:r:z	0	1	0	0	0
Sal. (IIIb) 61:c:z35	1 0	0	2	2	0
Sal. (IIIb) 61:k:1,5 Sal. (IIIb) 61:l,v,z13:1,5	0	1	0	0	0
Sal. (IIIb) 61:1,v,z13:z35	1	0	0	0	0
Sal. (IIIb) 61:I,v:z35	0	1	0	0	0
Sal. (IIIb) 61:r:z53	1	0	0	0	0
Sal. (IIIb) 61:-:1,5	0	0	1	0	1
Sal. (IIIb) 65:(k):z53	0	0	0	1	0
Sal. (IV)	0	0	0	1	0
Sal. (IV) 6,7:z4,z24:- (Kralendyk)	0	1	0	0	0
Sal. (IV) 16:z4,z32:- (Chameleon)	0	0	2	0	1
Sal. (IV) 40:z4,z32:- Sal. (IV) 41:z4,z23:-	0	0	1	0	0
Sal. (IV) 44:24:-	0	0	0	1	0
Sal. (IV) 44:z4,z23:-	2	1	1	2	1
Sal. (IV) 44:z4,z32:-	0	0	1	0	1
Sal. (IV) 45:g,z51:-	1	2	2	3	1
Sal. (IV) 48:g,z51:- (Marina)	2	2	1	2	4
Sal. (IV) 50:g,z51:- (Wassenaar)	2	0	1	0	2
Sal. (IV) 50:z4,z23:- (Flint)	0	1	0	2	0
Sal. Rough Os:f,g:-	0	0	0	0	1
Sal. Rough Os:g,m,s:- Sal. Rough Os:z4,z23:-	0	0	0	0	1
San Diego	5	6	6	9	3
Schwartzengrund	3	2	0	7	13
Senftenberg	1	1	1	2	6
Senftenberg, var Rz27	0	0	1	0	0
Shubra	1	0	1	1	0
Singapore	0	0	2	0	0
Sinstorf	0	1 6	0	0	1 12
Stanley Stanleyville	6 0	0	4	5	12 0
Stoneferry	0	0	0	0	0
Sundsvall	1	0	0	0	0
Tallahassee	1	0	0	0	0
Telelkebir	0	1	7	1	0
Tennessee	2	5	10	13	20
Thompson	55	19	17	18	28
Thompson, var 14 +	0	1	0	0	0
Tucson	0	0	2	0	0
Typhimurium	246	196	207	177	182
Typhimurium, var Copenhagen	1	35	42	45	37
Uganda	0	0	0	1	0

N = number of cases reported.
% = percentage of cases with the serotype occurring for the year.
* Please see Technical Notes (pp. 73-77).

SEROTYPE	2003*	2004	2005	2006	2007
Uganda, var 15 +	1	0	0	0	0
Urbana	3	5	1	2	1
Uzaramo	1	1	0	0	1
Virchow	1	4	2	2	2
Wandsworth	0	1	0	0	0
Waycross	0	0	1	0	0
Weltevreden	2	1	1	0	1
Westhampton	0	1	0	0	0
Woodinville	1	0	0	0	0
Worthington	1	0	0	1	1
SUB-TOTAL	1,146	989	1,155	1,133	1,163

SEROGROUP Group A Group B Group C Group C1 Group C2 Group D Group E Group G SUB-TOTAL

UNGROUPED, UNTYPED	99	88	75	87	121
GRAND TOTAL	1,326	1,195	1,343	1,299	1,323

MENINGOCOCCAL DISEASE SEROGROUPS BY YEAR OF ONSET, OHIO, 2003-2007

SEROGROUP	2003*	2004	2005	2006	2007
Group A	0	0	0	0	0
Group B	11	18	19	16	6
Group C	9	13	9	10	7
Group W-135	0	0	1	2	2
Group X	0	1	0	0	0
Group Y	19	21	9	8	10
Group Z	1	0	1	0	0
Unknown	20	10	6	14	7
TOTAL	60	63	45	50	32

PROFILES OF SELECTED NOTIFIABLE DISEASES

CHOLERA

Number of cases in 2007:	1	Rate in 2007:	0.0
Number of cases in 2006:	0	Rate in 2006:	0.0

* Rates are based on U.S. Census midpoint estimates for each year and are per 100,000 population.

Cholera is caused by a Gram-negative, rod-shaped bacterium, *Vibrio cholerae* serogroup O1 or O139, which produces potent toxins. These toxins cause acute, violent diarrhea and dehydration that can lead to death within two to three hours if untreated. Cholera is acquired from ingestion of food or water contaminated with toxigenic *V. cholerae*. The organism can be found in humans, coastal waters, fish and shellfish. Cholera occurs worldwide, but is rare in the United States. Most cases of cholera in the United States are attributed to travel to endemic areas or the consumption of raw/undercooked seafood.¹

The single case of cholera that occurred in 2007 was the first case reported in Ohio since 1993. The causative agent was characterized as *V. cholerae* serogroup O1, biotype El Tor, serotype Ogawa. This case acquired cholera while in Pakistan.

CRYPTOSPORIDIOSIS


Number of cases in 2007:	611	Rate in 2007:	5.3	
Number of cases in 2006:	366	Rate in 2006:	3.2	

* Rates are based on U.S. Census midpoint estimates for each year and are per 100,000 population.

Cryptosporidiosis is a diarrheal disease caused by microscopic parasites of the genus *Cryptosporidium: Cryptosporidium parvum, Cryptosporidium hominis, Cryptosporidium meleagridis, Cryptosporidium muris, Cryptosporidium felis* and *Cryptosporidium canis.*² Cryptosporidiosis is characterized by watery diarrhea, abdominal cramps, low-grade fever, weight loss, dehydration, loss of appetite, nausea and vomiting.³ The parasite is transmitted via the fecal-oral route; a person becomes infected by swallowing the parasite. *Cryptosporidium* is shed in the stool from an infected person or animal. As a result, *Cryptosporidium* is found in water, soil, food or other surfaces contaminated with infected feces.

Over the past two decades, cryptosporidiosis has become known as one of the most widespread causes of waterborne disease in humans in the United States.⁴ In 2005, southwest Ohio experienced a multi-county outbreak of cryptosporidiosis at a community swimming pool. This outbreak involved residents in Brown, Butler, Clermont, Clinton, Hamilton, Highland and Warren counties.

As seen in Figure 1, the incidence of cryptosporidiosis in Ohio and in the United States has increased over the past five years. Ohio's rate was above the national rate for cryptosporidiosis infection for the five years compared.



Ohio data for 2003 are by year of report. Ohio data for 2004-2007 are by year of onset.
Source of U.S. disease data: Nationally Notifiable Diseases Surveillance System (NNDSS) Annual Summary of Notifiable Diseases for 2003-2006. U.S. data for 2007 are provisional NNDSS data published in MMWR Vol. 56, Nos. 51 and 52.
Source of Ohio disease data: Ohio Department of Health Infectious Disease Surveillance.
Source of population data: U.S. Census midpoint estimates.

ENTEROHEMORRHAGIC ESCHERICHIA COLI


Number of cases in 2007:	138	Rate in 2007:	1.2	
Number of cases in 2006:	211	Rate in 2006:	1.8	

* Rates are based on U.S. Census midpoint estimates for each year and are per 100,000 population.

This infection is caused by *Escherichia coli*, a Gram-negative, rod-shaped bacterium that produces shiga toxins. It is also known as shiga toxin-producing *E. coli*. Persons infected with enterohemorrhagic *E. coli* usually experience mild to severe diarrhea without fever. Humans and cattle are the primary sources for shiga toxin-producing *E. coli*, and disease is mainly transmitted by water and food contaminated with human or animal waste.⁵ Enterohemorrhagic *E. coli* occurs worldwide, but is mostly recognized in developed countries.⁶ More cases occur during the summer months and among children.⁵

In Ohio, enterohemorrhagic *E. coli* infections are characterized as one of three reportable conditions: *E. coli* O157:H7, *E. coli* not O157:H7 and *E. coli* of an unknown serotype. Infections caused by *E. coli* O157:H7 or *E. coli* O157:Non-motile (unflagellated) are classified as enterohemorrhagic *E. coli* O157:H7. Infections caused by shiga toxin-producing *E. coli* bacteria of a known serotype other than O157:H7 or O157:Non-motile are reported as enterohemorrhagic *E. coli* not O157:H7. Shiga toxin-producing *E. coli* bacteria that are isolated but not serotyped are reported as enterohemorrhagic *E. coli* unknown serotype.

The majority of enterohemorrhagic *E. coli* infections in 2007 were caused by O157:H7 (Figure 2). However, shiga toxin-producing serotypes other than O157:H7 and unknown serotypes were also reported. Like previous years, cases of disease due to *E. coli* O157:H7 increased beginning in May, peaked July through September and declined the remainder of the year. Infections attributed to *E. coli* not O157:H7 followed this same seasonal pattern; however, incidence of *E. coli* unknown serotype infections peaked later, in October.



HAEMOPHILUS INFLUENZAE, INVASIVE DISEASE


Number of cases in 2007:	114	Rate in 2007:	1.0	
Number of cases in 2006:	93	Rate in 2006:	0.8	

* Rates are based on U.S. Census midpoint estimates for each year and are per 100,000 population.

Haemophilus influenzae (*H. influenzae*) is caused by a Gram-negative encapsulated coccobacillus bacterium that can cause a variety of infections and produce an assortment of clinical syndromes.⁷ In Ohio, only invasive disease due to *H. influenzae* is reportable. Several types of invasive disease may be caused by *H. influenzae*, including meningitis, bacteremia, cellulitis, epiglottitis, osteomyelitis, pericarditis, pneumonia or septic arthritis. *H. influenzae* is spread from person to person by direct contact with respiratory secretions or through airborne respiratory droplets. *H. influenzae* can be part of the normal bacterial flora of the upper respiratory tract, and asymptomatic carriers are a source of infection.

Invasive disease due to *H. influenzae* is primarily a disease of the elderly, those with compromised immune systems and under-vaccinated or unvaccinated children. Few cases of invasive *H. influenzae* type b (Hib) are reported in Ohio each year since the introduction of the Hib vaccine in the United States in 1990. Infants are recommended to receive three primary doses of the Hib vaccine at 2, 4 and 6 months of age.⁸ A booster dose is also recommended between 12-15 months of age.

The greatest burden of invasive disease from *H. influenzae* in Ohio from 2003-2007 occurred among children less than 1 year of age and adults 80 years of age and older (Figure 3). Although less than 4 percent (three of 78) of all cases among children less than 5 years of age were reported with invasive Hib during the five-year period, the true morbidity that may have been preventable through vaccination is unknown. Sixty-four percent (50 of 78) of cases reported among children less than 5 years of age 2003-2007 did not report a serotype (i.e., were blank or unknown). Storing isolates for further serotyping is strongly encouraged for this high-risk age group so the true burden of disease among the very young is better understood.




LEGIONELLOSIS

Number of cases in 2007:	231	Rate in 2007:	2.0	
Number of cases in 2006:	237	Rate in 2006:	2.1	

* Rates are based on U.S. Census midpoint estimates for each year and are per 100,000 population.

Legionellosis is a respiratory infection caused by *Legionella*, a Gram-negative, rod-shaped bacterium. Most infections are attributed to *Legionella pneumophila* serogroup 1, but any *Legionella* organism can cause disease. Two distinct illnesses are associated with legionellosis: Legionnaires' disease and Pontiac fever. Legionnaires' disease is characterized by fever, myalgia, cough and pneumonia. Pontiac fever is a milder respiratory illness without pneumonia. *Legionella* bacteria are ubiquitous in water and have been identified in ponds, lakes, creeks, cooling towers, air conditioners, hot and cold water taps, showers and hot tubs. Legionellosis is transmitted via the airborne route, mainly through inhalation of aerosolized water. Cases occur most frequently in the summer and fall. Persons at greatest risk for acquiring disease are over 50 years of age, smoke and are immunocompromised.⁹

As seen in Figure 4, nearly all cases of legionellosis reported in 2003-2007 were Legionnaires' disease (93 percent). The incidence of legionellosis increased with age and peaked in individuals 80 years and older. Few to no cases were reported in children, adolescents and young adults. The very few cases of Pontiac fever reported mostly occurred in 70-79-year-olds. More cases were reported with an unknown type of infection as age increased; however, only 6 percent of cases were reported with an unknown type of infection over the past five years.




LISTERIOSIS

Number of cases in 2007:	33	Rate in 2007:	0.3	
Number of cases in 2006:	43	Rate in 2006:	0.4	

* Rates are based on U.S. Census midpoint estimates for each year and are per 100,000 population.

Listeriosis is an infection caused by consuming food contaminated with the bacterium *Listeria monocytogenes*. Symptoms of listeriosis include fever, muscle aches and sometimes gastrointestinal symptoms such as nausea or diarrhea.¹⁰ If the infection spreads to the nervous system, symptoms can include headache, stiff neck, confusion and/or convulsions. Those at greatest risk for complications from listeriosis include pregnant women, newborns and adults with weakened immune systems.¹⁰ Only invasive disease due to *L. monocytogenes* is reportable in Ohio.

Figure 5 demonstrates the age distribution of invasive listeriosis disease over the past five years. The majority of cases occurred in individuals over 59 years of age (111 cases, 61 percent). Neonatal cases accounted for 12 percent of invasive listeriosis disease during this same time period.



MENINGITIS, ASEPTIC

Number of cases in 2007:	816	Rate in 2007:	7.1	
Number of cases in 2006:	905	Rate in 2006:	7.9	

* Rates are based on U.S. Census midpoint estimates for each year and are per 100,000 population.

Aseptic meningitis refers to meningitis for which a cause is unapparent after initial evaluation. The majority of cases are caused by viruses, most often involving enteroviruses such as coxsackie virus and echovirus, but can also be caused by herpes simplex virus, mumps virus, measles virus, varicella zoster virus, lymphocytic choriomeningitis virus and adenovirus. Other causes of meningitis include invasive infection by bacteria, protozoans, rickettsiae, helminths or fungi; cases of meningitis with these etiologies are not reported as aseptic meningitis.¹

Symptoms of aseptic meningitis include headache, fever, malaise and anorexia followed by stiff neck and irritability. Abdominal pain, nausea and vomiting also commonly occur. Humans are the primary source for most viral etiologies, and transmission depends on the viral agent. For enteroviruses, infection is transmitted through direct contact with the respiratory secretions or feces of an infected person; airborne transmission through respiratory droplets also occurs. The incidence of aseptic meningitis peaks in the late summer and early fall, and most cases occur among infants and children.¹


The majority of aseptic meningitis cases in Ohio 2006-2007 were of an unknown etiology (Table 1). Among cases where an agent was specified, an enterovirus was most often identified over the past two years (26 percent) followed by herpes simplex virus (6 percent). Less common viral etiologies included JC virus, varicella zoster virus, coxsackie B virus, Epstein-Barr virus, adenovirus, echovirus and cytomegalovirus.

Etiologia Agonto	20	006	2007		Total	
Etiologic Agents	N	%	Ν	%	N	%
Unknown	626	69%	502	62%	1,128	66%
Enterovirus	213	24%	231	28%	444	26%
Herpes Simplex virus	43	5%	56	7%	99	6%
JC virus	6	1%	10	1%	16	1%
Varicella Zoster virus	4	0%	6	1%	10	1%
Coxsackie B virus	4	0%	5	1%	9	1%
Epstein-Barr virus	3	0%	3	0%	6	0%
Adenovirus	4	0%	0	0%	4	0%
Echovirus	0	0%	3	0%	3	0%
Cytomegalovirus	2	0%	0	0%	2	0%
Total	905	100%	816	100%	1,721	100%

Table 1: Reported Etiologic Agents for Aseptic Meningitis, Ohio.

Source of disease data: Ohio Department of Health Infectious Disease Surveillance.

Like previous years, aseptic meningitis followed a seasonal pattern in Ohio during 2007 (Figure 6). Cases increased beginning in June and peaked in August. The most dramatic increase in incidence occurred among infants and children aged 0-9 years, which increased fourfold from 13 cases in June to 59 cases in August. Adults 30 years and over demonstrated a higher burden of disease throughout the year except in July and August; however, the incidence among this age group experienced a longer and more gradual increase from March to August as compared to other age groups.



MENINGOCOCCAL DISEASE


Number of cases in 2007:	32	Rate in 2007:	0.3	
Number of cases in 2006:	50	Rate in 2006:	0.4	

* Rates are based on U.S. Census midpoint estimates for each year and are per 100,000 population.

Meningococcal disease is an invasive infection of *Neisseria meningitidis*, a Gram-negative, sphere-shaped bacterium usually found grouped in pairs. There are 13 serogroups of *N. meningitidis*; the most common in the United States are groups B, C and Y.¹² Individuals infected with *N. meningitidis* most commonly experience meningitis and/or meningococcemia. Meningococcemia is characterized by fever, chills, malaise, prostration and a rash. Other complications such as bacteremia, pneumonia, septic arthritis, conjunctivitis and pericarditis can also occur. Meningococcal disease is spread person to person through infected respiratory droplets. An estimated 5 percent to 25 percent of the population is asymptomatically colonized with the bacteria; these carriers play a major role in transmission of disease. Incidence in the United States is greatest among children less than 5 years of age, especially infants 3 to 5 months of age.¹³

Two vaccines are available in the United States for individuals aged 2 years and older that protect against meningococcal disease caused by groups A, C, Y and W-135. The Advisory Committee on Immunization Practices recommends the meningococcal vaccine for all adolescents and persons at risk, including college freshmen living in dormitories, microbiologists routinely exposed to *N. meningitidis*, military recruits, persons traveling to countries where meningococcal disease is endemic and persons with certain immune system disorders.¹⁴

As seen in Figure 7, the highest incidence of meningococcal disease in Ohio occurred among infants when compared to all other age groups combined during 2007 (six cases per 100,000). Meningococcal disease among children aged 1-4 years was lower, at one case per 100,000. No cases occurred in children 5-9 years, but there was a slight increase in the rate of disease for teenagers and young adults aged 15-24 years. Most adults had a low incidence of disease, but the burden of disease among adults 80 years and older was approximately one case per 100,000. The majority of group B meningococcal serogroups, which are not included in current vaccines, occurred in infants and young children, while the incidence of invasive disease among the remaining serogroups was distributed fairly evenly across age groups. Serogroup information was not reported for 22 percent of cases. Although the greatest burden of disease in Ohio is found among infants, preventing disease in this vulnerable population remains a challenge because current vaccines are not approved for use in infants.



PERTUSSIS


Number of cases in 2007:	837	Rate in 2007:	7.3	
Number of cases in 2006:	594	Rate in 2006:	5.2	

* Rates are based on U.S. Census midpoint estimates for each year and are per 100,000 population.

Pertussis, otherwise known as whooping cough, is an acute, infectious disease caused by the bacterium *Bordetella pertussis* (*B. pertussis*).¹⁵ Symptoms initially include a mild upper respiratory infection, resembling the common cold. Episodes of a more severe, rapid cough and high-pitched "whoop" generally follow and may last for several weeks. Coughing attacks may occur more frequently at night and result in a discharge of thick, clear mucous. Pertussis is spread by direct contact with the discharges from the nose and/or throat of infected persons. An infected person can transmit pertussis from the onset of symptoms to three weeks after the initial coughing episode. Pertussis can occur at any age, with infants being at the greatest risk for complications and death. Adolescents and adults do not usually exhibit the classic inspiratory whoop often seen in the very young with *B. pertussis*. This can lead to the misdiagnosis and underreporting of cases and transmission to susceptible infants.

The DTaP (diphtheria, tetanus toxoids and acellular pertussis) vaccine is recommended for all infants at 2, 4 and 6 months of age.¹⁵ An additional dose of DTaP vaccine is recommended at 15-18 months of age and 4-6 years of age.

The majority of pertussis cases in Ohio are reported among children less than 5 years of age (Figure 8). However, there is an increasing number of adolescent and adult cases. This could possibly be due to waning of vaccine immunity. In 2005, Tdap (tetanus, diphtheria and pertussis) vaccine was introduced for older children, adolescents and adults.¹⁶ Tdap is currently recommended as a once-only booster for adolescents and adults.




SALMONELLOSIS

Number of cases in 2007:	1,323	Rate in 2007:	11.5
Number of cases in 2006:	1,299	Rate in 2006:	11.3

* Rates are based on U.S. Census midpoint estimates for each year and are per 100,000 population.

Salmonellosis is an infectious disease caused by a group of bacteria known as *Salmonella*.¹⁷ Salmonellosis is an acute gastrointestinal illness characterized by fever, headache, abdominal cramps, diarrhea and vomiting. Humans may acquire *Salmonella* directly via the fecal-oral route, from animals or from ingestion of contaminated food or water. Salmonellosis occurs worldwide with children less than 5 years of age, the elderly and the immunocompromised the most likely to develop severe infections.¹⁸

More than 1,000 cases of salmonellosis have been reported in each of the past five years in Ohio. There are more than 2,000 known serotypes of *Salmonella* bacteria, with serotypes Typhimurium and Enteritidis accounting for more than half of all human *Salmonella* isolates. Figure 9 displays the incidence of the most common *Salmonella* serotypes reported in Ohio from 2003-2007. *Salmonella* Enteritidis and Typhimurium were the most commonly isolated serotypes among Ohio's salmonellosis cases.




SHIGELLOSIS

Number of cases in 2007:	1,277	Rate in 2007:	11.1
Number of cases in 2006:	200	Rate in 2006:	1.7

* Rates are based on U.S. Census midpoint estimates for each year and are per 100,000 population.

Shigellosis is an infectious disease caused by a group of bacteria known as *Shigella*.¹⁹ *Shigella* species are Gram-negative, non-spore forming, rod-shaped bacilli in the family Enterobacteriaceae.²⁰ There are four species of *Shigella: Shigella boydii, Shigella dysenteriae, Shigella flexneri* and *Shigella sonnei. Shigella* species primarily infect the large intestine, causing clinical manifestations that range from loose or watery stools to more severe symptoms including fever, abdominal tenderness or cramps and mucoid stools with or without blood.²¹ *Shigella* is spread directly via person-to-person contact by the fecal-oral route.¹⁹ Transmission by eating contaminated foods and/or swallowing contaminated water may also occur.

Figure 10 demonstrates the burden of shigellosis over the past five years in Ohio by age group. Although most recognized cases occur in children less than 10 years of age (1,296), persons of all ages are at risk for shigellosis. Among *Shigella* isolates reported in Ohio 2003-2007, 81 percent were S. *sonnei*, 6 percent were S. *flexneri* and less than 1 percent of cases were identified as either S. *boydii* or S. *dysenteriae*. In addition, approximately 13 percent of shigellosis cases did not have a species reported.




STREPTOCOCCAL DISEASE, GROUP A, INVASIVE

Number of cases in 2007:	226	Rate in 2007:	2.0
Number of cases in 2006:	245	Rate in 2006:	2.1

* Rates are based on U.S. Census midpoint estimates for each year and are per 100,000 population.

Invasive Group A *Streptococcus* (GAS) is caused when a normally sterile site is infected with the bacteria *Streptococcus pyogenes*. *S. pyogenes* is a bacteria commonly found in the throat and on the skin of healthy people with no symptoms of illness. Those with underlying chronic health conditions such as diabetes, cancer or HIV infection are at a greater risk to develop invasive GAS disease.²³

As seen in Figure 11, over the past five years, the majority of GAS cases in Ohio were isolated from blood (1,035) followed by synovial fluid (49), peritoneal, pericardial and/or pleural fluids (21) and cerebrospinal fluid (15). The number of invasive GAS cases reported has been declining since 2003 (2003: 287, 2004: 199, 2005: 245 and 2007: 226), while the proportion of cases isolated from blood has increased during this same time period (2003: 85 percent, 2004: 91 percent, 2005: 93 percent, 2006: 89 percent and 2007: 91 percent).




STREPTOCOCCAL DISEASE, GROUP B, IN NEWBORN

Number of cases in 2007:	49	Rate in 2007:	0.4	
Number of cases in 2006:	63	Rate in 2006:	0.5	

* Rates are based on U.S. Census midpoint estimates for each year and are per 100,000 population.

Group B *Streptococcus* (GBS) is a type of bacterium that causes illness in pregnant women, their newborn babies, the elderly and adults with chronic illnesses. GBS is the most common cause of life-threatening infections in newborns, including sepsis and meningitis. As such, routine prenatal screening of pregnant women for GBS colonization at 35-37 weeks gestation is recommended in the United States.²⁴ Newborn GBS is a reportable condition in Ohio for infants 3 months or less of age, and unlike several other reportable bacterial pathogens, it is reportable from both sterile and non-sterile specimen sites.

As seen in Figure 12, the majority of newborn infections in Ohio from Group B *Streptococcus* were reported from normally sterile specimen sites. Since 2003, the proportion of cases isolated from a normally sterile site continues to increase. The only sterile sites from which newborn GBS was isolated over the past five years were blood or serum (84 percent) and cerebrospinal fluid (16 percent).



VARICELLA


Number of cases in 2007:	4,364	Rate in 2007:	38.1
Number of cases in 2006:	8,859	Rate in 2006:	77.2

* Rates are based on U.S. Census midpoint estimates for each year and are per 100,000 population.

Varicella, also known as chickenpox, is caused by the varicella zoster virus, a member of the herpesvirus family.²⁵ The most common symptoms of chickenpox are fever, malaise and a generalized itchy rash first seen on the head and trunk. This is followed by rapid progression to macules, papules and vesicular lesions that produce blisters on other areas of the body. These blisters will dry, crust over and form scabs. Lesions that have scabbed over are not infectious. Varicella is spread by direct contact with the drainage from infectious lesions or airborne respiratory tract secretions. Varicella occurs worldwide and is common in the United States. The disease occurs most frequently in winter and early spring. Most people get chickenpox during their childhood years. Disease in adults is often severe and may result in complications (e.g., secondary bacterial infections).

The first varicella vaccine was licensed by the U.S. Food and Drug Administration in 1995. Routine vaccination is recommended for all healthy children 12 months through 15 months of age, with a second dose recommended between 4 and 6 years of age. In addition, those 13 years of age and older without a history of disease and susceptible adults are also targeted for vaccination.²⁶

As seen in Figure 13, the majority of varicella cases reported in Ohio between 2006 and 2007 occurred in the 5-9-year age group. It is not known what proportion of this age group was unvaccinated. As of Jan. 1, 2006, varicella became a Class A(3) reportable disease in Ohio, reportable by individual case at the end of the work week. Prior to 2006, varicella was reportable as an aggregate (total number of cases) at the end of each work week. The reason for the sharp decline of cases between 2006 and 2007 is unknown.




PROFILES OF SELECTED OUTBREAKS

The Outbreak Response and Bioterrorism Investigation Program (ORBIT) at the Ohio Department of Health (ODH) assisted local health jurisdictions in Ohio in the investigation of 309 outbreaks during 2007. These outbreaks were detected in 61 of 88 counties throughout the state. The number of Ohioans known to be ill from these outbreaks was 5,855. The outbreaks were classified as: person-to-person (117), foodborne (87), staphylococcal skin infections (39), outbreaks of a Class A agent (28), scabies (18), hospital-acquired (eight), waterborne (nine), conjunctivitis (two) and pediculosis (one). Causative agents identified during the outbreak investigations included: *Balamuthia mandrillaris, Clostridium botulinum, Clostridium perfringens, Cryptosporidium, E. coli* O157, *Legionella* spp., Norovirus, *Salmonella* spp., *Sarcoptes scabiei, Serratia marcescens, Shigella sonnei, Staphylococcus aureus* (including methicillin-resistant) and *Tinea* spp. Point-source outbreaks that are neither foodborne nor waterborne account for an increasing percentage of outbreaks investigated. Details on selected types of outbreaks are discussed below.

FOODBORNE OUTBREAKS

In 2007, 27 of the 87 foodborne outbreaks reported in Ohio were confirmed foodborne disease outbreaks. These outbreaks met the general definition of a foodborne outbreak: "An incident in which two or more persons experience a similar illness after ingestion of a common food, and epidemiologic analysis implicates the food as the source of the illness." These 27 outbreaks also met the agent-specific criteria for confirmation of outbreaks, as shown in Figure 1. For these 27 foodborne outbreaks, the causative agent was distributed as follows: Norovirus (16), *Salmonella* (seven), *Clostridium perfringens* (one), *Clostridium botulinum* (one), *E. coli* O157 (one) and scombroid fish poisoning (one).



UNUSUAL INCIDENCE OUTBREAKS

In 2007, ORBIT assisted local health jurisdictions in Ohio to investigate 117 outbreaks classified as "Unusual Incidence." These outbreaks were detected in 35 of Ohio's 88 counties (Table 1). The number of Ohioans known to be ill from these outbreaks was 3,346. One-hundred two (87 percent) of these outbreaks were identified as gastrointestinal (GI) illnesses, primarily caused by Norovirus. Fifty-three (52 percent) of these GI outbreaks were confirmed Norovirus by stool testing at ODH Laboratory. The remaining suspect Norovirus outbreaks could not be confirmed either because no stool specimens were submitted or an inadequate number of stool specimens were positive (i.e., fewer than two). The Norovirus outbreaks occurred in a variety of settings, including assisted living/retirement communities, child care centers, correctional facilities, group homes, hospitals, long-term care facilities, private homes and schools.

County		# of Outbreaks (# of III Persons)		County	# of Outbreaks (# of III Persons)	
Allen	3	(120)] [Lake	7	(178)
Ashland	2	(96)] [Logan	1	(6)
Ashtabula	1	(7)		Lorain	7	(297)
Belmont	1	(45)		Lucas	3	(15)
Butler	1	(4)] [Medina	5	(69)
Clark	4	(129)		Montgomery	4	(147)
Clermont	2	(24)		Muskingum	2	(36)
Clinton	1	(75)		Pickaway	1	(50)
Cuyahoga	28	(726)		Pike	1	(11)
Delaware	3	(60)		Richland	3	(135)
Erie	1	(6)		Ross	1	(11)
Fairfield	1	(55)	1	Sandusky	7	(256)
Franklin	9	(250)		Seneca	1	(104)
Hamilton	7	(159)		Shelby	1	(8)
Harrison	1	(41)		Stark	2	(79)
Henry	1	(10)		Summit	2	(28)
Hocking	1	(46)		Wood	1	(60)
Jefferson	1	(3)	1 1	Total	117	(3,346)

Source of outbreak data: Ohio Department of Health Outbreak Response and Bioterrorism Investigation Program.

WATERBORNE OUTBREAKS

In 2007, nine waterborne outbreaks were reported in Ohio from seven counties (Table 2). Counties reporting included Auglaize (1), Cuyahoga (3), Franklin (1), Lake (1), Medina (1), Mercer (1) and Warren (1). The outbreaks affected 749 individuals and ranged in size from 1 to 692 (median = 4). These outbreaks met the CDC case definition.

Table 2: Waterborne Disease Outbreaks by Month of Onset, Ohio, 2007									
County	Month	Predominant Symptoms	1000	ases ths)	Type of Water	Etiology	Setting		
Warren	Feb.	Respiratory	692	(0)	Recreational	Chemical	Water park		
Auglaize	Mar.	Skin	2	(0)	Recreational	Rash (unknown)	Hot tub		
Cuyahoga	Mar.	GI	4	(0)	Drinking	Suspect Chemical	Bottled water		
Lake	Mar.	Multi (skin, eye, resp.)	31	(0)	Recreational	Suspect chemical	Pool		
Franklin	Mar.	Skin	4	(0)	Recreational	Rash (unknown)	Pool/Spa		
Medina	Jun.	Meningo- encephalitis	1	(1)	Recreational	Balamuthia mandrillaris	Pond		
Mercer	Sep.	GI	10	(0)	Recreational	Cryptosporidium	Pond		
Cuyahoga	Oct.	Respiratory	2	(0)	Recreational	Legionella spp.	Hotel		
Cuyahoga	Nov.	Respiratory	3	(0)	Unknown Intent	Legionella spp.	Healthcare- associated		


Source of outbreak data: Ohio Department of Health Outbreak Response and Bioterrorism Investigation Program.

OUTBREAKS INVOLVING STAPHYLOCCUS AUREUS

In accordance with the Ohio Administrative Code (OAC) 3701-3-02, suspected or confirmed staphylococcal skin infection outbreaks and healthcare-associated outbreaks, including those caused by staphylococcal bacteria, are reportable to local public health districts.

In 2007, there were 39 outbreaks due to *Staphylococcus aureus* (SA) bacteria reported to ODH. Methicillin-resistant *S. aureus* (MRSA) was identified in 29 (74 percent) of the outbreaks reported in 2007. Ill persons related to these outbreaks numbered 230. *S. aureus*, often called "staph," are bacteria commonly carried on the skin or in the nose of healthy people. Approximately 25 percent to 30 percent of the population is colonized (when bacteria are present but not causing an infection) with staph bacteria. Colonization by *S. aureus* bacteria at these sites is often, however not always, a precursor to staphylococcal infections. A staph bacterium is one of the most common causes of skin infections in the United States.

Some staph bacteria are resistant to antibiotics. MRSA is resistant to all available betalactam agents (penicillins and cephalosporins). The epidemiology of infections caused by MRSA is rapidly changing. In the past 10 years, infections caused by this organism have emerged in the community. The figure below, Figure 2, depicts the number of outbreaks caused by *S. aureus* (SA) and MRSA reported to ODH in 2007.



The majority of outbreaks reported in 2007 involved students on sports teams in school settings (Figure 2). Obstacles to the investigation of many of these outbreaks have been delayed reporting and the misconception that laws providing privacy to individual students do not allow outbreaks to be investigated by public health. However, once outbreaks in school settings are identified, school officials and public health are quick to identify possible causes of transmission and to initiate appropriate steps to prevent additional cases.

New strains of MRSA have emerged in the community with implications for management of skin infections and other staphylococcal infections. Patient education on proper wound care is a critical component of case management for patients with skin infections. Strategies

focusing on increased awareness, early detection and appropriate management, enhanced hygiene and maintenance of a clean environment have been successful in controlling outbreaks of infections.

MULTISTATE INVESTIGATIONS

In 2007, Ohio had cases in three multistate foodborne outbreaks involving products that were distributed nationwide. These are summarized briefly below:

In February 2007, an outbreak of *Salmonella* Tennessee was recognized by pulsed-field gel electrophoresis (PFGE). There were 425 cases reported nationwide; 19 were from Ohio. Serotyping and PFGE analysis of Ohio's clinical isolates was done by the ODH Laboratory. This outbreak was associated with the consumption of several brands of peanut butter, which were made at a single plant in Georgia. A nationwide recall of the implicated peanut butter occurred on Feb. 14, 2007.

In July and August 2007, Ohio reported three cases of foodborne botulism. These cases were linked to consumption of Castleberry hot dog chili sauce. This product was recalled nationwide. ODH Laboratory identified botulinum toxin and grew the bacterium, *Clostridium botulinum*, from leftover sauce from one of the Ohio cases.

In October 2007, a nationwide outbreak of *Salmonella* (I) 4,[5],12:i:- was recognized by PFGE. There were 345 cases nationwide, 21 of which were from Ohio. Serotyping and PFGE analysis of Ohio's clinical isolates was done by the ODH Laboratory. These cases were associated with the consumption of frozen pot pies. A nationwide recall of several brands of these products occurred on Oct. 11, 2007.

Further information about these outbreaks can be found at the following sites:

Salmonella Tennessee: <u>http://www.cdc.gov/ncidod/dbmd/diseaseinfo/salmonellosis</u> 2007/outbreak_notice.htm

Botulism: http://www.cdc.gov/botulism/botulism.htm

Salmonella (I) 4,[5],12:i:-: http://www.cdc.gov/salmonella/4512eyeminus.html

Also in 2007, there was one multistate outbreak involving dog food and one involving turtles. These are summarized below:

During spring/summer 2007, Ohio had three human cases and one dog that were PFGE linked to *Salmonella* Schwartzengrund. This is a very rare strain of *Salmonella* (0.6 percent of all *Salmonella* cases as of January 2008) that infected both people and dogs in 19 states. The common link in these cases appeared to be related to dog food that was manufactured in the same plant.

In September 2007, a nationwide outbreak of *Salmonella* Paratyphi B, var. Java was uncovered by PFGE. There were 133 cases nationwide from 33 states; three of these were from Ohio. Serotyping and PFGE analysis of Ohio's clinical isolates was done by the ODH Laboratory. These cases were associated with contact with small turtles. More than 60 percent of cases had contact with turtles, and 87 percent of those had contact with illegal small turtles with a carapace size less than four inches.

Further information about these outbreaks can be found at the following sites:

Salmonella Schwarzengrund: <u>http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5719</u> <u>a4.htm</u>

Salmonella Paratyphi B, var. Java: <u>http://www.cdc.gov/mmwr/preview/mmwrhtml/mm</u> 5703a3.htm

TECHNICAL NOTES

NOTES ON SPECIFIC DISEASES:

Anaplasmosis: formerly known as human granulocytic ehrlichiosis (HGE) and caused by *Anaplasma phagocytophilum*.

Botulism, Foodborne: the three cases in 2007 were part of a nationwide outbreak.

Coccidioidomycosis: became a reportable disease in Ohio Jan. 1, 2006.

Ehrlichia chaffeensis: formerly known as human monocytic ehrlichiosis (HME).

Encephalitis, Post Other Infection: includes encephalitis following a non-central nervous system viral illness or after vaccine was administered.

Hepatitis: chronic cases of hepatitis B and past or present cases of hepatitis C became reportable in Ohio Apr. 4, 2003; counts prior to 2003 included acute cases only. "Month" refers to the month the case was reported to the Centers for Disease Control and Prevention (CDC). Due to the chronic nature of hepatitis B and C, all conditions associated with hepatitis B and C are shown by date of report to better capture and describe disease incidence.

Herpes, Congenital: reporting moved to the Sexually Transmitted Disease (STD) Surveillance Program in 2006. Please contact the ODH STD Surveillance Program at (614) 466-1388 for congenital herpes surveillance data for 2006 and beyond.

Influenza-associated Pediatric Mortality: became a reportable condition in Ohio Jan. 1, 2005, for children less than 18 years of age. "Month" refers to the month of death of the case.

LaCrosse Encephalitis: case reporting to the CDC through ArboNet began in 2003 by the ODH Bureau of Infectious Disease Control (BIDC), Zoonotic Disease Program (ZDP). ArboNet is an electronic-based surveillance system created by the CDC to streamline arboviral disease reporting from state public health departments. Please refer to <u>http://www.odh.ohio.gov/odhPrograms/idc/zoodis/vbdp/vbdp1.aspx</u> for further information on vector-borne diseases.

Lyme Disease: as of Oct. 14, 2008, there were three cases of Lyme disease reported in 2008 with illness onset dates in 2007.

Meningitis, Other Bacterial: includes cases of bacterial meningitis for which the agent was specified, excluding Group A *Streptococcus*, Group B *Streptococcus* (in newborns), *Haemophilus influenzae*, *Listeria monocytogenes*, *Mycobacterium tuberculosis*, *Neisseria meningitidis* and *Streptococcus pneumoniae*. Cases of meningitis due to these agents are reported as those specific conditions.

Rabies, Animal: refers only to cases among animal species. The last reported case of human rabies in Ohio occurred in 1971.

St. Louis Encephalitis: case reporting to the CDC through ArboNet began in 2003 by the ODH BIDC, ZDP. ArboNet is an electronic-based surveillance system created by the CDC to streamline arboviral disease reporting from state public health departments. Please refer to http://www.odh.ohio.gov/odhPrograms/idc/zoodis/vbdp/vbdp1.aspx for more information on vector-borne diseases.

Streptococcus pneumoniae, Invasive Disease, Age < 5 Years: became nationally notifiable in 2003 for all children less than 5 years of age, regardless of drug-resistance pattern.

Streptococcus pneumoniae, Invasive Disease, Drug Resistant, Ages 5+ Years: became nationally notifiable in 2003 for all ages with antibiotic resistance. Numbers include cases 5 years of age and older with intermediate resistance or resistance to one or more antimicrobial agents.

Streptococcus pneumoniae, Invasive Disease, Drug Susceptible, Ages 5+ Years: numbers include cases 5 years of age and older with invasive *Streptococcus pneumoniae* that are susceptible or of unknown susceptibility to all antimicrobial agents tested.

Vancomycin-resistant Enterococcal Disease: no longer reportable in Ohio as of Apr. 14, 2003. Data for 2003 reflect cases with disease onset dates from Jan. 1 through Apr. 13, 2003.

Varicella: became a Class A reportable disease Jan. 1, 2006. Prior to 2006, varicella was a Class B reportable disease and was reported in aggregate form on a weekly basis. Date of onset was not reported; therefore, all previous data were compiled by date of report.

West Nile Virus: the first human case in Ohio was reported in August 2002. Case reporting to the CDC through ArboNet began in 2003 by the ODH BIDC, ZDP. ArboNet is an electronic-based surveillance system created by the CDC to streamline arboviral disease reporting from state public health departments. Please refer to <u>http://www.odh.ohio.gov/odhPrograms/idc/zoodis/vbdp/vbdp1.aspx</u> for more information on vector-borne diseases.

NOTES ON OUTBREAKS:

Numbers indicate the number of outbreaks reported and do not reflect the number of cases involved in the outbreak. Therefore, outbreak data are not included in the "Age in Years" and "Gender" tables, and rates were not calculated in any table. Outbreak data are by year of report, so "Month" refers to the month of report. The source of outbreak data is the ODH BIDC, Outbreak Response and Bioterrorism Investigation Program. *Six multicounty and multistate outbreaks are not included in the "County" table; thus, county totals do not match totals.* A multicounty outbreak is an outbreak where the exposure occurred in more than one county, while a multistate outbreak is an outbreak where the exposure occurred in more than one state.

Foodborne: for the definition of a foodborne outbreak, see "Surveillance for Foodborne Disease Outbreaks – United States, 1998-2002" in: CDC Surveillance Summaries, Nov. 10, 2006. MMWR 2006; 55 (No. SS-10). (Available on the Web at: http://www.cdc.gov/mmwr/preview/mmwrhtml/ss5510a1.htm).

Waterborne: for the definition of a waterborne outbreak, see "Surveillance for Waterborne Disease and Outbreaks Associated with Recreational Water – United States, 2003-2004" and "Surveillance for Waterborne Disease and Outbreaks Associated with Drinking Water – United States, 2003-2004" in: CDC Surveillance Summaries, Dec. 22, 2006. MMWR 2006; 55 (No. SS-12). (On the Web at http://www.cdc.gov/mmwr/PDF/ss/ss5512.pdf).

Unspecified: includes outbreaks of Class A diseases that are neither foodborne, waterborne nor nosocomial.

Conjunctivitis: includes outbreaks of conjunctivitis of bacterial, viral or unknown etiology.

Nosocomial: includes hospital-acquired outbreaks of all etiologies.

Pediculosis: includes louse-associated outbreaks of all origins (head, body and pubic/crab).

Scabies: includes scabies outbreaks, both confirmed and suspected.

Staphylococcal Skin Infections: includes staphylococcal outbreaks in which isolates were antibiotic-susceptible as well as outbreaks in which isolates were methicillin-resistant *Staphylococcus aureus* (MRSA).

Unusual Incidence of Non-Class A, Class B or Class C Disease: includes outbreaks in which the causative agent was not a Class A, B or C disease. Most of these were outbreaks of Norovirus that were point-source or person-to-person spread.

DISEASES NOT INCLUDED IN TABLES:

There were no known cases in Ohio of the following reportable diseases during at least the past five years; thus, they are not included in the 2003-2007 disease tables:

- Anthrax
- Botulism, wound
- Diphtheria
- Eastern equine encephalitis
- Ehrlichiosis, other/unspecified agent
- Encephalitis, post mumps
- Encephalitis, post chickenpox
- Hantavirus
- Plague
- Poliomyelitis
- Powassan encephalitis

- Psittacosis
- Rabies, human
- Reye syndrome
- Rubella, congenital and not congenital
- Severe acute respiratory syndrome
- Smallpox
- Staphylococcus aureus, resistant to vancomycin
- Viral hemorrhagic fever
- Western equine encephalitis
- Yellow fever

There were no outbreaks of the following reported with onset 2005-2007:

Blastomycosis

Sporotrichosis

Histoplasmosis

• Toxoplasmosis

Diseases not included in the "Age in Years," "Gender," "Month of Onset" and "County of Residence" tables (pp. 10-45) had no known cases reported in 2007.

NOTE ON SALMONELLA SEROTYPES AND MENINGOCOCCAL DISEASE SEROGROUPS:

The bacteriology laboratory at the Ohio Department of Health (ODH) performs serotyping of *Salmonella* isolates and serogrouping of *Neisseria meningitidis* isolates. Hospital and other clinical laboratories are encouraged to send *Salmonella* and *Neisseria meningitidis* isolates to the ODH Laboratory for serotyping and serogrouping. The ODH Laboratory also requests *Escherichia coli, Listeria, Vibrio, Haemophilus influenzae* (in children under 5 years of age) and vancomycin resistant or intermediate resistant *Staphylococcus aureus* isolates. For further information on the submission of isolates, please contact the bacteriology laboratory at (614) 644-4656.

REFERENCES

- 1. Ohio Department of Health. Cholera. In: *Infectious Disease Control Manual*. Columbus, OH: Ohio Department of Health; 2007.
- Centers for Disease Control and Prevention Division of Parasitic Diseases. Cryptosporidiosis. 2008. Available at: <u>http://www.dpd.cdc.gov/dpdx/HTML/Cryptosporidiosis.htm</u>. Accessed August 2008.
- 3. Ohio Department of Health. Cryptosporidiosis. In: *Infectious Disease Control Manual*. Columbus, OH: Ohio Department of Health; 2007.
- Centers for Disease Control and Prevention Division of Parasitic Diseases. Cryptosporidiosis Fact Sheet. 2008. Available at: <u>http://www.cdc.gov/crypto/factsheets/infect.html</u>. Accessed August 2008.
- 5. Ohio Department of Health. Shiga Toxin-Producing Enterohemorrhagic *E. coli*. In: *Infectious Disease Control Manual*. Columbus, OH: Ohio Department of Health; 2007.
- 6. World Health Organization. Enterohaemorrhagic *E. coli* (EHEC). 2005. Available at: <u>http://www.who.int/mediacentre/factsheets/fs125/en/</u>. Accessed October 22, 2008.
- 7. Ohio Department of Health. *Haemophilus influenzae*, Invasive Disease. In: *Infectious Disease Control Manual*. Columbus, OH: Ohio Department of Health; 2007.
- Iqbal K, Mayer L, Srivastava P, Messonnier NR, Bisgard KM. Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases. *Haemophilus influenzae* Type B Invasive Disease. In: Roush SW, McIntyre L, Baldy LM, ed. *Manual for the Surveillance of Vaccine-Preventable Diseases.* 4th ed. Atlanta, GA: Centers for Disease Control and Prevention; 2008: 2-6.
- 9. Ohio Department of Health. Legionellosis. In: *Infectious Disease Control Manual*. Columbus, OH: Ohio Department of Health; 2007.
- 10. Ohio Department of Health. Listeriosis. In: *Infectious Disease Control Manual*. Columbus, OH: Ohio Department of Health; 2007.
- 11. Ohio Department of Health. Aseptic Meningitis. In: *Infectious Disease Control Manual*. Columbus, OH: Ohio Department of Health; 2007.
- American Academy of Pediatrics. Meningococcal Infections. In: Pickering LK, ed. Red Book: 2003 Report of the Committee on Infectious Diseases. 26th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2003: 430-436.

- 13. Ohio Department of Health. Meningococcal Disease. In: *Infectious Disease Control Manual*. Columbus, OH: Ohio Department of Health; 2007.
- Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases. Meningococcal Disease and Meningococcal Vaccines. 2008. Available at: <u>http://www.cdc.gov/vaccines/vpd-vac/mening/vac-mening-fs.htm</u>. Accessed on October 23, 2008.
- 15. Ohio Department of Health. Pertussis. In: *Infectious Disease Control Manual*. Columbus, OH: Ohio Department of Health; 2007.
- Brown K, Cassiday P, Tondella ML, Cohn A, Bisgard K. Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases. Pertussis. In: Roush SW, McIntyre L, Baldy LM, ed. *Manual for the Surveillance of Vaccine-Preventable Diseases.* 4th ed. Atlanta, GA: Centers for Disease Control and Prevention; 2008: 10-6.
- 17. Ohio Department of Health. Salmonellosis. In: *Infectious Disease Control Manual*. Columbus, OH: Ohio Department of Health; 2007.
- Centers for Disease Control of Prevention Division of Foodborne, Bacterial and Mycotic Diseases. Salmonellosis. Available at: <u>http://www.cdc.gov/nczved/dfbmd/disease_listing/salmonellosis_gi.html</u>. Accessed August 2008.
- 19. Ohio Department of Health. Shigellosis. In: *Infectious Disease Control Manual*. Columbus, OH: Ohio Department of Health; 2007.
- American Public Health Association. Shigellosis. In: Heymann DL, ed. Control of Communicable Diseases Manual. 17th ed. Washington, DC: American Public Health Association; 2000: 451-455.
- American Academy of Pediatrics. Shigella Infections. In: Pickering LK, ed. Red Book: 2003 Report of the Committee on Infectious Diseases. 26th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2003: 551-553.
- Centers for Disease Control and Prevention Division of Foodborne, Bacterial and Mycotic Diseases. Shigellosis. 2008. Available at: <u>http://www.cdc.gov/nczved/dfbmd/disease_listing/shigellosis_gi.html</u>. Accessed August 2008.
- 23. Ohio Department of Health. *Streptococcus*, Group A, Invasive Disease. In: *Infectious Disease Control Manual*. Columbus, OH: Ohio Department of Health; 2007.
- 24. Ohio Department of Health. *Streptococcus*, Group B, Disease of the Newborn. In: *Infectious Disease Control Manual.* Columbus, OH: Ohio Department of Health; 2007.
- 25. Ohio Department of Health. Varicella. In: *Infectious Disease Control Manual*. Columbus, OH: Ohio Department of Health; 2007.
- Lopez A, Bridges C, Schmid S, Guris D, Seward J. Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases. Varicella. In: Roush SW, McIntyre L, Baldy LM, ed. *Manual for the Surveillance of Vaccine-Preventable Diseases.* 4th ed. Atlanta, GA: Centers for Disease Control and Prevention; 2008: 17-2.